_pmid,_doi,_publicationTitle,_year,_toolName,_toolType,_usageType,publicationId,resourceId,usageId
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,Matrigel spheroids,advanced_cellular_models,Experimental Usage,,,
PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,primary cultures derived from plexiform neurofibromas,advanced_cellular_models,Experimental Usage,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,oviductal organoids,advanced_cellular_models,Development,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,OSE organoids,advanced_cellular_models,Development,,,
PMID:41022755 | PMID:26904939,10.1038/s41467-025-63619-4 | 10.1016/j.celrep.2016.01.074,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,neurofibromaspheres,advanced_cellular_models,Experimental Usage,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,S462 spheres,advanced_cellular_models,Experimental Usage,,,
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,optic glioma neurospheres,advanced_cellular_models,Experimental Usage,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,hiMGL cells,advanced_cellular_models,Development,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,spheroid culture system,advanced_cellular_models,Experimental Usage,,,
PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,TAME chips,advanced_cellular_models,Experimental Usage,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,3D tumor spheroid model,advanced_cellular_models,Experimental Usage,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,neurosphere cultures,advanced_cellular_models,Experimental Usage,,,
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,3D rBM overlay model,advanced_cellular_models,Experimental Usage,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,embryonic mouse spheres,advanced_cellular_models,Experimental Usage,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,neurofibromasphere model,advanced_cellular_models,Experimental Usage,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,cNF organoids,advanced_cellular_models,Development,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,3D microtissues,advanced_cellular_models,Development,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,BioCoat Matrigel invasion chambers (Becton Dickinson),advanced_cellular_models,Experimental Usage,,,
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,NF1 patient-derived induced pluripotent stem cells (iPSCs),advanced_cellular_models,Experimental Usage,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,129T2/SvEmsJ::C57Bl/6NTac Nf1+/- and Nf1+/+,animal_models,Experimental Usage,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,C57BL6/J Nf1+/−;Trp53+/−,animal_models,Experimental Usage,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,Nf1 c.5425 C > T ; Arg1809Cys,animal_models,Experimental Usage,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,R681X Nf1,animal_models,Experimental Usage,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,Nf1 flox/flox ; Hoxb7-Cre,animal_models,Experimental Usage,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,Nf1 f/neo ; hGFAP-Cre,animal_models,Experimental Usage,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,Nf1-IF,animal_models,Experimental Usage,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,Nf1-PS,animal_models,Experimental Usage,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,Nf1-IFPS,animal_models,Experimental Usage,,,
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,Nf1(ob) (-/-),animal_models,Experimental Usage,,,
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,2.3-kb α1(I) collagen-cre Nf1 flox/flox,animal_models,Experimental Usage,,,
PMID:36890585 | PMID:40684195 | PMID:19191334 | PMID:21439418 | PMID:34935315 | PMID:25772366 | PMID:29847659 | PMID:29787563 | PMID:28525381 | PMID:25535838 | PMID:20200958,10.1186/s40478-023-01525-w | 10.1186/s40478-025-02075-z | 10.1002/glia.20845 | 10.1016/j.bone.2011.03.760 | 10.1117/1.JBO.26.12.125001 | 10.1016/j.celrep.2015.02.041 | 10.1167/iovs.17-22588 | 10.1371/journal.pone.0190001 | 10.18632/oncotarget.17589 | 10.7554/eLife.05151 | 10.1002/jbmr.42,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model. | Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma. | The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1. | Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,Nf1 flox/flox,animal_models,Experimental Usage,,,
PMID:33078583 | PMID:21681782 | PMID:21551250 | PMID:21726432,10.1002/jcsm.12632 | 10.1002/ajh.22035 | 10.1158/0008-5472.CAN-10-4577 | 10.1186/1741-7015-9-82,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis. | Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype. | Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development. | MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,Nf1 flox,animal_models,Experimental Usage,,,
PMID:32781282 | PMID:21199799 | PMID:8582272 | PMID:21949590 | PMID:40590220 | PMID:36890585 | PMID:40684195 | PMID:23071067 | PMID:26190969 | PMID:21439418 | PMID:25772366 | PMID:29847659 | PMID:18242513 | PMID:28525381 | PMID:16835260 | PMID:18632543,10.1016/j.trsl.2020.08.001 | 10.1158/0008-5472.CAN-10-2732 | 10.1242/dev.121.11.3583 | 10.2478/v10134-010-0025-8 | 10.1172/JCI188932 | 10.1186/s40478-023-01525-w | 10.1186/s40478-025-02075-z | 10.1158/0008-5472.CAN-12-1728 | 10.3389/fncel.2015.00234 | 10.1016/j.bone.2011.03.760 | 10.1016/j.celrep.2015.02.041 | 10.1167/iovs.17-22588 | 10.1016/j.ccr.2008.01.003 | 10.18632/oncotarget.17589 | 10.1093/hmg/ddl165 | 10.1001/jama.300.3.287,"Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1. | Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice. | Neurofibromin-deficient fibroblasts fail to form perineurium in vitro. | ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE. | A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms. | In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome. | Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. | The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation. | Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling. | Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.",,Nf1+/-,animal_models,Experimental Usage,,,
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,y w Mer4,animal_models,Experimental Usage,,,
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,4/FM7; T80-Gal4 y w Mer4,animal_models,Experimental Usage,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,PLP CreERT2; Nf1 f/−; ROSA-LacZ,animal_models,Experimental Usage,,,
PMID:34935315 | PMID:24465906 | PMID:21726432,10.1117/1.JBO.26.12.125001 | 10.1371/journal.pone.0086115 | 10.1186/1741-7015-9-82,"Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy. | Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1. | MIA is a potential biomarker for tumour load in neurofibromatosis type 1.",,Nf1Prx1-/-,animal_models,Experimental Usage,,,
PMID:21963652 | PMID:19191334 | PMID:23225063 | PMID:25772366,10.1016/j.expneurol.2011.09.005 | 10.1002/glia.20845 | 10.1002/ana.23793 | 10.1016/j.celrep.2015.02.041,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice. | Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,Nf1+/− GFAP CKO,animal_models,Experimental Usage,,,
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,Nf1(flox/-);Col2.3Cre(+),animal_models,Development,,,
PMID:38502231 | PMID:34010628,10.1172/JCI176748 | 10.1016/j.stem.2021.04.029,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,cisNP,animal_models,Experimental Usage,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,y [1] sc[*] v [1] sev [21]; P{y[+t7.7] v[+t1.8] = TKO.GS01796}attP40,animal_models,Experimental Usage,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,P{ KK101909 }VIE‐260B,animal_models,Experimental Usage,,,
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,Nf1Dsk9/+,animal_models,Experimental Usage,,,
PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,P0SchΔ39-121,animal_models,Experimental Usage,,,
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,"Trp53, Nf1, Suz12 triple mutant",animal_models,Experimental Usage,,,
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,C57BL/6J,animal_models,Experimental Usage,,,
PMID:33442015 | PMID:31527226 | PMID:33658640 | PMID:38127282,10.1038/s41591-020-01193-6 | 10.1158/1535-7163.MCT-19-0123 | 10.1038/s41416-021-01270-8 | 10.1158/1078-0432.CCR-23-2548,"Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. | Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.",,Nf1flox/flox;PostnCre,animal_models,Experimental Usage,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,NF1 fl/fl Tp53 fl/fl Eed fl/fl;Dhh-Cre,animal_models,Experimental Usage,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,NF1 R1947/+,animal_models,Development,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,Nf1fl/fl,animal_models,Experimental Usage,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,OPG Nf1fl/mut (Nf1+/−),animal_models,Experimental Usage,,,
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,Nf1 hGFAP CKO,animal_models,Experimental Usage,,,
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,Nf1 NcreER CKO,animal_models,Experimental Usage,,,
PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,Nf1 fcr,animal_models,Experimental Usage,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,NPcis,animal_models,Experimental Usage,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,"Nf1 flox/mut; GFAP-Cre, Nf1+/− GFAP CKO",animal_models,Experimental Usage,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,Nf1 P1,animal_models,Experimental Usage,,,
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,Postn-Cre; Nf2flox/flox,animal_models,Experimental Usage,,,
PMID:41444363 | PMID:24817309,10.1038/s41598-025-32031-9 | 10.1371/journal.pone.0097320,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model. | Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,Nf2flox/flox,animal_models,Experimental Usage,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,"Dhh::Cre, Nf1fl/fl, Pten",animal_models,Experimental Usage,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,Mut3,animal_models,Experimental Usage,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,Mut4,animal_models,Experimental Usage,,,
PMID:21216928 | PMID:26883872 | PMID:20551058,10.1158/1535-7163.MCT-10-0654 | 10.1016/j.jprot.2016.02.004 | 10.1158/0008-5472.CAN-09-3769,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes. | 3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Nf1 flox/flox; GFAP-Cre,animal_models,Experimental Usage,,,
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,DhhCre;Nf1fl/fl,animal_models,Experimental Usage,,,
PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,Nf1Col1,animal_models,Experimental Usage,,,
PMID:28256556 | PMID:26904939,10.1038/srep43315 | 10.1016/j.celrep.2016.01.074,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,Nf1fl/fl;DhhCre,animal_models,Experimental Usage,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,Stat3(fl/fl);Nf1(fl/fl);DhhCre,animal_models,Experimental Usage,,,
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,Nf1f/f;Trp53f/f;Nes-TK,animal_models,Experimental Usage,,,
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,Nf1f/f;Trp53f/f;CGD,animal_models,Experimental Usage,,,
PMID:32839340 | PMID:18242513,10.1073/pnas.2008391117 | 10.1016/j.ccr.2008.01.003,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific | The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,Nf1 fl/+,animal_models,Experimental Usage,,,
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,Nf1/p53-/-,animal_models,Experimental Usage,,,
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,"Mx1-Cre, Nf1 flox/flox",animal_models,Experimental Usage,,,
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,9a−/9a− Nf1,animal_models,Experimental Usage,,,
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,Nf1flox/null; GFAP-Cre,animal_models,Experimental Usage,,,
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,Nf1flox/R681*; GFAP-Cre,animal_models,Experimental Usage,,,
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,Nf1flox/null; Ptenflox/wt; GFAP-Cre,animal_models,Experimental Usage,,,
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,Nf1flox/null; Olig2-Cre,animal_models,Experimental Usage,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,cis Nf1+/−;P53+/−,animal_models,Experimental Usage,,,
PMID:17924978 | PMID:38945076,10.1111/j.1750-3639.2007.00105.x | 10.1016/j.redox.2024.103249,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations. | Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,Nf2 flox2/flox2,animal_models,Experimental Usage,,,
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,Nf2 flox2/flox2 ;p16 Ink4a*/*,animal_models,Experimental Usage,,,
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,H7;Nf1mut,animal_models,Experimental Usage,,,
PMID:24375753 | PMID:20551058 | PMID:28525381,10.1002/ana.24093 | 10.1158/0008-5472.CAN-09-3769 | 10.18632/oncotarget.17589,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. | The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/mut;GFAP-Cre,animal_models,Experimental Usage,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,DhhCre,animal_models,Experimental Usage,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,Nf1flox/flox;Arf flox/flox;PostnCre+,animal_models,Experimental Usage,,,
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/wt,animal_models,Experimental Usage,,,
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/mut,animal_models,Experimental Usage,,,
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/flox; Olig2-Cre,animal_models,Experimental Usage,,,
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/mut; Olig2-Cre,animal_models,Experimental Usage,,,
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/flox; Prom1-CreER,animal_models,Experimental Usage,,,
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/mut; Prom1-CreER,animal_models,Experimental Usage,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,PLP-CreERT:: Nf1 f/f ; Cdkn2a f/f,animal_models,Experimental Usage,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Periostin-CRE;NF2 fl/fl,animal_models,Experimental Usage,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Periostin-CRE;NF2 fl/fl YAP fl/fl,animal_models,Experimental Usage,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Periostin-CRE;NF2 fl/fl TAZ fl/fl,animal_models,Experimental Usage,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,P0-CRE,animal_models,Experimental Usage,,,
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,Postn-cre;Nf2f/f,animal_models,Experimental Usage,,,
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,DhhCre;Nf1f/f;Luciferase,animal_models,Experimental Usage,,,
PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal,,NPcis (Stock #008191),animal_models,Experimental Usage,,,
PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal,,Nf1 (#017640),animal_models,Experimental Usage,,,
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,Tg(U6x:nf2a/b-4sgRNA),animal_models,Development,,,
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,NF1 R1947X minipig,animal_models,Development,,,
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,TetOff-Osx-/-Nf1,animal_models,Experimental Usage,,,
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,Osx-/-Nf1flox/flox,animal_models,Experimental Usage,,,
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,"Osx-tTA,tetO-cre;Nf1flox/flox",animal_models,Experimental Usage,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,Nf2 mice,animal_models,Experimental Usage,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,hGFAP-cre,animal_models,Experimental Usage,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,Math1-cre,animal_models,Experimental Usage,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,L7-cre,animal_models,Experimental Usage,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,Nestin-creER,animal_models,Experimental Usage,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,Nf1-Arf flox/flox ;Postn-Cre,animal_models,Experimental Usage,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,tyrosine hydroxylase,antibodies,Experimental Usage,,,
PMID:34415582 | PMID:41022755 | PMID:40590220 | PMID:31545171 | PMID:31015291 | PMID:32461556 | PMID:29715273 | PMID:36890585 | PMID:34257279,10.1002/glia.24075 | 10.1038/s41467-025-63619-4 | 10.1172/JCI188932 | 10.7554/eLife.48983 | 10.1126/scisignal.aau8749 | 10.1038/s41467-020-16432-0 | 10.1371/journal.pone.0196726 | 10.1186/s40478-023-01525-w | 10.1038/s41467-021-24505-x,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury. | Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1. | Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins. | Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. | Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic. | Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,GFP,antibodies,Experimental Usage,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,TRIM23,antibodies,Experimental Usage,,,
PMID:32642734 | PMID:31462295 | PMID:39321200 | PMID:30479396 | PMID:38127282 | PMID:38216572 | PMID:37246765 | PMID:36598417,10.1093/noajnl/vdz026 | 10.1186/s40478-019-0792-5 | 10.1158/1078-0432.CCR-24-1454 | 10.1038/s41467-018-07452-y | 10.1158/1078-0432.CCR-23-2548 | 10.1038/s41467-024-44755-9 | 10.1093/neuonc/noad097 | 10.1158/2159-8290.CD-22-0786,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1. | Telomere alterations in neurofibromatosis type 1-associated solid tumors. | Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment. | NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology. | Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,H3K27me3,antibodies,Experimental Usage,,,
PMID:32642734 | PMID:32461556 | PMID:38502231 | PMID:24509877 | PMID:36322658 | PMID:34040258 | PMID:35511749 | PMID:26904939 | PMID:36241865 | PMID:24817309,10.1093/noajnl/vdz026 | 10.1038/s41467-020-16432-0 | 10.1172/JCI176748 | 10.1038/onc.2013.506 | 10.1126/sciadv.abo5442 | 10.1038/s41586-021-03580-6 | 10.1158/1535-7163.MCT-21-0947 | 10.1016/j.celrep.2016.01.074 | 10.1038/s12276-022-00850-9 | 10.1371/journal.pone.0097320,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1. | Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway. | Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,Cleaved-caspase 3,antibodies,Experimental Usage,,,
PMID:40394150 | PMID:32699356 | PMID:32948135 | PMID:32642734 | PMID:35589737 | PMID:19191334 | PMID:32461556 | PMID:29715273 | PMID:34040258 | PMID:35945463 | PMID:29941005 | PMID:29438698 | PMID:24681606 | PMID:30055648 | PMID:33032988 | PMID:26904939 | PMID:40684195 | PMID:32642733 | PMID:36148553 | PMID:33356508 | PMID:37246765 | PMID:24371224 | PMID:25535838 | PMID:33591953 | PMID:38945076 | PMID:34930951 | PMID:39996452 | PMID:21216928,10.1038/s41416-025-03055-9 | 10.1038/s41467-020-17382-3 | 10.1186/s12885-020-07397-w | 10.1093/noajnl/vdz026 | 10.1038/s41467-022-30466-6 | 10.1002/glia.20845 | 10.1038/s41467-020-16432-0 | 10.1371/journal.pone.0196726 | 10.1038/s41586-021-03580-6 | 10.1007/s00401-022-02478-5 | 10.1186/s13023-018-0843-1 | 10.1016/j.ccell.2018.01.005 | 10.18632/oncotarget.1609 | 10.1186/s13104-018-3630-0 | 10.1158/0008-5472.CAN-20-1365 | 10.1016/j.celrep.2016.01.074 | 10.1186/s40478-025-02075-z | 10.1093/noajnl/vdz061 | 10.1093/brain/awac342 | 10.1177/0963689720964383 | 10.1093/neuonc/noad097 | 10.1158/0008-5472.CAN-13-2062 | 10.7554/eLife.05151 | 10.1172/jci.insight.146351 | 10.1016/j.redox.2024.103249 | 10.1038/s41536-021-00195-3 | 10.1111/cns.70287 | 10.1158/1535-7163.MCT-10-0654,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin. | Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model. | Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1. | Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. | Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. | Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study. | Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma. | C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas. | Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1. | Chromosome 8 gain is associated with high-grade transformation in MPNST. | Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation. | A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy. | Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells. | Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,Ki67,antibodies,Experimental Usage,,,
PMID:32699356 | PMID:18451155 | PMID:35589737 | PMID:19191334 | PMID:35945463 | PMID:20554030 | PMID:33356508 | PMID:25535838 | PMID:34930951 | PMID:25772366 | PMID:36241865 | PMID:20551058 | PMID:19144871,10.1038/s41467-020-17382-3 | 10.1158/0008-5472.CAN-07-6867 | 10.1038/s41467-022-30466-6 | 10.1002/glia.20845 | 10.1007/s00401-022-02478-5 | 10.1016/j.jneuroim.2010.05.002 | 10.1177/0963689720964383 | 10.7554/eLife.05151 | 10.1038/s41536-021-00195-3 | 10.1016/j.celrep.2015.02.041 | 10.1038/s12276-022-00850-9 | 10.1158/0008-5472.CAN-09-3769 | 10.3181/0809-RM-275,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | Pten haploinsufficiency accelerates formation of high-grade astrocytomas. | Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. | Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1. | A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. | Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,GFAP,antibodies,Experimental Usage,,,
PMID:36890585 | PMID:35589737 | PMID:38502231 | PMID:36322658 | PMID:34040258 | PMID:37990867 | PMID:20554030 | PMID:34930951 | PMID:20551058,10.1186/s40478-023-01525-w | 10.1038/s41467-022-30466-6 | 10.1172/JCI176748 | 10.1126/sciadv.abo5442 | 10.1038/s41586-021-03580-6 | 10.1242/dmm.049861 | 10.1016/j.jneuroim.2010.05.002 | 10.1038/s41536-021-00195-3 | 10.1158/0008-5472.CAN-09-3769,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic. | Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia. | CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Iba-1,antibodies,Experimental Usage,,,
PMID:38907342 | PMID:37770931 | PMID:35589737 | PMID:35945463 | PMID:38216587 | PMID:29438698 | PMID:38744290 | PMID:38216572 | PMID:36598417 | PMID:39415595,10.1186/s40478-024-01821-z | 10.1186/s40478-023-01639-1 | 10.1038/s41467-022-30466-6 | 10.1007/s00401-022-02478-5 | 10.1038/s41467-023-40408-5 | 10.1016/j.ccell.2018.01.005 | 10.1016/j.crmeth.2024.100772 | 10.1038/s41467-024-44755-9 | 10.1158/2159-8290.CD-22-0786 | 10.1242/dmm.050862,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response. | Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas. | Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | Epigenetic reprogramming shapes the cellular landscape of schwannoma. | Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA. | Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.",,SOX10,antibodies,Experimental Usage,,,
PMID:35589737 | PMID:34930951,10.1038/s41467-022-30466-6 | 10.1038/s41536-021-00195-3,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. | A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,Rbpms,antibodies,Experimental Usage,,,
PMID:35589737 | PMID:23328114 | PMID:25772366,10.1038/s41467-022-30466-6 | 10.18632/oncotarget.793 | 10.1016/j.celrep.2015.02.041,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. | Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,Tuj-1,antibodies,Experimental Usage,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,Peripherin,antibodies,Experimental Usage,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,ISL1,antibodies,Experimental Usage,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,P-cadherin,antibodies,Experimental Usage,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,DCT,antibodies,Experimental Usage,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,K14,antibodies,Experimental Usage,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,LacZ,antibodies,Experimental Usage,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,GFP/YFP,antibodies,Experimental Usage,,,
PMID:28465357 | PMID:29438698,10.1101/gad.298703.117 | 10.1016/j.ccell.2018.01.005,Identification of hair shaft progenitors that create a niche for hair pigmentation. | Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,Krox20,antibodies,Experimental Usage,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,KIT,antibodies,Experimental Usage,,,
PMID:38216123 | PMID:38481529 | PMID:37446790 | PMID:39890807 | PMID:29438698 | PMID:29847659 | PMID:36241865,10.1016/j.molmet.2024.101876 | 10.3389/fcell.2024.1359561 | 10.3390/molecules28135128 | 10.1038/s41598-024-84493-y | 10.1016/j.ccell.2018.01.005 | 10.1167/iovs.17-22588 | 10.1038/s12276-022-00850-9,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer. | Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1. | Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway. | Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism. | Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,neurofibromin,antibodies,Experimental Usage,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,pERα S118,antibodies,Experimental Usage,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,pERK T202/Y204,antibodies,Experimental Usage,,,
PMID:38216123 | PMID:24681606,10.1016/j.molmet.2024.101876 | 10.18632/oncotarget.1609,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,pAKT S473,antibodies,Experimental Usage,,,
PMID:33078583 | PMID:38216123 | PMID:39129390 | PMID:34257279 | PMID:18367665,10.1002/jcsm.12632 | 10.1016/j.molmet.2024.101876 | 10.1002/1878-0261.13704 | 10.1038/s41467-021-24505-x | 10.1124/jpet.107.135830,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis. | NF1 deficiency drives metabolic reprogramming in ER+ breast cancer. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila. | Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,β-tubulin,antibodies,Experimental Usage,,,
PMID:34040258 | PMID:34930951,10.1038/s41586-021-03580-6 | 10.1038/s41536-021-00195-3,NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,BRN3A,antibodies,Experimental Usage,,,
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,Thy1.1,antibodies,Experimental Usage,,,
PMID:34930951 | PMID:23328114,10.1038/s41536-021-00195-3 | 10.18632/oncotarget.793,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy. | Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,Caspase9,antibodies,Experimental Usage,,,
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,Cmyc,antibodies,Experimental Usage,,,
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,Oct4,antibodies,Experimental Usage,,,
PMID:36890585 | PMID:25535838 | PMID:34930951 | PMID:36241865,10.1186/s40478-023-01525-w | 10.7554/eLife.05151 | 10.1038/s41536-021-00195-3 | 10.1038/s12276-022-00850-9,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1. | A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,NeuN,antibodies,Experimental Usage,,,
PMID:40217315 | PMID:30479396 | PMID:29941005 | PMID:34010628 | PMID:40684195 | PMID:33356508 | PMID:34930951,10.1186/s13073-025-01462-4 | 10.1038/s41467-018-07452-y | 10.1186/s13023-018-0843-1 | 10.1016/j.stem.2021.04.029 | 10.1186/s40478-025-02075-z | 10.1177/0963689720964383 | 10.1038/s41536-021-00195-3,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations. | NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study. | Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas. | A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,CD45,antibodies,Experimental Usage,,,
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,STEM121,antibodies,Experimental Usage,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,HLA-DR,antibodies,Experimental Usage,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,CD33,antibodies,Experimental Usage,,,
PMID:30542164 | PMID:38907342 | PMID:41149489 | PMID:36890585 | PMID:28256556,10.1038/s41586-018-0774-y | 10.1186/s40478-024-01821-z | 10.3390/curroncol32100569 | 10.1186/s40478-023-01525-w | 10.1038/srep43315,"Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. | snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response. | Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90. | Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic. | An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.",,CD11b,antibodies,Experimental Usage,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,CD9,antibodies,Experimental Usage,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,CD81,antibodies,Experimental Usage,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,TOMM20,antibodies,Experimental Usage,,,
PMID:41149489 | PMID:27956228,10.3390/curroncol32100569 | 10.1053/j.gastro.2016.12.002,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90. | Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,HSP90,antibodies,Experimental Usage,,,
PMID:36730269 | PMID:41149489 | PMID:33273014 | PMID:29847659 | PMID:20554030 | PMID:26219339 | PMID:21072183 | PMID:18483311 | PMID:38216572 | PMID:24371224 | PMID:32419643,10.1371/journal.pone.0277305 | 10.3390/curroncol32100569 | 10.1074/jbc.RA120.014960 | 10.1167/iovs.17-22588 | 10.1016/j.jneuroim.2010.05.002 | 10.18632/oncotarget.4858 | 10.1371/journal.pone.0013791 | 10.1158/1535-7163.MCT-07-2335 | 10.1038/s41467-024-44755-9 | 10.1158/0008-5472.CAN-13-2062 | 10.1177/1533033820919759,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90. | mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. | Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,AKT,antibodies,Experimental Usage,,,
PMID:33442015 | PMID:36730269 | PMID:41149489 | PMID:38216572 | PMID:24371224 | PMID:32419643,10.1038/s41591-020-01193-6 | 10.1371/journal.pone.0277305 | 10.3390/curroncol32100569 | 10.1038/s41467-024-44755-9 | 10.1158/0008-5472.CAN-13-2062 | 10.1177/1533033820919759,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. | Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. | Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,pAKT,antibodies,Experimental Usage,,,
PMID:36730269 | PMID:41564118 | PMID:41149489 | PMID:39129390 | PMID:29847659 | PMID:34257279 | PMID:38714355 | PMID:38216572 | PMID:18413802,10.1371/journal.pone.0277305 | 10.1371/journal.pone.0340183 | 10.3390/curroncol32100569 | 10.1002/1878-0261.13704 | 10.1167/iovs.17-22588 | 10.1038/s41467-021-24505-x | 10.1158/1535-7163.MCT-23-0510 | 10.1038/s41467-024-44755-9 | 10.1158/1535-7163.MCT-07-0518,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,ERK,antibodies,Experimental Usage,,,
PMID:32699356 | PMID:36730269 | PMID:41564118 | PMID:41149489 | PMID:27956228 | PMID:24509877 | PMID:24681606 | PMID:28166733 | PMID:40684195 | PMID:38216572 | PMID:37246765 | PMID:24371224 | PMID:25535838,10.1038/s41467-020-17382-3 | 10.1371/journal.pone.0277305 | 10.1371/journal.pone.0340183 | 10.3390/curroncol32100569 | 10.1053/j.gastro.2016.12.002 | 10.1038/onc.2013.506 | 10.18632/oncotarget.1609 | 10.1186/s12864-017-3519-7 | 10.1186/s40478-025-02075-z | 10.1038/s41467-024-44755-9 | 10.1093/neuonc/noad097 | 10.1158/0008-5472.CAN-13-2062 | 10.7554/eLife.05151,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90. | Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. | MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,p-Erk,antibodies,Experimental Usage,,,
PMID:41022755 | PMID:40590220 | PMID:21072183 | PMID:29670214 | PMID:37681415 | PMID:25043591 | PMID:20200958 | PMID:24375753,10.1038/s41467-025-63619-4 | 10.1172/JCI188932 | 10.1371/journal.pone.0013791 | 10.1038/s41598-018-24310-5 | 10.1172/jci.insight.168445 | 10.1002/jbmr.2316 | 10.1002/jbmr.42 | 10.1002/ana.24093,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. | Restoring functional neurofibromin by protein transduction. | Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation. | Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice. | Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts. | Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,ERK1/2,antibodies,Experimental Usage,,,
PMID:41022755 | PMID:24932921 | PMID:33436083 | PMID:33934112 | PMID:29670214 | PMID:25043591 | PMID:20200958,10.1038/s41467-025-63619-4 | 10.1002/jbmr.2298 | 10.1186/s13072-020-00380-6 | 10.1038/s41419-021-03716-6 | 10.1038/s41598-018-24310-5 | 10.1002/jbmr.2316 | 10.1002/jbmr.42,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1. | Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling. | HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | Restoring functional neurofibromin by protein transduction. | Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice. | Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,phospho-ERK1/2,antibodies,Experimental Usage,,,
PMID:40590220 | PMID:36420221 | PMID:31836666 | PMID:24595234 | PMID:36689660 | PMID:40225167 | PMID:16835260,10.1172/JCI188932 | 10.1016/j.omtn.2022.10.026 | 10.1074/jbc.RA119.010934 | 10.1371/journal.pone.0090853 | 10.1073/pnas.2208960120 | 10.1155/2023/9628049 | 10.1093/hmg/ddl165,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype | Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. | In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization. | Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome. | Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,Flag,antibodies,Experimental Usage,,,
PMID:31836666 | PMID:40225167,10.1074/jbc.RA119.010934 | 10.1155/2023/9628049,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. | Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,V5,antibodies,Experimental Usage,,,
PMID:41022755 | PMID:31836666 | PMID:40225167 | PMID:36689660,10.1038/s41467-025-63619-4 | 10.1074/jbc.RA119.010934 | 10.1155/2023/9628049 | 10.1073/pnas.2208960120,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. | Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,HA,antibodies,Experimental Usage,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,pEGFR,antibodies,Experimental Usage,,,
PMID:36730269 | PMID:31836666 | PMID:38502231 | PMID:37164978 | PMID:38481529 | PMID:38127282 | PMID:33658640 | PMID:36689660,10.1371/journal.pone.0277305 | 10.1074/jbc.RA119.010934 | 10.1172/JCI176748 | 10.1038/s41467-023-38432-6 | 10.3389/fcell.2024.1359561 | 10.1158/1078-0432.CCR-23-2548 | 10.1038/s41416-021-01270-8 | 10.1073/pnas.2208960120,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,Vinculin,antibodies,Experimental Usage,,,
PMID:31836666 | PMID:37681415 | PMID:36689660,10.1074/jbc.RA119.010934 | 10.1172/jci.insight.168445 | 10.1073/pnas.2208960120,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. | Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,KRAS,antibodies,Experimental Usage,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,collagen IV,antibodies,Experimental Usage,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,MyHC type 1,antibodies,Experimental Usage,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,MyHC type 2A,antibodies,Experimental Usage,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,laminin,antibodies,Experimental Usage,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,Pax7,antibodies,Experimental Usage,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,myosin heavy chain,antibodies,Experimental Usage,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,beta III tubulin,antibodies,Experimental Usage,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,perilipin A/B,antibodies,Experimental Usage,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,PPARG,antibodies,Experimental Usage,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,phosphor (pThr172) AMPKa,antibodies,Experimental Usage,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,AMPKα,antibodies,Experimental Usage,,,
PMID:33078583 | PMID:38201517 | PMID:41022755 | PMID:18451155 | PMID:32438526 | PMID:32457840 | PMID:24509877 | PMID:34040258 | PMID:33436083 | PMID:34011935 | PMID:41036607 | PMID:21072183 | PMID:26904939 | PMID:33934112 | PMID:20049725 | PMID:24371224 | PMID:23328114 | PMID:30274821 | PMID:32419643,10.1002/jcsm.12632 | 10.3390/cancers16010089 | 10.1038/s41467-025-63619-4 | 10.1158/0008-5472.CAN-07-6867 | 10.1002/lary.28671 | 10.3389/fonc.2020.00687 | 10.1038/onc.2013.506 | 10.1038/s41586-021-03580-6 | 10.1186/s13072-020-00380-6 | 10.1038/s41419-021-03802-9 | 10.1158/1535-7163.MCT-24-1053 | 10.1371/journal.pone.0013791 | 10.1016/j.celrep.2016.01.074 | 10.1038/s41419-021-03716-6 | 10.1002/emmm.200900027 | 10.1158/0008-5472.CAN-13-2062 | 10.18632/oncotarget.793 | 10.1016/j.ebiom.2018.09.042 | 10.1177/1533033820919759,"Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis. | Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers. | Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | Pten haploinsufficiency accelerates formation of high-grade astrocytomas. | Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells. | TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling. | MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling. | Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine. | Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors. | p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation. | HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. | Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. | Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.",,β-actin,antibodies,Experimental Usage,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,phosphor (s235/236) S6,antibodies,Experimental Usage,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,MyHC type 2B,antibodies,Experimental Usage,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,phosphor (Ser473) AKT,antibodies,Experimental Usage,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,phospho (Ser1101) IRS-1,antibodies,Experimental Usage,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,phospho (Ser636/639) IRS-1,antibodies,Experimental Usage,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,DIG-Fab,antibodies,Experimental Usage,,,
PMID:38201517 | PMID:18367665 | PMID:18413802 | PMID:36689660,10.3390/cancers16010089 | 10.1124/jpet.107.135830 | 10.1158/1535-7163.MCT-07-0518 | 10.1073/pnas.2208960120,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers. | Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,RAS,antibodies,Experimental Usage,,,
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,N-RAS,antibodies,Experimental Usage,,,
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,RAB5A,antibodies,Experimental Usage,,,
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,RAP1A,antibodies,Experimental Usage,,,
PMID:38201517 | PMID:33442015 | PMID:32383545 | PMID:23175151 | PMID:37446790 | PMID:32461556 | PMID:33273014 | PMID:38502231 | PMID:39129390 | PMID:28126595 | PMID:23535903 | PMID:24681606 | PMID:34065204 | PMID:23685747 | PMID:26219339 | PMID:38714355 | PMID:36148553 | PMID:38203448 | PMID:24824755 | PMID:29847659 | PMID:29670214 | PMID:25043298 | PMID:36241865,10.3390/cancers16010089 | 10.1038/s41591-020-01193-6 | 10.15252/embr.201949117 | 10.1038/bjc.2012.518 | 10.3390/molecules28135128 | 10.1038/s41467-020-16432-0 | 10.1074/jbc.RA120.014960 | 10.1172/JCI176748 | 10.1002/1878-0261.13704 | 10.1016/j.ebiom.2017.01.020 | 10.1158/2159-8290.CD-13-0081 | 10.18632/oncotarget.1609 | 10.3390/ijms22105367 | 10.1038/ng.2641 | 10.18632/oncotarget.4858 | 10.1158/1535-7163.MCT-23-0510 | 10.1093/brain/awac342 | 10.3390/ijms25010277 | 10.1371/journal.pone.0096733 | 10.1167/iovs.17-22588 | 10.1038/s41598-018-24310-5 | 10.1038/onc.2014.185 | 10.1038/s12276-022-00850-9,"Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers. | Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. | Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca | MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression. | Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway. | Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. | mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target. | Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | Restoring functional neurofibromin by protein transduction. | Oncogenic role of Merlin/NF2 in glioblastoma. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.",,GAPDH,antibodies,Experimental Usage,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,MYF-4,antibodies,Experimental Usage,,,
PMID:24040940 | PMID:25851896 | PMID:30479396 | PMID:24681606 | PMID:40025578 | PMID:30055648 | PMID:18636037 | PMID:38744290 | PMID:36148553 | PMID:33356508 | PMID:41001593 | PMID:33591953 | PMID:36598417 | PMID:21111000 | PMID:33767727 | PMID:15255999 | PMID:15240917 | PMID:19144871,10.1186/1479-5876-11-213 | 10.3988/jcn.2015.11.2.172 | 10.1038/s41467-018-07452-y | 10.18632/oncotarget.1609 | 10.1186/s40478-025-01965-6 | 10.1186/s13104-018-3630-0 | 10.1097/MAO.0b013e31817f7398 | 10.1016/j.crmeth.2024.100772 | 10.1093/brain/awac342 | 10.1177/0963689720964383 | 10.1080/23723556.2025.2561292 | 10.1172/jci.insight.146351 | 10.1158/2159-8290.CD-22-0786 | 10.1016/j.jneumeth.2010.10.021 | 10.3389/fgene.2021.603195 | 10.1186/1476-4598-3-20 | 10.1155/S1110724304308107 | 10.3181/0809-RM-275,"Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors. | Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures. | NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study. | A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma. | C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas. | Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor. | Chromosome 8 gain is associated with high-grade transformation in MPNST. | Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA. | A novel imaging-compatible sciatic nerve schwannoma model. | Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing. | Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR. | Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone. | Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.",,S100,antibodies,Experimental Usage,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,HMB45,antibodies,Experimental Usage,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,Melan-A,antibodies,Experimental Usage,,,
PMID:29941005 | PMID:25851896,10.1186/s13023-018-0843-1 | 10.3988/jcn.2015.11.2.172,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study. | Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,CD90,antibodies,Experimental Usage,,,
PMID:41022755 | PMID:38175707 | PMID:41444363 | PMID:38216572 | PMID:37246765 | PMID:39110684 | PMID:34646065,10.1038/s41467-025-63619-4 | 10.1172/jci.insight.168826 | 10.1038/s41598-025-32031-9 | 10.1038/s41467-024-44755-9 | 10.1093/neuonc/noad097 | 10.1371/journal.pone.0308207 | 10.1155/2021/9386823,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas. | Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology. | Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers. | Survival and,,S100B,antibodies,Experimental Usage,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,HMGA2,antibodies,Experimental Usage,,,
PMID:27956228 | PMID:24371224,10.1053/j.gastro.2016.12.002 | 10.1158/0008-5472.CAN-13-2062,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,beta-Catenin,antibodies,Experimental Usage,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,CK19,antibodies,Experimental Usage,,,
PMID:27956228 | PMID:24509877 | PMID:20049725 | PMID:32396062,10.1053/j.gastro.2016.12.002 | 10.1038/onc.2013.506 | 10.1002/emmm.200900027 | 10.7554/eLife.55137,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. | MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,SOX9,antibodies,Experimental Usage,,,
PMID:32457840 | PMID:20195187 | PMID:21072183 | PMID:31015291 | PMID:28126595 | PMID:29715273 | PMID:30274821 | PMID:39415595 | PMID:38945076 | PMID:24595234,10.3389/fonc.2020.00687 | 10.1097/MAO.0b013e3181d2777f | 10.1371/journal.pone.0013791 | 10.1126/scisignal.aau8749 | 10.1016/j.ebiom.2017.01.020 | 10.1371/journal.pone.0196726 | 10.1016/j.ebiom.2018.09.042 | 10.1242/dmm.050862 | 10.1016/j.redox.2024.103249 | 10.1371/journal.pone.0090853,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling. | Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis. | p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. | Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins. | Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target. | Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. | Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b. | Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation. | In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.",,Merlin,antibodies,Experimental Usage,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,collagen XV,antibodies,Experimental Usage,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,collagen XVIII,antibodies,Experimental Usage,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,K1,antibodies,Experimental Usage,,,
PMID:41022755 | PMID:28166733 | PMID:38714355 | PMID:39472976 | PMID:41564118 | PMID:30479396 | PMID:39129390 | PMID:34257279 | PMID:34011935 | PMID:25535838,10.1038/s41467-025-63619-4 | 10.1186/s12864-017-3519-7 | 10.1158/1535-7163.MCT-23-0510 | 10.1186/s40478-024-01875-z | 10.1371/journal.pone.0340183 | 10.1038/s41467-018-07452-y | 10.1002/1878-0261.13704 | 10.1038/s41467-021-24505-x | 10.1038/s41419-021-03802-9 | 10.7554/eLife.05151,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma. | NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes. | Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila. | Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,NF1,antibodies,Experimental Usage,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,LUMICAN,antibodies,Experimental Usage,,,
PMID:30542164 | PMID:30479396 | PMID:38502231 | PMID:30531922 | PMID:36322658 | PMID:38216587 | PMID:39321200 | PMID:37410426,10.1038/s41586-018-0774-y | 10.1038/s41467-018-07452-y | 10.1172/JCI176748 | 10.1038/s41591-018-0263-8 | 10.1126/sciadv.abo5442 | 10.1038/s41467-023-40408-5 | 10.1158/1078-0432.CCR-24-1454 | 10.1158/1078-0432.CCR-23-0749,"Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. | NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | The molecular landscape of glioma in patients with Neurofibromatosis 1. | Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Epigenetic reprogramming shapes the cellular landscape of schwannoma. | Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment. | CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,CD3,antibodies,Experimental Usage,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,CD28,antibodies,Experimental Usage,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,CD69,antibodies,Experimental Usage,,,
PMID:30479396 | PMID:38502231 | PMID:40025578,10.1038/s41467-018-07452-y | 10.1172/JCI176748 | 10.1186/s40478-025-01965-6,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,CD4,antibodies,Experimental Usage,,,
PMID:30479396 | PMID:30531922 | PMID:34040258 | PMID:39321200,10.1038/s41467-018-07452-y | 10.1038/s41591-018-0263-8 | 10.1038/s41586-021-03580-6 | 10.1158/1078-0432.CCR-24-1454,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | The molecular landscape of glioma in patients with Neurofibromatosis 1. | NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,CD8,antibodies,Experimental Usage,,,
PMID:30479396 | PMID:38502231 | PMID:33356508 | PMID:39321200,10.1038/s41467-018-07452-y | 10.1172/JCI176748 | 10.1177/0963689720964383 | 10.1158/1078-0432.CCR-24-1454,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas. | Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,FoxP3,antibodies,Experimental Usage,,,
PMID:30479396 | PMID:37410426,10.1038/s41467-018-07452-y | 10.1158/1078-0432.CCR-23-0749,"NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,B220,antibodies,Experimental Usage,,,
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,MIA,antibodies,Experimental Usage,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,AQP4,antibodies,Experimental Usage,,,
PMID:36730269 | PMID:19191334,10.1371/journal.pone.0277305 | 10.1002/glia.20845,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,NG2,antibodies,Experimental Usage,,,
PMID:19191334 | PMID:25772366,10.1002/glia.20845 | 10.1016/j.celrep.2015.02.041,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,O4,antibodies,Experimental Usage,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,LHX2,antibodies,Experimental Usage,,,
PMID:19191334 | PMID:37164978,10.1002/glia.20845 | 10.1038/s41467-023-38432-6,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,APC,antibodies,Experimental Usage,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,FOXG1,antibodies,Experimental Usage,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,FOXP2,antibodies,Experimental Usage,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,HOXB3,antibodies,Experimental Usage,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,GLAST,antibodies,Experimental Usage,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,NF1GRP-D,antibodies,Experimental Usage,,,
PMID:19191334 | PMID:32642733 | PMID:38203448 | PMID:21216928,10.1002/glia.20845 | 10.1093/noajnl/vdz061 | 10.3390/ijms25010277 | 10.1158/1535-7163.MCT-10-0654,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,α-tubulin,antibodies,Experimental Usage,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,DDK tag,antibodies,Experimental Usage,,,
PMID:31015291 | PMID:40684195,10.1126/scisignal.aau8749 | 10.1186/s40478-025-02075-z,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,RFP,antibodies,Experimental Usage,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,YAP1,antibodies,Experimental Usage,,,
PMID:36730269 | PMID:40225167,10.1371/journal.pone.0277305 | 10.1155/2023/9628049,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,MYC,antibodies,Experimental Usage,,,
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,phosphorylated ERK Thr202/Tyr204,antibodies,Experimental Usage,,,
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,phosphorylated Akt Ser473,antibodies,Experimental Usage,,,
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,phosphorylated S6 Ser235/236,antibodies,Experimental Usage,,,
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,γH2AX Ser139,antibodies,Experimental Usage,,,
PMID:33934112 | PMID:35393510 | PMID:33658640 | PMID:24824755,10.1038/s41419-021-03716-6 | 10.1038/s41418-022-00991-4 | 10.1038/s41416-021-01270-8 | 10.1371/journal.pone.0096733,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,HIF1α,antibodies,Experimental Usage,,,
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,BNIP3,antibodies,Experimental Usage,,,
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,BECLIN1,antibodies,Experimental Usage,,,
PMID:38203448 | PMID:24824755,10.3390/ijms25010277 | 10.1371/journal.pone.0096733,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,LC3,antibodies,Experimental Usage,,,
PMID:32699356 | PMID:32948135 | PMID:32461556 | PMID:35945463 | PMID:30274821 | PMID:30055648 | PMID:24371224,10.1038/s41467-020-17382-3 | 10.1186/s12885-020-07397-w | 10.1038/s41467-020-16432-0 | 10.1007/s00401-022-02478-5 | 10.1016/j.ebiom.2018.09.042 | 10.1186/s13104-018-3630-0 | 10.1158/0008-5472.CAN-13-2062,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model. | Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,p53,antibodies,Experimental Usage,,,
PMID:32699356 | PMID:18451155 | PMID:29715273 | PMID:35945463 | PMID:20554030 | PMID:20551058,10.1038/s41467-020-17382-3 | 10.1158/0008-5472.CAN-07-6867 | 10.1371/journal.pone.0196726 | 10.1007/s00401-022-02478-5 | 10.1016/j.jneuroim.2010.05.002 | 10.1158/0008-5472.CAN-09-3769,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | Pten haploinsufficiency accelerates formation of high-grade astrocytomas. | Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Olig2,antibodies,Experimental Usage,,,
PMID:32699356 | PMID:18451155,10.1038/s41467-020-17382-3 | 10.1158/0008-5472.CAN-07-6867,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,Pten,antibodies,Experimental Usage,,,
PMID:32699356 | PMID:24509877 | PMID:25535838,10.1038/s41467-020-17382-3 | 10.1038/onc.2013.506 | 10.7554/eLife.05151,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,p-S6,antibodies,Experimental Usage,,,
PMID:32699356 | PMID:36322658 | PMID:29438698 | PMID:18636037 | PMID:18242513 | PMID:32396062 | PMID:25535838,10.1038/s41467-020-17382-3 | 10.1126/sciadv.abo5442 | 10.1016/j.ccell.2018.01.005 | 10.1097/MAO.0b013e31817f7398 | 10.1016/j.ccr.2008.01.003 | 10.7554/eLife.55137 | 10.7554/eLife.05151,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study. | The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. | Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,BrdU,antibodies,Experimental Usage,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,PAX8,antibodies,Experimental Usage,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,Ac-alpha-Tubulin,antibodies,Experimental Usage,,,
PMID:32461556 | PMID:24371224,10.1038/s41467-020-16432-0 | 10.1158/0008-5472.CAN-13-2062,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,Cytokeratin-8,antibodies,Experimental Usage,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,γH2A.X,antibodies,Experimental Usage,,,
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,ABCC1,antibodies,Experimental Usage,,,
PMID:34415582 | PMID:20551058,10.1002/glia.24075 | 10.1158/0008-5472.CAN-09-3769,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,mCherry,antibodies,Experimental Usage,,,
PMID:34415582 | PMID:32396062,10.1002/glia.24075 | 10.7554/eLife.55137,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury. | Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,glutamine synthetase,antibodies,Experimental Usage,,,
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,NHE1,antibodies,Experimental Usage,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,ERBB3 Y1197,antibodies,Experimental Usage,,,
PMID:33273014 | PMID:20195187,10.1074/jbc.RA120.014960 | 10.1097/MAO.0b013e3181d2777f,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,ERBB3,antibodies,Experimental Usage,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,EPHA2 S897,antibodies,Experimental Usage,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,NDRG1 T346,antibodies,Experimental Usage,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,Akt S473,antibodies,Experimental Usage,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,Akt T308,antibodies,Experimental Usage,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,p70S6K T389,antibodies,Experimental Usage,,,
PMID:33273014 | PMID:26219339,10.1074/jbc.RA120.014960 | 10.18632/oncotarget.4858,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,p70S6K,antibodies,Experimental Usage,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,ribosomal S6 S240/244,antibodies,Experimental Usage,,,
PMID:33273014 | PMID:26219339,10.1074/jbc.RA120.014960 | 10.18632/oncotarget.4858,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,S6,antibodies,Experimental Usage,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,IGF1R Y1135/36/IR Y1150/51,antibodies,Experimental Usage,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,IGF1R,antibodies,Experimental Usage,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,FOXO1/3a T24/T32,antibodies,Experimental Usage,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,FOXO3,antibodies,Experimental Usage,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,EPHA2,antibodies,Experimental Usage,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,secreted form of NRG1,antibodies,Experimental Usage,,,
PMID:33273014 | PMID:26219339,10.1074/jbc.RA120.014960 | 10.18632/oncotarget.4858,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,NDRG1,antibodies,Experimental Usage,,,
PMID:33273014 | PMID:38216572 | PMID:19144871,10.1074/jbc.RA120.014960 | 10.1038/s41467-024-44755-9 | 10.3181/0809-RM-275,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,NF2/merlin,antibodies,Experimental Usage,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,STING,antibodies,Experimental Usage,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,TBK1,antibodies,Experimental Usage,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,p-TBK1,antibodies,Experimental Usage,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,IRF3,antibodies,Experimental Usage,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,p-IRF3,antibodies,Experimental Usage,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,NF-κB,antibodies,Experimental Usage,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,p-NF-κB,antibodies,Experimental Usage,,,
PMID:38502231 | PMID:40025578 | PMID:39321200 | PMID:37410426,10.1172/JCI176748 | 10.1186/s40478-025-01965-6 | 10.1158/1078-0432.CCR-24-1454 | 10.1158/1078-0432.CCR-23-0749,"STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment. | Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment. | CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,PD-L1,antibodies,Experimental Usage,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,CTLA-4,antibodies,Experimental Usage,,,
PMID:38502231 | PMID:30531922,10.1172/JCI176748 | 10.1038/s41591-018-0263-8,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | The molecular landscape of glioma in patients with Neurofibromatosis 1.,,CD20,antibodies,Experimental Usage,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,CD8α,antibodies,Experimental Usage,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,iNOS,antibodies,Experimental Usage,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,mannose receptor,antibodies,Experimental Usage,,,
PMID:38502231 | PMID:39415595,10.1172/JCI176748 | 10.1242/dmm.050862,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,p-H3,antibodies,Experimental Usage,,,
PMID:38502231 | PMID:38714355 | PMID:33658640,10.1172/JCI176748 | 10.1158/1535-7163.MCT-23-0510 | 10.1038/s41416-021-01270-8,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,cleaved PARP,antibodies,Experimental Usage,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,PD-1,antibodies,Experimental Usage,,,
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,IL6 receptor,antibodies,Experimental Usage,,,
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,TNFα,antibodies,Experimental Usage,,,
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,IL3,antibodies,Experimental Usage,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,βIII-tubulin,antibodies,Experimental Usage,,,
PMID:41022755 | PMID:38744290,10.1038/s41467-025-63619-4 | 10.1016/j.crmeth.2024.100772,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,NGFR,antibodies,Experimental Usage,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,Human Nuclear Antigen,antibodies,Experimental Usage,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,Drosophila neurofibromin,antibodies,Experimental Usage,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,human neurofibromin,antibodies,Experimental Usage,,,
PMID:39129390 | PMID:29847659 | PMID:34257279 | PMID:34011935 | PMID:38714355 | PMID:39472976 | PMID:18413802,10.1002/1878-0261.13704 | 10.1167/iovs.17-22588 | 10.1038/s41467-021-24505-x | 10.1038/s41419-021-03802-9 | 10.1158/1535-7163.MCT-23-0510 | 10.1186/s40478-024-01875-z | 10.1158/1535-7163.MCT-07-0518,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila. | Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma. | NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,phospho-ERK,antibodies,Experimental Usage,,,
PMID:39129390 | PMID:33658640 | PMID:25043298,10.1002/1878-0261.13704 | 10.1038/s41416-021-01270-8 | 10.1038/onc.2014.185,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | Oncogenic role of Merlin/NF2 in glioblastoma.,,PARP,antibodies,Experimental Usage,,,
PMID:39129390 | PMID:38203448,10.1002/1878-0261.13704 | 10.3390/ijms25010277,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,LC3B,antibodies,Experimental Usage,,,
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,p44/42 MAPK (ERK1/2),antibodies,Experimental Usage,,,
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2),antibodies,Experimental Usage,,,
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,phosphatidylinositol 3-kinase (PI3K),antibodies,Experimental Usage,,,
PMID:31462295 | PMID:30531922 | PMID:35945463,10.1186/s40478-019-0792-5 | 10.1038/s41591-018-0263-8 | 10.1007/s00401-022-02478-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors. | The molecular landscape of glioma in patients with Neurofibromatosis 1. | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,ATRX,antibodies,Experimental Usage,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,GZMB,antibodies,Experimental Usage,,,
PMID:30531922 | PMID:38216587,10.1038/s41591-018-0263-8 | 10.1038/s41467-023-40408-5,The molecular landscape of glioma in patients with Neurofibromatosis 1. | Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,CD68,antibodies,Experimental Usage,,,
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,"indoleamine 2,3-dioxygenase",antibodies,Experimental Usage,,,
PMID:38931352 | PMID:34011935,10.3390/ph17060685 | 10.1038/s41419-021-03802-9,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer. | Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,AHR,antibodies,Experimental Usage,,,
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,TDO2,antibodies,Experimental Usage,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,phospho-Merlin,antibodies,Experimental Usage,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,HDAC1,antibodies,Experimental Usage,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,PDLIM2,antibodies,Experimental Usage,,,
PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,EMA,antibodies,Experimental Usage,,,
PMID:30055648 | PMID:33356508 | PMID:39996452,10.1186/s13104-018-3630-0 | 10.1177/0963689720964383 | 10.1111/cns.70287,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas. | Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,vimentin,antibodies,Experimental Usage,,,
PMID:33442015 | PMID:29847659 | PMID:41444363 | PMID:34010628 | PMID:18483311 | PMID:38127282,10.1038/s41591-020-01193-6 | 10.1167/iovs.17-22588 | 10.1038/s41598-025-32031-9 | 10.1016/j.stem.2021.04.029 | 10.1158/1535-7163.MCT-07-2335 | 10.1158/1078-0432.CCR-23-2548,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model. | Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,CD31,antibodies,Experimental Usage,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,AXL,antibodies,Experimental Usage,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,pAXL,antibodies,Experimental Usage,,,
PMID:33442015 | PMID:26904939,10.1038/s41591-020-01193-6 | 10.1016/j.celrep.2016.01.074,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,pGSK-3β,antibodies,Experimental Usage,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,pMEK1/2,antibodies,Experimental Usage,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,CalbindinD-28K,antibodies,Experimental Usage,,,
PMID:29715273 | PMID:24509877 | PMID:40684195,10.1371/journal.pone.0196726 | 10.1038/onc.2013.506 | 10.1186/s40478-025-02075-z,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,MBP,antibodies,Experimental Usage,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,phospho-Histone H3,antibodies,Experimental Usage,,,
PMID:29715273 | PMID:26219339,10.1371/journal.pone.0196726 | 10.18632/oncotarget.4858,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,NF2,antibodies,Experimental Usage,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,phospho S518-Merlin,antibodies,Experimental Usage,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,cyclophilin B,antibodies,Experimental Usage,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,MAF,antibodies,Experimental Usage,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,DEPTOR,antibodies,Experimental Usage,,,
PMID:24509877 | PMID:21551250 | PMID:34040258 | PMID:40025578 | PMID:26904939 | PMID:40684195 | PMID:20049725,10.1038/onc.2013.506 | 10.1158/0008-5472.CAN-10-4577 | 10.1038/s41586-021-03580-6 | 10.1186/s40478-025-01965-6 | 10.1016/j.celrep.2016.01.074 | 10.1186/s40478-025-02075-z | 10.1002/emmm.200900027,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development. | NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,S100β,antibodies,Experimental Usage,,,
PMID:24509877 | PMID:25535838,10.1038/onc.2013.506 | 10.7554/eLife.05151,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,BLBP,antibodies,Experimental Usage,,,
PMID:29941005 | PMID:30055648 | PMID:38744290 | PMID:33767727,10.1186/s13023-018-0843-1 | 10.1186/s13104-018-3630-0 | 10.1016/j.crmeth.2024.100772 | 10.3389/fgene.2021.603195,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening. | Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,CD34,antibodies,Experimental Usage,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,RHAMM,antibodies,Experimental Usage,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,TPX2,antibodies,Experimental Usage,,,
PMID:18451155 | PMID:36322658 | PMID:40684195 | PMID:23328114 | PMID:36241865,10.1158/0008-5472.CAN-07-6867 | 10.1126/sciadv.abo5442 | 10.1186/s40478-025-02075-z | 10.18632/oncotarget.793 | 10.1038/s12276-022-00850-9,Pten haploinsufficiency accelerates formation of high-grade astrocytomas. | Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,nestin,antibodies,Experimental Usage,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,AURKA,antibodies,Experimental Usage,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,phospho-AURKA (Thr288),antibodies,Experimental Usage,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,p-histone H3 (Ser10),antibodies,Experimental Usage,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,p-RHAMM (Thr703),antibodies,Experimental Usage,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,PDGFRβ,antibodies,Experimental Usage,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,α-SMA,antibodies,Experimental Usage,,,
PMID:36322658 | PMID:33934112 | PMID:38203448,10.1126/sciadv.abo5442 | 10.1038/s41419-021-03716-6 | 10.3390/ijms25010277,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,GLUT1,antibodies,Experimental Usage,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,VEGFA,antibodies,Experimental Usage,,,
PMID:36322658 | PMID:36148553,10.1126/sciadv.abo5442 | 10.1093/brain/awac342,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,ALDH1A1,antibodies,Experimental Usage,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,ZEB1,antibodies,Experimental Usage,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,IGFBP2,antibodies,Experimental Usage,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,EYA4,antibodies,Experimental Usage,,,
PMID:36730269 | PMID:36322658 | PMID:38744290 | PMID:36241865 | PMID:24371224,10.1371/journal.pone.0277305 | 10.1126/sciadv.abo5442 | 10.1016/j.crmeth.2024.100772 | 10.1038/s12276-022-00850-9 | 10.1158/0008-5472.CAN-13-2062,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,SOX2,antibodies,Experimental Usage,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,YAP/TAZ,antibodies,Experimental Usage,,,
PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,,GAP43,antibodies,Experimental Usage,,,
PMID:37520682 | PMID:28256556,10.1016/j.omtn.2023.06.018 | 10.1038/srep43315,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1. | An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,p75 NGFR,antibodies,Experimental Usage,,,
PMID:34040258 | PMID:40684195,10.1038/s41586-021-03580-6 | 10.1186/s40478-025-02075-z,NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,PDGFRα,antibodies,Experimental Usage,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,NLGN3,antibodies,Experimental Usage,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,ADAM10,antibodies,Experimental Usage,,,
PMID:34040258 | PMID:30274821 | PMID:35511749 | PMID:38216572 | PMID:18367665,10.1038/s41586-021-03580-6 | 10.1016/j.ebiom.2018.09.042 | 10.1158/1535-7163.MCT-21-0947 | 10.1038/s41467-024-44755-9 | 10.1124/jpet.107.135830,NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,caspase-3,antibodies,Experimental Usage,,,
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,tau 1,antibodies,Experimental Usage,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,B-Actin,antibodies,Experimental Usage,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,PTCH1,antibodies,Experimental Usage,,,
PMID:23535903 | PMID:26904939,10.1158/2159-8290.CD-13-0081 | 10.1016/j.celrep.2016.01.074,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.",,β-catenin,antibodies,Experimental Usage,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,activated β-catenin,antibodies,Experimental Usage,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,GSK3B,antibodies,Experimental Usage,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,AXIN1,antibodies,Experimental Usage,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,CCND1,antibodies,Experimental Usage,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,HK2,antibodies,Experimental Usage,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,MPP2,antibodies,Experimental Usage,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,ATP5A,antibodies,Experimental Usage,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,UQCRC2,antibodies,Experimental Usage,,,
PMID:32383545 | PMID:23175151,10.15252/embr.201949117 | 10.1038/bjc.2012.518,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca | MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,MMP9,antibodies,Experimental Usage,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,TOM20,antibodies,Experimental Usage,,,
PMID:36730269 | PMID:41564118 | PMID:38481529,10.1371/journal.pone.0277305 | 10.1371/journal.pone.0340183 | 10.3389/fcell.2024.1359561,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,Beta-Actin,antibodies,Experimental Usage,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,neurofibromin/NF1,antibodies,Experimental Usage,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,FBXW11/bTrCP2,antibodies,Experimental Usage,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,pERK Thr202/Tyr204,antibodies,Experimental Usage,,,
PMID:35614131 | PMID:33934112,10.1038/s41418-022-01020-0 | 10.1038/s41419-021-03716-6,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation. | HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,TRAP1,antibodies,Experimental Usage,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,ATP50/OSCP,antibodies,Experimental Usage,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,ATPB,antibodies,Experimental Usage,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,SDHA,antibodies,Experimental Usage,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,Cyclophilin,antibodies,Experimental Usage,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,synaptophysin,antibodies,Experimental Usage,,,
PMID:35945463 | PMID:34065204 | PMID:30055648,10.1007/s00401-022-02478-5 | 10.3390/ijms22105367 | 10.1186/s13104-018-3630-0,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,p16,antibodies,Experimental Usage,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,histone H3 K27M mutant protein,antibodies,Experimental Usage,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,histone H3 lysine 27 trimethylation,antibodies,Experimental Usage,,,
PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,CD16/CD32,antibodies,Experimental Usage,,,
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,MMP2,antibodies,Experimental Usage,,,
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,MMP3,antibodies,Experimental Usage,,,
PMID:40217315 | PMID:24371224,10.1186/s13073-025-01462-4 | 10.1158/0008-5472.CAN-13-2062,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,CD24,antibodies,Experimental Usage,,,
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,CD44,antibodies,Experimental Usage,,,
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,HLA Class I ABC,antibodies,Experimental Usage,,,
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,MHC Class II,antibodies,Experimental Usage,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,Pericentrin,antibodies,Experimental Usage,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,γTubulin,antibodies,Experimental Usage,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,Acetylated Tubulin,antibodies,Experimental Usage,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,CD13,antibodies,Experimental Usage,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,CD14,antibodies,Experimental Usage,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,CD105,antibodies,Experimental Usage,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,CD146,antibodies,Experimental Usage,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,CD271,antibodies,Experimental Usage,,,
PMID:37990867 | PMID:24371224,10.1242/dmm.049861 | 10.1158/0008-5472.CAN-13-2062,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,OCT3/4,antibodies,Experimental Usage,,,
PMID:37990867 | PMID:24371224,10.1242/dmm.049861 | 10.1158/0008-5472.CAN-13-2062,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,NANOG,antibodies,Experimental Usage,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,TRA-1-60,antibodies,Experimental Usage,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,SSEA-4,antibodies,Experimental Usage,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,MKK3,antibodies,Experimental Usage,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,p38,antibodies,Experimental Usage,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,phospho-p38,antibodies,Experimental Usage,,,
PMID:29438698 | PMID:36148553,10.1016/j.ccell.2018.01.005 | 10.1093/brain/awac342,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,TAZ,antibodies,Experimental Usage,,,
PMID:29438698 | PMID:36148553,10.1016/j.ccell.2018.01.005 | 10.1093/brain/awac342,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,YAP,antibodies,Experimental Usage,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,TAZ/YAP,antibodies,Experimental Usage,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,TEAD1,antibodies,Experimental Usage,,,
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,phospho-Akt,antibodies,Experimental Usage,,,
PMID:36730269 | PMID:36689660,10.1371/journal.pone.0277305 | 10.1073/pnas.2208960120,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,Ubiquitin,antibodies,Experimental Usage,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,pCHEK1 S296,antibodies,Experimental Usage,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,BMI1,antibodies,Experimental Usage,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,H3K27Ac,antibodies,Experimental Usage,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,H3,antibodies,Experimental Usage,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,CDK9,antibodies,Experimental Usage,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,CPNase,antibodies,Experimental Usage,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,MAG,antibodies,Experimental Usage,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,pS2 RNApol II,antibodies,Experimental Usage,,,
PMID:20195187 | PMID:28166733 | PMID:25043298,10.1097/MAO.0b013e3181d2777f | 10.1186/s12864-017-3519-7 | 10.1038/onc.2014.185,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis. | A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma. | Oncogenic role of Merlin/NF2 in glioblastoma.,,EGFR,antibodies,Experimental Usage,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,ErbB2,antibodies,Experimental Usage,,,
PMID:20195187 | PMID:30055648 | PMID:36420221 | PMID:33658640,10.1097/MAO.0b013e3181d2777f | 10.1186/s13104-018-3630-0 | 10.1016/j.omtn.2022.10.026 | 10.1038/s41416-021-01270-8,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,actin,antibodies,Experimental Usage,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,MPM-2,antibodies,Experimental Usage,,,
PMID:32948135 | PMID:30274821 | PMID:33032988 | PMID:18413802,10.1186/s12885-020-07397-w | 10.1016/j.ebiom.2018.09.042 | 10.1158/0008-5472.CAN-20-1365 | 10.1158/1535-7163.MCT-07-0518,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,cyclin D1,antibodies,Experimental Usage,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,B-Raf,antibodies,Experimental Usage,,,
PMID:34011935 | PMID:18413802,10.1038/s41419-021-03802-9 | 10.1158/1535-7163.MCT-07-0518,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,phospho-MEK1/2,antibodies,Experimental Usage,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,phospho-Rb,antibodies,Experimental Usage,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,MDM2,antibodies,Experimental Usage,,,
PMID:20554030 | PMID:20551058,10.1016/j.jneuroim.2010.05.002 | 10.1158/0008-5472.CAN-09-3769,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,CXCL12,antibodies,Experimental Usage,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,Endoglin,antibodies,Experimental Usage,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,p-PKA substrate,antibodies,Experimental Usage,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,pS473-AKT,antibodies,Experimental Usage,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,CXCR4,antibodies,Experimental Usage,,,
PMID:18451155 | PMID:20554030 | PMID:23685747 | PMID:36241865 | PMID:20551058,10.1158/0008-5472.CAN-07-6867 | 10.1016/j.jneuroim.2010.05.002 | 10.1038/ng.2641 | 10.1038/s12276-022-00850-9 | 10.1158/0008-5472.CAN-09-3769,Pten haploinsufficiency accelerates formation of high-grade astrocytomas. | CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,CNPase,antibodies,Experimental Usage,,,
PMID:20554030 | PMID:20551058,10.1016/j.jneuroim.2010.05.002 | 10.1158/0008-5472.CAN-09-3769,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,phosphorylated CXCR4,antibodies,Experimental Usage,,,
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,phosphorylated PKA,antibodies,Experimental Usage,,,
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,PKA,antibodies,Experimental Usage,,,
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,phosphorylated CREB,antibodies,Experimental Usage,,,
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,CREB,antibodies,Experimental Usage,,,
PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,P-glycoprotein,antibodies,Experimental Usage,,,
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,p-4EBP,antibodies,Experimental Usage,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,HSP70,antibodies,Experimental Usage,,,
PMID:21072183 | PMID:36689660,10.1371/journal.pone.0013791 | 10.1073/pnas.2208960120,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,GST,antibodies,Experimental Usage,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,RASA1,antibodies,Experimental Usage,,,
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,p-RB1-S807/811,antibodies,Experimental Usage,,,
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,RB1,antibodies,Experimental Usage,,,
PMID:34065204 | PMID:37410426,10.3390/ijms22105367 | 10.1158/1078-0432.CCR-23-0749,"RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner. | CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,RABL6A,antibodies,Experimental Usage,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,nc82,antibodies,Experimental Usage,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,FOXR2,antibodies,Experimental Usage,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,Nuclear Pore Complex Proteins,antibodies,Experimental Usage,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,HER1,antibodies,Experimental Usage,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,HER2,antibodies,Experimental Usage,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,VEGFR2,antibodies,Experimental Usage,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,B7H3,antibodies,Experimental Usage,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,CD171,antibodies,Experimental Usage,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,EGFRvIII,antibodies,Experimental Usage,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,TGFβ1,antibodies,Experimental Usage,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,CD8a,antibodies,Experimental Usage,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,CD45RO,antibodies,Experimental Usage,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,CCR7,antibodies,Experimental Usage,,,
PMID:21072183 | PMID:34011935,10.1371/journal.pone.0013791 | 10.1038/s41419-021-03802-9,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. | Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,Mek1/2,antibodies,Experimental Usage,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,MMP1,antibodies,Experimental Usage,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,collagen I,antibodies,Experimental Usage,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,S100 protein,antibodies,Experimental Usage,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,neurofibromin 1,antibodies,Experimental Usage,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,Ki67 antigen,antibodies,Experimental Usage,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,glial fibrillary acidic protein,antibodies,Experimental Usage,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,phosphorylated Akt,antibodies,Experimental Usage,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,BrdUrd,antibodies,Experimental Usage,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,doublecortin,antibodies,Experimental Usage,,,
PMID:18451155 | PMID:36241865,10.1158/0008-5472.CAN-07-6867 | 10.1038/s12276-022-00850-9,Pten haploinsufficiency accelerates formation of high-grade astrocytomas. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,β3-tubulin,antibodies,Experimental Usage,,,
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,S100A10,antibodies,Experimental Usage,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,Cdk1,antibodies,Experimental Usage,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,phospho-Cdk1 Tyr15,antibodies,Experimental Usage,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,Histone H3,antibodies,Experimental Usage,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,Acetyl-Histone H3 Lys18,antibodies,Experimental Usage,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,SAPK/JNK,antibodies,Experimental Usage,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,phospho-SAPK/JNK Thr183/Tyr185,antibodies,Experimental Usage,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,p70S6 Kinase,antibodies,Experimental Usage,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,phospho-p70 Thr389 S6 Kinase,antibodies,Experimental Usage,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,phospho-S6 (Ser240/244),antibodies,Experimental Usage,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,phospho-S6 (S240/244),antibodies,Experimental Usage,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,phospho-p70 S6K (T389),antibodies,Experimental Usage,,,
PMID:26219339 | PMID:18483311,10.18632/oncotarget.4858 | 10.1158/1535-7163.MCT-07-2335,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,phospho-Akt (S473),antibodies,Experimental Usage,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,phospho-NDRG1 (T346),antibodies,Experimental Usage,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,SGK1,antibodies,Experimental Usage,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,phospho-PAK1 (S144),antibodies,Experimental Usage,,,
PMID:26219339 | PMID:21072183,10.18632/oncotarget.4858 | 10.1371/journal.pone.0013791,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,PAK1,antibodies,Experimental Usage,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,4EBP1,antibodies,Experimental Usage,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,Rac1,antibodies,Experimental Usage,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,Rheb,antibodies,Experimental Usage,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,tubulin,antibodies,Experimental Usage,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,SUZ12,antibodies,Experimental Usage,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,Pak2,antibodies,Experimental Usage,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,phospho-MEK1 (Ser298),antibodies,Experimental Usage,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,phospho-Erk1/2 (Thr202/Tyr204),antibodies,Experimental Usage,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,phospho-Akt (Thr308),antibodies,Experimental Usage,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,phospho-Pak1–3 (Ser141),antibodies,Experimental Usage,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,DUSP6,antibodies,Experimental Usage,,,
PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,panendothelial cell antigen,antibodies,Experimental Usage,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,P-Stat3 (Y705),antibodies,Experimental Usage,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,P-Jak2,antibodies,Experimental Usage,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,Jak2,antibodies,Experimental Usage,,,
PMID:33658640 | PMID:26904939,10.1038/s41416-021-01270-8 | 10.1016/j.celrep.2016.01.074,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,p-STAT3,antibodies,Experimental Usage,,,
PMID:26904939 | PMID:33658640,10.1016/j.celrep.2016.01.074 | 10.1038/s41416-021-01270-8,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,Stat3,antibodies,Experimental Usage,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,P-β-catenin,antibodies,Experimental Usage,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,GSK3β,antibodies,Experimental Usage,,,
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,CD16/32,antibodies,Experimental Usage,,,
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,Ter119,antibodies,Experimental Usage,,,
PMID:18242513 | PMID:38175707,10.1016/j.ccr.2008.01.003 | 10.1172/jci.insight.168826,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. | Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,p75,antibodies,Experimental Usage,,,
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,α4 integrin,antibodies,Experimental Usage,,,
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,"Lineage markers (CD3e, CD11b, CD45R/B220, Ly6G/Ly6C, TER-119)",antibodies,Experimental Usage,,,
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,phospho-histone-H3 (Ser 10),antibodies,Experimental Usage,,,
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,"Various (phospho-S6, phospho-4EBP1, phospho-STAT3, AKT, etc.)",antibodies,Experimental Usage,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,phospho-MEK,antibodies,Experimental Usage,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,RAD51,antibodies,Experimental Usage,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,BRCA2,antibodies,Experimental Usage,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,MGMT,antibodies,Experimental Usage,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,yH2AX,antibodies,Experimental Usage,,,
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,Ago2,antibodies,Experimental Usage,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,citrate synthetase,antibodies,Experimental Usage,,,
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,Etv5,antibodies,Experimental Usage,,,
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,podoplanin,antibodies,Experimental Usage,,,
PMID:40684195 | PMID:28256556,10.1186/s40478-025-02075-z | 10.1038/srep43315,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,F4/80,antibodies,Experimental Usage,,,
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,CSF1,antibodies,Experimental Usage,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,tomato,antibodies,Experimental Usage,,,
PMID:40684195 | PMID:38744290,10.1186/s40478-025-02075-z | 10.1016/j.crmeth.2024.100772,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,cKIT,antibodies,Experimental Usage,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,POSTN,antibodies,Experimental Usage,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,TNC,antibodies,Experimental Usage,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,PGP9.5,antibodies,Experimental Usage,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,Aqp1,antibodies,Experimental Usage,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,KIF11,antibodies,Experimental Usage,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,KIF15,antibodies,Experimental Usage,,,
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,PGDS,antibodies,Experimental Usage,,,
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,phospho-S6K (T389),antibodies,Experimental Usage,,,
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,S6K1,antibodies,Experimental Usage,,,
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,Mib1,antibodies,Experimental Usage,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,PDE4A,antibodies,Experimental Usage,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,LCA,antibodies,Experimental Usage,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,phosphorylated protein kinase A substrate,antibodies,Experimental Usage,,,
PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the,,Ly6G,antibodies,Experimental Usage,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,MPZ,antibodies,Experimental Usage,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,Survivin,antibodies,Experimental Usage,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,CENPF,antibodies,Experimental Usage,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,CD56,antibodies,Experimental Usage,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,CD117/c-kit,antibodies,Experimental Usage,,,
PMID:38744290 | PMID:24371224,10.1016/j.crmeth.2024.100772 | 10.1158/0008-5472.CAN-13-2062,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,PanCytokeratin,antibodies,Experimental Usage,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,S100A11,antibodies,Experimental Usage,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,beta tubulin,antibodies,Experimental Usage,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,pMEK,antibodies,Experimental Usage,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,MEK,antibodies,Experimental Usage,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,pPAK,antibodies,Experimental Usage,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,Caspase-7,antibodies,Experimental Usage,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Neurofilament,antibodies,Experimental Usage,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Pan-TEAD,antibodies,Experimental Usage,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,CTGF,antibodies,Experimental Usage,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,Notch1,antibodies,Experimental Usage,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,S518-Merlin,antibodies,Experimental Usage,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,"Na+,K+-ATPase",antibodies,Experimental Usage,,,
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,NeuroD1,antibodies,Experimental Usage,,,
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,Phospho-Rb Ser 780,antibodies,Experimental Usage,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,pSmad3,antibodies,Experimental Usage,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,Zpr-1,antibodies,Experimental Usage,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,Zn-5,antibodies,Experimental Usage,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,HuC/D,antibodies,Experimental Usage,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,PKC β1,antibodies,Experimental Usage,,,
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,β-tubulin III,antibodies,Experimental Usage,,,
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,Gal α 1-3Gal,antibodies,Experimental Usage,,,
PMID:21963652 | PMID:24375753,10.1016/j.expneurol.2011.09.005 | 10.1002/ana.24093,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice. | Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,DARPP32,antibodies,Experimental Usage,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,p-MAPK,antibodies,Experimental Usage,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,total MAPK,antibodies,Experimental Usage,,,
PMID:21963652 | PMID:24375753,10.1016/j.expneurol.2011.09.005 | 10.1002/ana.24093,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice. | Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,p-DARPP32,antibodies,Experimental Usage,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,Cy3/Cy5,antibodies,Experimental Usage,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,DAXX,antibodies,Experimental Usage,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,"HLA-A,B,C",antibodies,Experimental Usage,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,H-2,antibodies,Experimental Usage,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,human nuclei,antibodies,Experimental Usage,,,
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,FAP,antibodies,Experimental Usage,,,
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,LAMA2,antibodies,Experimental Usage,,,
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,SLC22A3,antibodies,Experimental Usage,,,
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,PRRX1,antibodies,Experimental Usage,,,
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,Phospho-p44/42 ERK1/2,antibodies,Experimental Usage,,,
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,p44/42 ERK1/2,antibodies,Experimental Usage,,,
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,phosphor-p44/p42 MAPK (ERK1/2),antibodies,Experimental Usage,,,
PMID:37681415 | PMID:24375753,10.1172/jci.insight.168445 | 10.1002/ana.24093,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation. | Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,p-ERK1/2,antibodies,Experimental Usage,,,
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,EGFP,antibodies,Experimental Usage,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,c-Met,antibodies,Experimental Usage,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,phosphorylated c-Met,antibodies,Experimental Usage,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,mesothelin,antibodies,Experimental Usage,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,phospho P-Met,antibodies,Experimental Usage,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,MAPK,antibodies,Experimental Usage,,,
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,p55/MPP1,antibodies,Development,,,
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,NF-H,antibodies,Experimental Usage,,,
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,Caspr,antibodies,Experimental Usage,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,CD11c,antibodies,Experimental Usage,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,CD19,antibodies,Experimental Usage,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,CD163,antibodies,Experimental Usage,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,CSF1R,antibodies,Experimental Usage,,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,ColIA,antibodies,Experimental Usage,,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,Abl,antibodies,Experimental Usage,,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,c-abl,antibodies,Experimental Usage,,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,TGF-β,antibodies,Experimental Usage,,,
PMID:25535838 | PMID:36241865,10.7554/eLife.05151 | 10.1038/s12276-022-00850-9,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,MAP2,antibodies,Experimental Usage,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,NF-200,antibodies,Experimental Usage,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,P-mTOR,antibodies,Experimental Usage,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Rictor,antibodies,Experimental Usage,,,
PMID:32948135 | PMID:36241865,10.1186/s12885-020-07397-w | 10.1038/s12276-022-00850-9,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,bcl2,antibodies,Experimental Usage,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,myelin basic protein,antibodies,Experimental Usage,,,
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,pErbB2,antibodies,Experimental Usage,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,Calbindin,antibodies,Experimental Usage,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,GABARα6,antibodies,Experimental Usage,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,Tbr2,antibodies,Experimental Usage,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,Calretinin,antibodies,Experimental Usage,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,P27,antibodies,Experimental Usage,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,β-gal,antibodies,Experimental Usage,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,BIM,antibodies,Experimental Usage,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,b-tubulin,antibodies,Experimental Usage,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,COL4A,antibodies,Experimental Usage,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,histone H3 (tri methyl K27),antibodies,Experimental Usage,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,XBP1,antibodies,Experimental Usage,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,XBP1u,antibodies,Experimental Usage,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,XBP1s,antibodies,Experimental Usage,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,Parkin,antibodies,Experimental Usage,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,PINK1,antibodies,Experimental Usage,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,ATP5H,antibodies,Experimental Usage,,,
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,p21,antibodies,Experimental Usage,,,
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,bcl6,antibodies,Experimental Usage,,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,phospho-RB1 S807/811,antibodies,Experimental Usage,,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,kappa light chain,antibodies,Experimental Usage,,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,SIAH,antibodies,Experimental Usage,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,Ref-1,antibodies,Experimental Usage,,,
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,nitrated Hsp90,antibodies,Experimental Usage,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,NPcis cell line,cell_lines,Experimental Usage,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,BJFF.6,cell_lines,Experimental Usage,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,Normal human Schwann cells (Sciencell),cell_lines,Experimental Usage,,,
PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,TOP-10F' cells,cell_lines,Experimental Usage,,,
PMID:38216123 | PMID:40507334,10.1016/j.molmet.2024.101876 | 10.3390/cancers17111852,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer. | Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,MCF7,cell_lines,Experimental Usage,,,
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,human retinal ganglion cells (hRGC),cell_lines,Experimental Usage,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,Primary Schwannoma Cells,cell_lines,Experimental Usage,,,
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,Nf1 flox/flox calvaria osteoblasts,cell_lines,Experimental Usage,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,DH10Bac cells,cell_lines,Experimental Usage,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,BL21(DE3),cell_lines,Experimental Usage,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,Sf9 cells,cell_lines,Experimental Usage,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,Tni-FNL cells,cell_lines,Experimental Usage,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,NF1-null HEK293T cell line,cell_lines,Development,,,
PMID:40590220 | PMID:35789380 | PMID:31836666 | PMID:29402968 | PMID:31015291 | PMID:40225167 | PMID:34415582 | PMID:39269317 | PMID:23175151 | PMID:38216587 | PMID:20554030 | PMID:28166733 | PMID:33934112,10.1172/JCI188932 | 10.1158/2159-8290.CD-21-1671 | 10.1074/jbc.RA119.010934 | 10.1038/s41598-018-20894-0 | 10.1126/scisignal.aau8749 | 10.1155/2023/9628049 | 10.1002/glia.24075 | 10.1158/1078-0432.CCR-24-1750 | 10.1038/bjc.2012.518 | 10.1038/s41467-023-40408-5 | 10.1016/j.jneuroim.2010.05.002 | 10.1186/s12864-017-3519-7 | 10.1038/s41419-021-03716-6,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. | Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. | Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies. | Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins. | Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome. | Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury. | MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression. | Epigenetic reprogramming shapes the cellular landscape of schwannoma. | CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma. | HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,HEK293T cells,cell_lines,Experimental Usage,,,
PMID:38201517 | PMID:37164978 | PMID:24681606 | PMID:23685747 | PMID:41036607 | PMID:38203448 | PMID:23535903,10.3390/cancers16010089 | 10.1038/s41467-023-38432-6 | 10.18632/oncotarget.1609 | 10.1038/ng.2641 | 10.1158/1535-7163.MCT-24-1053 | 10.3390/ijms25010277 | 10.1158/2159-8290.CD-13-0081,"Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers. | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,S462TY,cell_lines,Experimental Usage,,,
PMID:38201517 | PMID:18367665,10.3390/cancers16010089 | 10.1124/jpet.107.135830,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers. | Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,iSC,cell_lines,Experimental Usage,,,
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,A549,cell_lines,Experimental Usage,,,
PMID:38201517 | PMID:41022755 | PMID:39269317 | PMID:18367665 | PMID:37246765 | PMID:33658640 | PMID:24824755 | PMID:39129390 | PMID:18413802 | PMID:24681606 | PMID:23685747 | PMID:20049725 | PMID:32642733 | PMID:18483311 | PMID:38127282 | PMID:38216572 | PMID:38203448 | PMID:23535903 | PMID:41036607 | PMID:33032988,10.3390/cancers16010089 | 10.1038/s41467-025-63619-4 | 10.1158/1078-0432.CCR-24-1750 | 10.1124/jpet.107.135830 | 10.1093/neuonc/noad097 | 10.1038/s41416-021-01270-8 | 10.1371/journal.pone.0096733 | 10.1002/1878-0261.13704 | 10.1158/1535-7163.MCT-07-0518 | 10.18632/oncotarget.1609 | 10.1038/ng.2641 | 10.1002/emmm.200900027 | 10.1093/noajnl/vdz061 | 10.1158/1535-7163.MCT-07-2335 | 10.1158/1078-0432.CCR-23-2548 | 10.1038/s41467-024-44755-9 | 10.3390/ijms25010277 | 10.1158/2159-8290.CD-13-0081 | 10.1158/1535-7163.MCT-24-1053 | 10.1158/0008-5472.CAN-20-1365,"Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers. | Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin. | Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. | Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.",,ST88-14,cell_lines,Experimental Usage,,,
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,MCF10A,cell_lines,Experimental Usage,,,
PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,ipNF 95.11b,cell_lines,Experimental Usage,,,
PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,ipn 02.8,cell_lines,Experimental Usage,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,murine NF2 −/− Schwann cell line,cell_lines,Experimental Usage,,,
PMID:21111000 | PMID:38216587 | PMID:30617350 | PMID:30274821,10.1016/j.jneumeth.2010.10.021 | 10.1038/s41467-023-40408-5 | 10.1038/s41596-018-0105-7 | 10.1016/j.ebiom.2018.09.042,"A novel imaging-compatible sciatic nerve schwannoma model. | Epigenetic reprogramming shapes the cellular landscape of schwannoma. | A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.",,HEI-193,cell_lines,Experimental Usage,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,p53−/− mouse embryonic liver progenitor cells,cell_lines,Experimental Usage,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,293fs cells,cell_lines,Experimental Usage,,,
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,ipNF05.5 (mixed clone),cell_lines,Experimental Usage,,,
PMID:35741605 | PMID:40723243,10.3390/brainsci12060720 | 10.3390/cancers17142359,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas. | The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,ipNF05.5 (single clone),cell_lines,Experimental Usage,,,
PMID:35741605 | PMID:39129390 | PMID:40862755 | PMID:36689660 | PMID:39061138 | PMID:40723243,10.3390/brainsci12060720 | 10.1002/1878-0261.13704 | 10.3390/cells14161276 | 10.1073/pnas.2208960120 | 10.3390/cancers16142498 | 10.3390/cancers17142359,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization. | A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids. | The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,ipNF95.11bC,cell_lines,Experimental Usage,,,
PMID:35741605 | PMID:33934112 | PMID:33442015 | PMID:38136356,10.3390/brainsci12060720 | 10.1038/s41419-021-03716-6 | 10.1038/s41591-020-01193-6 | 10.3390/cancers15245811,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas. | HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. | Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF95.6,cell_lines,Experimental Usage,,,
PMID:35741605 | PMID:39129390 | PMID:38136356 | PMID:40723243,10.3390/brainsci12060720 | 10.1002/1878-0261.13704 | 10.3390/cancers15245811 | 10.3390/cancers17142359,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency. | The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,ipnNF95.11c,cell_lines,Experimental Usage,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,immortalized mouse Nf2 Schwann cells,cell_lines,Experimental Usage,,,
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,COS-7,cell_lines,Experimental Usage,,,
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,Nf1-/- mouse embryo fibroblasts,cell_lines,Experimental Usage,,,
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,T265-2c,cell_lines,Experimental Usage,,,
PMID:24824755 | PMID:20049725 | PMID:32642733 | PMID:18483311,10.1371/journal.pone.0096733 | 10.1002/emmm.200900027 | 10.1093/noajnl/vdz061 | 10.1158/1535-7163.MCT-07-2335,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,90-8,cell_lines,Experimental Usage,,,
PMID:24040940 | PMID:33032988,10.1186/1479-5876-11-213 | 10.1158/0008-5472.CAN-20-1365,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,NF96.2,cell_lines,Experimental Usage,,,
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,NF02.2,cell_lines,Experimental Usage,,,
PMID:24040940 | PMID:33032988,10.1186/1479-5876-11-213 | 10.1158/0008-5472.CAN-20-1365,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,NF94.3,cell_lines,Experimental Usage,,,
PMID:33673681 | PMID:30531922,10.3390/cancers13050999 | 10.1038/s41591-018-0263-8,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of | The molecular landscape of glioma in patients with Neurofibromatosis 1.,,HEK293 cells,cell_lines,Experimental Usage,,,
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and,,LLC-PK1 ATCC CL-101,cell_lines,Experimental Usage,,,
PMID:33934112 | PMID:32457840,10.1038/s41419-021-03716-6 | 10.3389/fonc.2020.00687,"HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,MiaPaCa-2,cell_lines,Experimental Usage,,,
PMID:33934112 | PMID:32457840,10.1038/s41419-021-03716-6 | 10.3389/fonc.2020.00687,"HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,PANC1,cell_lines,Experimental Usage,,,
PMID:33934112 | PMID:32457840,10.1038/s41419-021-03716-6 | 10.3389/fonc.2020.00687,"HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,BxPc3,cell_lines,Experimental Usage,,,
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,AsPC-1,cell_lines,Experimental Usage,,,
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,HPDE H6c7,cell_lines,Experimental Usage,,,
PMID:33273014 | PMID:28126595 | PMID:26219339 | PMID:36148553,10.1074/jbc.RA120.014960 | 10.1016/j.ebiom.2017.01.020 | 10.18632/oncotarget.4858 | 10.1093/brain/awac342,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Ben-Men-1,cell_lines,Experimental Usage,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,AC-CRISPR,cell_lines,Experimental Usage,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,MN1-LF,cell_lines,Experimental Usage,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,H358 cells,cell_lines,Experimental Usage,,,
PMID:41022755 | PMID:32383545 | PMID:33658640 | PMID:38502231 | PMID:23328114 | PMID:37164978 | PMID:24681606 | PMID:23685747 | PMID:30055648 | PMID:20049725 | PMID:32642733 | PMID:18483311 | PMID:38127282 | PMID:41001593 | PMID:32948135 | PMID:37410426 | PMID:23535903 | PMID:35511749,10.1038/s41467-025-63619-4 | 10.15252/embr.201949117 | 10.1038/s41416-021-01270-8 | 10.1172/JCI176748 | 10.18632/oncotarget.793 | 10.1038/s41467-023-38432-6 | 10.18632/oncotarget.1609 | 10.1038/ng.2641 | 10.1186/s13104-018-3630-0 | 10.1002/emmm.200900027 | 10.1093/noajnl/vdz061 | 10.1158/1535-7163.MCT-07-2335 | 10.1158/1078-0432.CCR-23-2548 | 10.1080/23723556.2025.2561292 | 10.1186/s12885-020-07397-w | 10.1158/1078-0432.CCR-23-0749 | 10.1158/2159-8290.CD-13-0081 | 10.1158/1535-7163.MCT-21-0947,"Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition. | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression. | Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor. | Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model. | CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression. | Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.",,S462,cell_lines,Experimental Usage,,,
PMID:38502231 | PMID:35393510,10.1172/JCI176748 | 10.1038/s41418-022-00991-4,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,cis MPNST cell line,cell_lines,Experimental Usage,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,HTS-Luc MPNST cell line,cell_lines,Experimental Usage,,,
PMID:30542164 | PMID:32383545,10.1038/s41586-018-0774-y | 10.15252/embr.201949117,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. | Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,CT26,cell_lines,Experimental Usage,,,
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,U937,cell_lines,Experimental Usage,,,
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,Raji,cell_lines,Experimental Usage,,,
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,Eμ-ALL,cell_lines,Experimental Usage,,,
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,Human CD19scFv-CD28–4–1BB-CD3ζ CAR-T cells (PM-CAR1003),cell_lines,Experimental Usage,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,pNF9511bc,cell_lines,Experimental Usage,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,ipNF03.3,cell_lines,Experimental Usage,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,ipn023λ,cell_lines,Experimental Usage,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,RHT92,cell_lines,Experimental Usage,,,
PMID:41022755 | PMID:38714355,10.1038/s41467-025-63619-4 | 10.1158/1535-7163.MCT-23-0510,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,LN229,cell_lines,Experimental Usage,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,2V6.11,cell_lines,Experimental Usage,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,FiPS,cell_lines,Experimental Usage,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,"NF1−/−−/− edited FiPS Ctrl1-SV4F-7, D12",cell_lines,Experimental Usage,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,3PNF_SiPSsv_MM_11,cell_lines,Experimental Usage,,,
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,M724,cell_lines,Experimental Usage,,,
PMID:39269317 | PMID:23175151 | PMID:29438698 | PMID:40025578 | PMID:36322658 | PMID:35511749 | PMID:32642733 | PMID:38216572,10.1158/1078-0432.CCR-24-1750 | 10.1038/bjc.2012.518 | 10.1016/j.ccell.2018.01.005 | 10.1186/s40478-025-01965-6 | 10.1126/sciadv.abo5442 | 10.1158/1535-7163.MCT-21-0947 | 10.1093/noajnl/vdz061 | 10.1038/s41467-024-44755-9,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression. | Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment. | Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,SNF96.2,cell_lines,Experimental Usage,,,
PMID:39269317 | PMID:35789380,10.1158/1078-0432.CCR-24-1750 | 10.1158/2159-8290.CD-21-1671,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,M1,cell_lines,Experimental Usage,,,
PMID:39269317 | PMID:35789380,10.1158/1078-0432.CCR-24-1750 | 10.1158/2159-8290.CD-21-1671,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,M3,cell_lines,Experimental Usage,,,
PMID:39269317 | PMID:35789380,10.1158/1078-0432.CCR-24-1750 | 10.1158/2159-8290.CD-21-1671,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,M4,cell_lines,Experimental Usage,,,
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,M5,cell_lines,Experimental Usage,,,
PMID:39269317 | PMID:35789380,10.1158/1078-0432.CCR-24-1750 | 10.1158/2159-8290.CD-21-1671,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,M6,cell_lines,Experimental Usage,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,Drosophila Schneider (S2R+) cells,cell_lines,Experimental Usage,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,dNF1‐KO,cell_lines,Development,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,hTERT ipn02.3 2λ CRL‐3392,cell_lines,Experimental Usage,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,"ipnNF09.4 (hTERT NF1 ipnNF09.4, RRID: CVCL_UI73)",cell_lines,Experimental Usage,,,
PMID:39129390 | PMID:40862755 | PMID:39061138 | PMID:33658640,10.1002/1878-0261.13704 | 10.3390/cells14161276 | 10.3390/cancers16142498 | 10.1038/s41416-021-01270-8,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures. | A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,"ipNF05.5 (hTERT NF1 ipNF05.5, RRID: CVCL_UI71)",cell_lines,Experimental Usage,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,U2OS,cell_lines,Experimental Usage,,,
PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,Epstein-Barr virus-transformed cell lines,cell_lines,Experimental Usage,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,Human meningeal cells (HMC),cell_lines,Experimental Usage,,,
PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,lymphoblastoid cell lines,cell_lines,Experimental Usage,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,OLN93 mouse oligodendrocyte cell line,cell_lines,Experimental Usage,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,SC4-immortalized Nf2-/- primary Schwann cells,cell_lines,Experimental Usage,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,RT4-D6PT2 schwannoma cell line,cell_lines,Experimental Usage,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,TC620 human oligodendroglioma cell line,cell_lines,Experimental Usage,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,Normal human Schwann cells (NHSC),cell_lines,Experimental Usage,,,
PMID:24509877 | PMID:18413802,10.1038/onc.2013.506 | 10.1158/1535-7163.MCT-07-0518,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,MPNST cell lines,cell_lines,Experimental Usage,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,MPNST 88-14 cells,cell_lines,Experimental Usage,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,MPNST S462-TY cells,cell_lines,Experimental Usage,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,2884 cell line,cell_lines,Experimental Usage,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,2885 cell line,cell_lines,Experimental Usage,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,hTERT NF1 ipn02.3 2λ,cell_lines,Experimental Usage,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,ipn95.11bC,cell_lines,Experimental Usage,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,MPNST642,cell_lines,Experimental Usage,,,
PMID:36322658 | PMID:37164978 | PMID:24681606 | PMID:23685747 | PMID:30055648 | PMID:41001593 | PMID:38203448 | PMID:32948135 | PMID:23535903,10.1126/sciadv.abo5442 | 10.1038/s41467-023-38432-6 | 10.18632/oncotarget.1609 | 10.1038/ng.2641 | 10.1186/s13104-018-3630-0 | 10.1080/23723556.2025.2561292 | 10.3390/ijms25010277 | 10.1186/s12885-020-07397-w | 10.1158/2159-8290.CD-13-0081,"Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model. | Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,T265,cell_lines,Experimental Usage,,,
PMID:36322658 | PMID:37164978 | PMID:24681606 | PMID:23685747 | PMID:20049725 | PMID:32642733 | PMID:18483311 | PMID:38203448 | PMID:37410426 | PMID:23535903 | PMID:35511749 | PMID:33032988,10.1126/sciadv.abo5442 | 10.1038/s41467-023-38432-6 | 10.18632/oncotarget.1609 | 10.1038/ng.2641 | 10.1002/emmm.200900027 | 10.1093/noajnl/vdz061 | 10.1158/1535-7163.MCT-07-2335 | 10.3390/ijms25010277 | 10.1158/1078-0432.CCR-23-0749 | 10.1158/2159-8290.CD-13-0081 | 10.1158/1535-7163.MCT-21-0947 | 10.1158/0008-5472.CAN-20-1365,"Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression. | Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.",,STS26T,cell_lines,Experimental Usage,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,ipn97.4 immortalized human Schwann cells,cell_lines,Experimental Usage,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,Schwann cells,cell_lines,Experimental Usage,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,optic glioma cells,cell_lines,Experimental Usage,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,HSC1λ,cell_lines,Experimental Usage,,,
PMID:37164978 | PMID:38136356,10.1038/s41467-023-38432-6 | 10.3390/cancers15245811,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF06.2A,cell_lines,Experimental Usage,,,
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,TVZ NSCs,cell_lines,Experimental Usage,,,
PMID:23535903 | PMID:24681606,10.1158/2159-8290.CD-13-0081 | 10.18632/oncotarget.1609,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.",,iHSC1λ,cell_lines,Experimental Usage,,,
PMID:23535903 | PMID:24681606,10.1158/2159-8290.CD-13-0081 | 10.18632/oncotarget.1609,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.",,iHSC2λ,cell_lines,Experimental Usage,,,
PMID:40590220 | PMID:36420221 | PMID:32383545,10.1172/JCI188932 | 10.1016/j.omtn.2022.10.026 | 10.15252/embr.201949117,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype | Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,HeLa cells,cell_lines,Experimental Usage,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,MDA-MB-231 cells,cell_lines,Experimental Usage,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,PN 04.4 cells,cell_lines,Experimental Usage,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,4T1 cells,cell_lines,Experimental Usage,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,RAW 264.7 cells,cell_lines,Experimental Usage,,,
PMID:32383545 | PMID:37446790,10.15252/embr.201949117 | 10.3390/molecules28135128,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca | Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,C2C12 cells,cell_lines,Experimental Usage,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,COLO 741 cells,cell_lines,Experimental Usage,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,MEC1 cells,cell_lines,Experimental Usage,,,
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,NF1-1 hiPSC line,cell_lines,Experimental Usage,,,
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,NF1-2 hiPSC line,cell_lines,Experimental Usage,,,
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,WT-1 hiPSC line,cell_lines,Experimental Usage,,,
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,WT-2 hiPSC line,cell_lines,Experimental Usage,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,LUVA cells,cell_lines,Experimental Usage,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,U87 glioblastoma cells,cell_lines,Experimental Usage,,,
PMID:35614131 | PMID:35393510,10.1038/s41418-022-01020-0 | 10.1038/s41418-022-00991-4,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation. | Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,sMPNST cells,cell_lines,Experimental Usage,,,
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,HT1080,cell_lines,Experimental Usage,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,"Human Schwann Cells (HSC, ScienCell Research Laboratories #1700)",cell_lines,Experimental Usage,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,"Mouse Schwann Cells (MSC, ScienCell Research Laboratories #M1700-57)",cell_lines,Experimental Usage,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,NF37,cell_lines,Experimental Usage,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,NF87,cell_lines,Experimental Usage,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,CT10,cell_lines,Experimental Usage,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,CT11,cell_lines,Experimental Usage,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,CT12,cell_lines,Experimental Usage,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,CTL BJFF.6 hiPSCs,cell_lines,Experimental Usage,,,
PMID:29438698 | PMID:38216572,10.1016/j.ccell.2018.01.005 | 10.1038/s41467-024-44755-9,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,SNF02.2,cell_lines,Experimental Usage,,,
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,human endothelial colony forming cells (ECFC),cell_lines,Experimental Usage,,,
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,human microvascular endothelial cells (HMVEC),cell_lines,Experimental Usage,,,
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,293FT packaging cells,cell_lines,Experimental Usage,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,TM-31,cell_lines,Experimental Usage,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,LN319,cell_lines,Experimental Usage,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,17,cell_lines,Experimental Usage,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,5653,cell_lines,Experimental Usage,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,5746,cell_lines,Experimental Usage,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,"Human Schwann cells (HSC; ScienCell, Carlsbad, CA)",cell_lines,Experimental Usage,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,LS141,cell_lines,Experimental Usage,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,DDLS,cell_lines,Experimental Usage,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,Human Schwann cells (HSCs),cell_lines,Experimental Usage,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,RT4-D6P2T schwannoma cells,cell_lines,Experimental Usage,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,LN428 human glioblastoma multiforme (GBM) cell line,cell_lines,Experimental Usage,,,
PMID:28831766,10.1007/s12104-017-9768-1,NMR resonance assignments of the EVH1 domain of neurofibromin's recruitment factor Spred1.,,BL21(DE3) Star,cell_lines,Experimental Usage,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,NF1-null 293T cells,cell_lines,Experimental Usage,,,
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,Primary human Schwann cells (NHSC),cell_lines,Experimental Usage,,,
PMID:28392281 | PMID:34065204,10.1016/j.expneurol.2017.04.001 | 10.3390/ijms22105367,Human stem cell modeling in neurofibromatosis type 1 (NF1). | RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,mouse embryonic fibroblasts (MEFs),cell_lines,Experimental Usage,,,
PMID:38000020 | PMID:38127282,10.1126/sciadv.adg8876 | 10.1158/1078-0432.CCR-23-2548,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,JH-2-002,cell_lines,Experimental Usage,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,JH-2-031,cell_lines,Experimental Usage,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,JH-2-079c,cell_lines,Experimental Usage,,,
PMID:38000020 | PMID:38127282,10.1126/sciadv.adg8876 | 10.1158/1078-0432.CCR-23-2548,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,JH-2-103,cell_lines,Experimental Usage,,,
PMID:23685747 | PMID:41036607,10.1038/ng.2641 | 10.1158/1535-7163.MCT-24-1053,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,iHSCs,cell_lines,Experimental Usage,,,
PMID:23685747 | PMID:40025578,10.1038/ng.2641 | 10.1186/s40478-025-01965-6,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,K562,cell_lines,Experimental Usage,,,
PMID:41564118 | PMID:38907342,10.1371/journal.pone.0340183 | 10.1186/s40478-024-01821-z,"Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,icNF97.2a,cell_lines,Development,,,
PMID:41564118 | PMID:38907342,10.1371/journal.pone.0340183 | 10.1186/s40478-024-01821-z,"Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,icNF97.2b,cell_lines,Development,,,
PMID:41564118 | PMID:38907342,10.1371/journal.pone.0340183 | 10.1186/s40478-024-01821-z,"Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,icNF98.4d,cell_lines,Development,,,
PMID:40025578 | PMID:25026211 | PMID:26219339,10.1186/s40478-025-01965-6 | 10.1016/j.ccr.2014.05.001 | 10.18632/oncotarget.4858,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment. | Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,293T cells,cell_lines,Experimental Usage,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,HFFs,cell_lines,Experimental Usage,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,NCI-H266,cell_lines,Experimental Usage,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,Neurofibromatosis 1 fibroblasts,cell_lines,Experimental Usage,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,MPNST-SP-01,cell_lines,Experimental Usage,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,MPNST-NF1-08,cell_lines,Experimental Usage,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,MPNST-NF1-9,cell_lines,Experimental Usage,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,HS-PSS,cell_lines,Experimental Usage,,,
PMID:32642733 | PMID:35511749,10.1093/noajnl/vdz061 | 10.1158/1535-7163.MCT-21-0947,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,HS-Sch-2,cell_lines,Experimental Usage,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,Human Foreskin Fibroblast (HFF),cell_lines,Experimental Usage,,,
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,ipNF95.11b C-RFP,cell_lines,Experimental Usage,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,AC007-hTERT,cell_lines,Experimental Usage,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,AC028,cell_lines,Experimental Usage,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,U87-MG,cell_lines,Experimental Usage,,,
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,Meso-33,cell_lines,Experimental Usage,,,
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,FC-1801,cell_lines,Experimental Usage,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,NIH-3T3,cell_lines,Experimental Usage,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,φNX packaging cell line,cell_lines,Experimental Usage,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,H1838,cell_lines,Experimental Usage,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,WM3918,cell_lines,Experimental Usage,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,M308,cell_lines,Experimental Usage,,,
PMID:18367665 | PMID:33658640 | PMID:33032988,10.1124/jpet.107.135830 | 10.1038/s41416-021-01270-8 | 10.1158/0008-5472.CAN-20-1365,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,NF90-8,cell_lines,Experimental Usage,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,NF10.1,cell_lines,Experimental Usage,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,NF11.1,cell_lines,Experimental Usage,,,
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,BY4743 background diploid yeast deletion strains,cell_lines,Experimental Usage,,,
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,Y258 background haploid yeast MORF strain,cell_lines,Experimental Usage,,,
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,MethoCult® M3434,cell_lines,Experimental Usage,,,
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,K4622 grade II glioma cell line,cell_lines,Experimental Usage,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,HSR-GBM1,cell_lines,Experimental Usage,,,
PMID:39472976 | PMID:38714355,10.1186/s40478-024-01875-z | 10.1158/1535-7163.MCT-23-0510,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,JHH-520 cell line,cell_lines,Experimental Usage,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,JHU-0879,cell_lines,Experimental Usage,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,JHU-1016B,cell_lines,Experimental Usage,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,JHH-136,cell_lines,Experimental Usage,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,B76,cell_lines,Experimental Usage,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,NGT-41,cell_lines,Experimental Usage,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,NMCG-1,cell_lines,Experimental Usage,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,DBTRG,cell_lines,Experimental Usage,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,T98G,cell_lines,Experimental Usage,,,
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,M059J,cell_lines,Experimental Usage,,,
PMID:32419643 | PMID:33934112,10.1177/1533033820919759 | 10.1038/s41419-021-03716-6,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma. | HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,U87,cell_lines,Experimental Usage,,,
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,U118,cell_lines,Experimental Usage,,,
PMID:32419643 | PMID:33934112 | PMID:25043298,10.1177/1533033820919759 | 10.1038/s41419-021-03716-6 | 10.1038/onc.2014.185,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma. | HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | Oncogenic role of Merlin/NF2 in glioblastoma.,,U251,cell_lines,Experimental Usage,,,
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,A172,cell_lines,Experimental Usage,,,
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,PNF-derived Schwann cells,cell_lines,Experimental Usage,,,
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,Wild-type and Nf1-/- primary astrocytes,cell_lines,Experimental Usage,,,
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,GBM1 cell line,cell_lines,Experimental Usage,,,
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,JHH-0879 cell line,cell_lines,Experimental Usage,,,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,Sf21 insect cells,cell_lines,Experimental Usage,,,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,E. coli DH10Multibac cells,cell_lines,Experimental Usage,,,
PMID:20049725 | PMID:18483311,10.1002/emmm.200900027 | 10.1158/1535-7163.MCT-07-2335,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,S520,cell_lines,Experimental Usage,,,
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,88-3,cell_lines,Experimental Usage,,,
PMID:20049725 | PMID:18483311,10.1002/emmm.200900027 | 10.1158/1535-7163.MCT-07-2335,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,YST1,cell_lines,Experimental Usage,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,icNF98.4c,cell_lines,Development,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,icNF00.10a,cell_lines,Development,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,icNF04.9a,cell_lines,Development,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,i28cNF,cell_lines,Development,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,i18cNF,cell_lines,Development,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,i21cNF,cell_lines,Development,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,Nf1−/− MEFs,cell_lines,Experimental Usage,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,ipNF 04.4 cells,cell_lines,Experimental Usage,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,CCD-1112Sk,cell_lines,Experimental Usage,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,Rosetta2(DE3) competent cells,cell_lines,Experimental Usage,,,
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,ST88-3,cell_lines,Experimental Usage,,,
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,T265p21,cell_lines,Experimental Usage,,,
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,DS-red STS26T cell line,cell_lines,Experimental Usage,,,
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,hTERT ipNF05.5,cell_lines,Experimental Usage,,,
PMID:37140985 | PMID:38127282,10.1172/JCI168227 | 10.1158/1078-0432.CCR-23-2548,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,hTERT ipn02.3 2λ,cell_lines,Experimental Usage,,,
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,E13.5 DRG neurosphere cells,cell_lines,Experimental Usage,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Daoy,cell_lines,Experimental Usage,,,
PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the,,GL261,cell_lines,Experimental Usage,,,
PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the,,GL261-luc,cell_lines,Experimental Usage,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,NF1-/- iPSC-derived neural crest cells,cell_lines,Experimental Usage,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,hTERT NF1 ipNF95.6 cell line,cell_lines,Experimental Usage,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,"M14 (ST88-14, RRID:CVCL_8916)",cell_lines,Experimental Usage,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,M10 (MPNST1),cell_lines,Experimental Usage,,,
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF05.5-MX,cell_lines,Experimental Usage,,,
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF95.11b C/T,cell_lines,Experimental Usage,,,
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF02.3 2λ,cell_lines,Experimental Usage,,,
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF02.8,cell_lines,Experimental Usage,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,NF95.11b,cell_lines,Experimental Usage,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,NF95.6,cell_lines,Experimental Usage,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,SNF94.3,cell_lines,Experimental Usage,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,JW18.2,cell_lines,Experimental Usage,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,JW23.3,cell_lines,Experimental Usage,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,KT21-MG1,cell_lines,Experimental Usage,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,293FT,cell_lines,Experimental Usage,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype,,NF2 primary fibroblasts,cell_lines,Experimental Usage,,,
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,Primary human vestibular schwannoma (VS) cell cultures,cell_lines,Experimental Usage,,,
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,Primary normal rat Schwann cells,cell_lines,Experimental Usage,,,
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,C6 cells,cell_lines,Experimental Usage,,,
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,ipNF05.5 Mixed Clones,cell_lines,Experimental Usage,,,
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,MOLM-13,cell_lines,Experimental Usage,,,
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,293T lenti-X cells,cell_lines,Experimental Usage,,,
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,Nf1flox/flox bone marrow stromal cells,cell_lines,Experimental Usage,,,
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,DH5α bacteria,cell_lines,Experimental Usage,,,
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,tail-tip fibroblasts (TTFs),cell_lines,Experimental Usage,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Neural stem cells,cell_lines,Experimental Usage,,,
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,Nf2-deficient spinal cord neural progenitor cells,cell_lines,Experimental Usage,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,BL21 (DE3) E.coli,cell_lines,Experimental Usage,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,H929,cell_lines,Experimental Usage,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,U266B1,cell_lines,Experimental Usage,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,U2932,cell_lines,Experimental Usage,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,HT229,cell_lines,Experimental Usage,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,HCC1937,cell_lines,Experimental Usage,,,
PMID:41001593 | PMID:32948135,10.1080/23723556.2025.2561292 | 10.1186/s12885-020-07397-w,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor. | Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,NSF1,cell_lines,Experimental Usage,,,
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,BRGN,cell_lines,Experimental Usage,,,
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,primary human Schwann cells (HSC),cell_lines,Experimental Usage,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,Normal human Schwann cells (HSC),cell_lines,Experimental Usage,,,
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,B8 fibroblasts,cell_lines,Experimental Usage,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,95.6,cell_lines,Experimental Usage,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,ipn02.3,cell_lines,Experimental Usage,,,
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,"normal human Schwann cells (Cat. No. 1700, ScienCell Research Laboratories)",cell_lines,Experimental Usage,,,
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,Mouse merlin-null schwannoma cells,cell_lines,Experimental Usage,,,
PMID:41468561,10.1212/WNL.0000000000214480,NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.,,Survey of Well-being of Young Children (SWYC),clinical_assessment_tools,Experimental Usage,,,
PMID:41468561,10.1212/WNL.0000000000214480,NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.,,Centers for Disease Control (CDC) growth charts,clinical_assessment_tools,Experimental Usage,,,
PMID:33963966,10.1007/s10803-021-05043-3,Cognitive and Electrophysiological Correlates of Working Memory Impairments in Neurofibromatosis Type 1.,,National Institute of Health diagnostic criteria for NF1,clinical_assessment_tools,Experimental Usage,,,
PMID:33963966,10.1007/s10803-021-05043-3,Cognitive and Electrophysiological Correlates of Working Memory Impairments in Neurofibromatosis Type 1.,,P300 event-related potential,clinical_assessment_tools,Experimental Usage,,,
PMID:33963966,10.1007/s10803-021-05043-3,Cognitive and Electrophysiological Correlates of Working Memory Impairments in Neurofibromatosis Type 1.,,WM nback task,clinical_assessment_tools,Experimental Usage,,,
PMID:33817379,10.1016/j.heliyon.2021.e06518,Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.,,P.L.E.A.S.E.® device,clinical_assessment_tools,Experimental Usage,,,
PMID:33817379,10.1016/j.heliyon.2021.e06518,Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.,,Dermlite DL3,clinical_assessment_tools,Experimental Usage,,,
PMID:33817379,10.1016/j.heliyon.2021.e06518,Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.,,NIH Consensus Development Conference NF1 diagnostic criteria,clinical_assessment_tools,Experimental Usage,,,
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,Numerical Rating Scale-11,clinical_assessment_tools,Experimental Usage,,,
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,Brief Pain Inventory Pain Interference subscale,clinical_assessment_tools,Experimental Usage,,,
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,Pediatric Quality of Life Inventory NF1 module,clinical_assessment_tools,Experimental Usage,,,
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,cNF-Skindex,clinical_assessment_tools,Experimental Usage,,,
PMID:32642740 | PMID:38811427,10.1093/noajnl/vdaa003 | 10.1186/s41687-024-00732-w,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada. | Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,EQ-5D-5L,clinical_assessment_tools,Experimental Usage,,,
PMID:32642740 | PMID:38811427,10.1093/noajnl/vdaa003 | 10.1186/s41687-024-00732-w,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada. | Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,SF-36,clinical_assessment_tools,Experimental Usage,,,
PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,World Health Organization Quality of Life Brief Version (WHOQOL-BREF),clinical_assessment_tools,Experimental Usage,,,
PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,Relaxation Response Resiliency Program for NF (3RP-NF),clinical_assessment_tools,Experimental Usage,,,
PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,Health Enhancement Program for NF (HEP-NF),clinical_assessment_tools,Experimental Usage,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,DPOAE,clinical_assessment_tools,Experimental Usage,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,ABR,clinical_assessment_tools,Experimental Usage,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,hind-limb clasping test,clinical_assessment_tools,Experimental Usage,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,ledge test,clinical_assessment_tools,Experimental Usage,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,rotarod assay,clinical_assessment_tools,Experimental Usage,,,
PMID:41598414,10.3390/jcm15020475,Dermoscopy-Guided High-Frequency Ultrasound Imaging of Subcentimeter Cutaneous and Subcutaneous Neurofibromas in Patients with Neurofibromatosis Type 1.,,Dermus SkinScanner,clinical_assessment_tools,Experimental Usage,,,
PMID:27081657 | PMID:28725547,10.1002/acn3.288 | 10.1016/j.nicl.2017.06.032,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I. | Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,Wechsler Abbreviated Scale of Intelligence (WASI),clinical_assessment_tools,Experimental Usage,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,Brief Visuospatial Memory Test – Revised (BVMT),clinical_assessment_tools,Experimental Usage,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,Letter‐Number Sequencing task (LNS),clinical_assessment_tools,Experimental Usage,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,Digit Cancellation,clinical_assessment_tools,Experimental Usage,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,Hopkins Verbal Learning Test (HVLT),clinical_assessment_tools,Experimental Usage,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,WISC‐III Object Assembly,clinical_assessment_tools,Experimental Usage,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,Achenbach Child Behavior Checklist (CBCL),clinical_assessment_tools,Experimental Usage,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,Young Adult Self Report (YASR),clinical_assessment_tools,Experimental Usage,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,Neuropsychological Assessment Battery (NAB) Mazes,clinical_assessment_tools,Experimental Usage,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,Delis–Kaplan Executive Function Scale (D‐KEFS) verbal fluency,clinical_assessment_tools,Experimental Usage,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,Behavior Rating Inventory of Executive Function (BRIEF),clinical_assessment_tools,Experimental Usage,,,
PMID:28725547 | PMID:27081657,10.1016/j.nicl.2017.06.032 | 10.1002/acn3.288,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity. | A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,Spatial capacity working memory (SCAP) task,clinical_assessment_tools,Experimental Usage,,,
PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,Hannover classification system,clinical_assessment_tools,Experimental Usage,,,
PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,Koos classification system,clinical_assessment_tools,Experimental Usage,,,
PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,RECIST guidelines,clinical_assessment_tools,Experimental Usage,,,
PMID:38321701,10.1177/17407745231217279,Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.,,Tinnitus Functional Index,clinical_assessment_tools,Experimental Usage,,,
PMID:38321701,10.1177/17407745231217279,Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.,,Patient-Reported Outcomes Rating Acceptance Tool for Endpoints (PRO-RATE),clinical_assessment_tools,Experimental Usage,,,
PMID:32572180 | PMID:28735371,10.1038/s41436-020-0873-7 | 10.1007/s10897-017-0128-1,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study. | Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,Brief Symptom Inventory 18 (BSI-18),clinical_assessment_tools,Experimental Usage,,,
PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,Behavior Problem Index (BPI),clinical_assessment_tools,Experimental Usage,,,
PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,CCSS Neurocognitive Questionnaire,clinical_assessment_tools,Experimental Usage,,,
PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,"Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v4.0)",clinical_assessment_tools,Experimental Usage,,,
PMID:37269078,10.1177/17407745231178839,Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.,,Children's Tumor Foundation NF Registry,clinical_assessment_tools,Experimental Usage,,,
PMID:37269078,10.1177/17407745231178839,Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.,,5-point Likert-type scales,clinical_assessment_tools,Experimental Usage,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,PEERS® intervention,clinical_assessment_tools,Experimental Usage,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,Kaufman Brief Intelligence Test– Second Edition (KBIT-2),clinical_assessment_tools,Experimental Usage,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,Wechsler Individual Achievement Test– Third Edition (WIAT-III) Word Reading subtest,clinical_assessment_tools,Experimental Usage,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version– Attention Deficit/Hyperactivity Disorder module (KSADS-ADHD),clinical_assessment_tools,Experimental Usage,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,Social Communication Questionnaire (SCQ),clinical_assessment_tools,Experimental Usage,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,Social Skills Improvement System Social-Emotional Learning (SSIS-SEL),clinical_assessment_tools,Experimental Usage,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,Social Responsiveness Scale– Second Edition (SRS-2),clinical_assessment_tools,Experimental Usage,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,Friendship Qualities Scale (FQS),clinical_assessment_tools,Experimental Usage,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,Quality of Socialization Questionnaire (QSQ),clinical_assessment_tools,Experimental Usage,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,Test of Adolescent Social Skills Knowledge (TASSK),clinical_assessment_tools,Experimental Usage,,,
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,Pain Interference Index (PII),clinical_assessment_tools,Development,,,
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,Pain Interference Index-Parent report (PII-P),clinical_assessment_tools,Development,,,
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,Modified Brief Pain Inventory (MBPI),clinical_assessment_tools,Experimental Usage,,,
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,Faces Pain Scale-Revised (FPS-R),clinical_assessment_tools,Experimental Usage,,,
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,Pain Rating Scale (PRS),clinical_assessment_tools,Experimental Usage,,,
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,Pain Rating Scale-Parent version (PRS-P),clinical_assessment_tools,Experimental Usage,,,
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,NF Disease Severity Scale,clinical_assessment_tools,Experimental Usage,,,
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,NF1 Disease Complications Scale,clinical_assessment_tools,Experimental Usage,,,
PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,Hematoxylin and eosin (H&E),clinical_assessment_tools,Experimental Usage,,,
PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,immunohistochemical staining,clinical_assessment_tools,Experimental Usage,,,
PMID:33442015 | PMID:40304934,10.1038/s41591-020-01193-6 | 10.1186/s41687-025-00877-2,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. | Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,NRS-11,clinical_assessment_tools,Experimental Usage,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,BPI-PI Scale,clinical_assessment_tools,Experimental Usage,,,
PMID:23432799 | PMID:33442015,10.1186/1477-7525-11-21 | 10.1038/s41591-020-01193-6,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity. | Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.",,PedsQL™ NF1 Module,clinical_assessment_tools,Development,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,FragEL DNA Fragmentation Detection Kit (Sigma Aldrich #QIA21),clinical_assessment_tools,Experimental Usage,,,
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,RECIST 1.1,clinical_assessment_tools,Experimental Usage,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,3-chamber social preference task,clinical_assessment_tools,Experimental Usage,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,Open field test,clinical_assessment_tools,Experimental Usage,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,Delay discounting task,clinical_assessment_tools,Experimental Usage,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,Cliff avoidance reaction test,clinical_assessment_tools,Experimental Usage,,,
PMID:22961690 | PMID:23432799,10.1002/pbc.24281 | 10.1186/1477-7525-11-21,"Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas. | Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,PedsQL 4.0 Generic Core Scales,clinical_assessment_tools,Experimental Usage,,,
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,Life Events Checklist (LEC),clinical_assessment_tools,Experimental Usage,,,
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,PROMIS depression short form,clinical_assessment_tools,Experimental Usage,,,
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,PROMIS pain interference short form,clinical_assessment_tools,Experimental Usage,,,
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,PROMIS cognitive function short form,clinical_assessment_tools,Experimental Usage,,,
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,MEMS Cap,clinical_assessment_tools,Experimental Usage,,,
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,Barriers to Adherence Questionnaire,clinical_assessment_tools,Experimental Usage,,,
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire,clinical_assessment_tools,Development,,,
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,EuroQol (EQ 5D),clinical_assessment_tools,Experimental Usage,,,
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,Riccardi NF severity grade classification,clinical_assessment_tools,Experimental Usage,,,
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,NIH Consensus Development Conference 1987 diagnostic criteria,clinical_assessment_tools,Experimental Usage,,,
PMID:27021207,10.1002/ajmg.a.37623,Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.,,Impact of Pediatric Illness Scale,clinical_assessment_tools,Experimental Usage,,,
PMID:27021207,10.1002/ajmg.a.37623,Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.,,Pain Management Inventory,clinical_assessment_tools,Development,,,
PMID:27021207,10.1002/ajmg.a.37623,Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.,,Post-Treatment Questionnaire,clinical_assessment_tools,Development,,,
PMID:40437318,10.1186/s41747-025-00594-x,Quantitative MRI of dorsal root ganglion alterations in neurofibromatosis type 1 patients with or without pain.,,visual analogue scale,clinical_assessment_tools,Experimental Usage,,,
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,NeuroConn DC-STIMULATOR MR,clinical_assessment_tools,Experimental Usage,,,
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,Vineland Adaptive Behaviour Scale—third edition,clinical_assessment_tools,Experimental Usage,,,
PMID:36316421 | PMID:35673329,10.1038/s41598-022-21907-9 | 10.1093/texcom/tgac021,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1. | Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,Conners 3 rating scale,clinical_assessment_tools,Experimental Usage,,,
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,Wechsler Adult and Children Intelligence Scales,clinical_assessment_tools,Experimental Usage,,,
PMID:27458360 | PMID:30192842,10.3389/fnhum.2016.00334 | 10.1371/journal.pone.0203520,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1. | Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,Corsi block-tapping task,clinical_assessment_tools,Experimental Usage,,,
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,Brazilian Wechsler Intelligence Scales (WAIS-III or WISC-III),clinical_assessment_tools,Experimental Usage,,,
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,School Achievement Test,clinical_assessment_tools,Experimental Usage,,,
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,Brazilian Criterion for Economic Classification (CCEB),clinical_assessment_tools,Experimental Usage,,,
PMID:40352015,10.7759/cureus.82033,Development of a Machine Learning Algorithm for the Prediction of WHO Grade 1 Meningioma Recurrence.,,Ki-67/MIB-1 index,clinical_assessment_tools,Experimental Usage,,,
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,Rey complex figure test,clinical_assessment_tools,Experimental Usage,,,
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,cancellation test,clinical_assessment_tools,Experimental Usage,,,
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,prism adaptation task,clinical_assessment_tools,Experimental Usage,,,
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,Stroop color word test,clinical_assessment_tools,Experimental Usage,,,
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,Wechsler Intelligence Scale for Children–Revised,clinical_assessment_tools,Experimental Usage,,,
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,Beery developmental test of visual-motor integration,clinical_assessment_tools,Experimental Usage,,,
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,judgment of line orientation task,clinical_assessment_tools,Experimental Usage,,,
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,Cirrus HD-OCT,clinical_assessment_tools,Experimental Usage,,,
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,Teller acuity cards,clinical_assessment_tools,Experimental Usage,,,
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,Cardiff acuity cards,clinical_assessment_tools,Experimental Usage,,,
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,Lea cards,clinical_assessment_tools,Experimental Usage,,,
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,KM (Konstantin Moutakis) cards,clinical_assessment_tools,Experimental Usage,,,
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,Humphrey Field Analyzer perimetry,clinical_assessment_tools,Experimental Usage,,,
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,World Health Organization Categories of Childhood VI scale,clinical_assessment_tools,Experimental Usage,,,
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,Numerical Rating Scale (NRS-11),clinical_assessment_tools,Experimental Usage,,,
PMID:32187457 | PMID:40304934,10.1056/NEJMoa1912735 | 10.1186/s41687-025-00877-2,Selumetinib in Children with Inoperable Plexiform Neurofibromas. | Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,Pain Interference Index,clinical_assessment_tools,Experimental Usage,,,
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,Pediatric Quality of Life Inventory (PedsQL) Generic Core Scales,clinical_assessment_tools,Experimental Usage,,,
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,Global Impression of Change scale,clinical_assessment_tools,Experimental Usage,,,
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,Patient-Reported Outcomes Measurement Information System (PROMIS) Mobility short form,clinical_assessment_tools,Experimental Usage,,,
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,Patient-Reported Outcomes Measurement Information System (PROMIS) Upper Extremity short form,clinical_assessment_tools,Experimental Usage,,,
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,"NCI Common Terminology Criteria for Adverse Events, version 4.0",clinical_assessment_tools,Experimental Usage,,,
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,volumetric magnetic resonance imaging analysis,clinical_assessment_tools,Experimental Usage,,,
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,Responsibility for Medication Questionnaire,clinical_assessment_tools,Experimental Usage,,,
PMID:37174087 | PMID:28029918,10.3390/cancers15092621 | 10.1056/NEJMoa1605943,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study. | Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,clinical_assessment_tools,Experimental Usage,,,
PMID:40737523,10.2196/71728,Clinician Perspectives of a Magnetic Resonance Imaging-Based 3D Volumetric Analysis Tool for Neurofibromatosis Type 2-Related Schwannomatosis: Qualitative Pilot Study.,,Likert scale questionnaire,clinical_assessment_tools,Experimental Usage,,,
PMID:35723774,10.1007/s10072-022-06203-8,A randomized controlled trial of remote microphone listening devices to treat auditory deficits in children with neurofibromatosis type 1.,,CNC-word test,clinical_assessment_tools,Experimental Usage,,,
PMID:35723774,10.1007/s10072-022-06203-8,A randomized controlled trial of remote microphone listening devices to treat auditory deficits in children with neurofibromatosis type 1.,,LIFE-R Questionnaire,clinical_assessment_tools,Experimental Usage,,,
PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,,Rex Gauge durometer,clinical_assessment_tools,Experimental Usage,,,
PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,,Delfin SkinFibroMeter,clinical_assessment_tools,Experimental Usage,,,
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,Vectra H1,clinical_assessment_tools,Experimental Usage,,,
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,LifeViz Micro,clinical_assessment_tools,Experimental Usage,,,
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,Cherry Imaging,clinical_assessment_tools,Experimental Usage,,,
PMID:25012216,10.1186/s40478-014-0082-1,A neuronal function of the tumor suppressor protein merlin.,,nerve conduction velocity,clinical_assessment_tools,Experimental Usage,,,
PMID:25012216,10.1186/s40478-014-0082-1,A neuronal function of the tumor suppressor protein merlin.,,electrophysiological measurements,clinical_assessment_tools,Experimental Usage,,,
PMID:25917366 | PMID:24375753,10.1038/mp.2015.48 | 10.1002/ana.24093,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1. | Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,Morris water maze,clinical_assessment_tools,Experimental Usage,,,
PMID:25917366 | PMID:32839340,10.1038/mp.2015.48 | 10.1073/pnas.2008391117,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1. | Brain-wide structural and functional disruption in mice with oligodendrocyte-specific,,Rotarod,clinical_assessment_tools,Experimental Usage,,,
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,EGI 128-electrode Hydrocel Sensor Net,clinical_assessment_tools,Experimental Usage,,,
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,Mullen Scales of Early Learning (MSEL),clinical_assessment_tools,Experimental Usage,,,
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,Autism Observation Score for Infants (AOSI),clinical_assessment_tools,Experimental Usage,,,
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,Infant Behaviour Questionnaire-Revised (IBQ-R),clinical_assessment_tools,Experimental Usage,,,
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,MacArthur Bates Communicative Development Inventory (CDI),clinical_assessment_tools,Experimental Usage,,,
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,NIH consensus criteria,clinical_assessment_tools,Experimental Usage,,,
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,"International Classification of Diseases, 10th Revision (ICD-10)",clinical_assessment_tools,Experimental Usage,,,
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,Systematized Nomenclature of Medicine (SNOMED),clinical_assessment_tools,Experimental Usage,,,
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,Logical Observation Identifiers Names and Codes (LOINC),clinical_assessment_tools,Experimental Usage,,,
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,Nebraska Lexicon,clinical_assessment_tools,Experimental Usage,,,
PMID:24619350 | PMID:32642740,10.1007/s00415-014-7303-1 | 10.1093/noajnl/vdaa003,Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2. | Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,NFTI-QOL,clinical_assessment_tools,Experimental Usage,,,
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,"mouse cytokine array (panel A, R&D system)",clinical_assessment_tools,Experimental Usage,,,
PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,NIH Consensus Conference criteria,clinical_assessment_tools,Experimental Usage,,,
PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,Lansky performance status,clinical_assessment_tools,Experimental Usage,,,
PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,Karnofsky performance status,clinical_assessment_tools,Experimental Usage,,,
PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS),clinical_assessment_tools,Experimental Usage,,,
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,BoN (Burden of NF1) questionnaire,clinical_assessment_tools,Development,,,
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,Dermatology Life Quality Index (DLQI),clinical_assessment_tools,Experimental Usage,,,
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,SF12,clinical_assessment_tools,Experimental Usage,,,
PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,Autism Diagnostic Interview Revised (ADI-R),clinical_assessment_tools,Experimental Usage,,,
PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,Autism Diagnostic Observation Schedule-2 (ADOS-2),clinical_assessment_tools,Experimental Usage,,,
PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,Wechsler Abbreviated Scale of Intelligence-II (WASI-II),clinical_assessment_tools,Experimental Usage,,,
PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,"Conners Parent Rating Scale (3rd edition, short form)",clinical_assessment_tools,Experimental Usage,,,
PMID:33082502,10.1038/s41598-020-74920-1,Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data.,,Magnetom Avanto,clinical_assessment_tools,Experimental Usage,,,
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,"Wechsler Adult Intelligence Scale, Version 4 (WAIS-IV)",clinical_assessment_tools,Experimental Usage,,,
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,University of Maryland Letter–Number Sequencing (LNS) task,clinical_assessment_tools,Experimental Usage,,,
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,Vineland Adaptive Behaviour Scale (VABS-III),clinical_assessment_tools,Experimental Usage,,,
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,adaptive auditory n-back task,clinical_assessment_tools,Experimental Usage,,,
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,non-adaptive visual n-back task,clinical_assessment_tools,Experimental Usage,,,
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,Brief Pain Inventory Short Form (BPI-SF),clinical_assessment_tools,Experimental Usage,,,
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,Patient Health Questionnaire (PHQ),clinical_assessment_tools,Experimental Usage,,,
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,Structured Clinical Interview for DSM Self Report version (SCID-SR),clinical_assessment_tools,Experimental Usage,,,
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,Generalized Anxiety Disorder 7 Item version (GAD-7),clinical_assessment_tools,Experimental Usage,,,
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,PHQ-9,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,Social Responsiveness Scale 2nd Edition,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,Autism Diagnostic Observation Scale 2nd Edition,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,Autism Diagnostic Interview-Revised,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,WPPSI-IV,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,WISC-V,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,TEA-Ch Sky Search,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,TEA-Ch Score!,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,Shape School,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,NEPSY-II Inhibition,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,Tower of Hanoi,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,TEA-Ch Creature Counting,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,WIAT-II Abbreviated,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,NEPSY-II Affect Recognition,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,Benton Facial Recognition Test,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,NEPSY-II ToM,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,Reading the Mind in the Eyes Test-Child,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,Faux Pas Task,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,Strange Stories,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,CELF-Preschool-2,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,CELF-4 Formulated Sentences,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,NEPSY-II Comprehension of Instructions,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,SRS-2,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,CADS,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,Conners 3,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,BRIEF-Preschool,clinical_assessment_tools,Experimental Usage,,,
PMID:34377779 | PMID:31558455,10.1212/NXG.0000000000000616 | 10.1136/bmjopen-2019-030601,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1. | Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,BRIEF,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,ABAS-3: 0–5 years,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,ABAS-3: 5–21 years,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,SSIS Rating Scale,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,Sensory Profile 2,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,CBCL: 1.5–5 years,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,CBCL: 6–18 years,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,CCC-2,clinical_assessment_tools,Experimental Usage,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,MEGA-PRESS,clinical_assessment_tools,Experimental Usage,,,
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,n-back task,clinical_assessment_tools,Experimental Usage,,,
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,Corsi block task,clinical_assessment_tools,Experimental Usage,,,
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,Wechslers Intelligence Scale for Children-Fourth edition (WISC-IV),clinical_assessment_tools,Experimental Usage,,,
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,Vineland Adaptive Behavior Scale—third edition,clinical_assessment_tools,Experimental Usage,,,
PMID:33085177 | PMID:38499890,10.1002/mgg3.1530 | 10.1186/s41687-024-00714-y,"The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas. | The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",,PlexiQoL,clinical_assessment_tools,Development,,,
PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",,Nottingham Health Profile (NHP),clinical_assessment_tools,Experimental Usage,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,WAIS-III,clinical_assessment_tools,Experimental Usage,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,WISC-III,clinical_assessment_tools,Experimental Usage,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,Nine-Hole Peg Test,clinical_assessment_tools,Experimental Usage,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,Rey-Osterrieth Complex Figure Test,clinical_assessment_tools,Experimental Usage,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,Rey Auditory-Verbal Learning Test (RAVLT),clinical_assessment_tools,Experimental Usage,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,Category Fluency Test,clinical_assessment_tools,Experimental Usage,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,Lexical Fluency Test,clinical_assessment_tools,Experimental Usage,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,Five Digits Test (FDT),clinical_assessment_tools,Experimental Usage,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,Tower of London Test,clinical_assessment_tools,Experimental Usage,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,GE Discovery 690,clinical_assessment_tools,Experimental Usage,,,
PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,UK NF2 Genetic Severity Score,clinical_assessment_tools,Experimental Usage,,,
PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,8-item NF2 disease-specific quality of life score,clinical_assessment_tools,Experimental Usage,,,
PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,hearing grade score,clinical_assessment_tools,Experimental Usage,,,
PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,Manchester NF2 diagnostic criteria,clinical_assessment_tools,Experimental Usage,,,
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,Noldus Cat-Walk XT system,clinical_assessment_tools,Experimental Usage,,,
PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,Wechsler Intelligence Scale for Children (WISC-III),clinical_assessment_tools,Experimental Usage,,,
PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,Diamond Digital color monitor (Mitsubishi Electric Australia),clinical_assessment_tools,Experimental Usage,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,Manchester Criteria,clinical_assessment_tools,Experimental Usage,,,
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,MC-780MA Tanita Tokyo body composition analyzer,clinical_assessment_tools,Experimental Usage,,,
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,Citec hand-held dynamometer,clinical_assessment_tools,Experimental Usage,,,
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,Handwriting Speed Test,clinical_assessment_tools,Experimental Usage,,,
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,6-minute-walk test,clinical_assessment_tools,Experimental Usage,,,
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,PedsQL Generic 4.0,clinical_assessment_tools,Experimental Usage,,,
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,PedsQL Neuromuscular 3.0,clinical_assessment_tools,Experimental Usage,,,
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,CBCL/6-18,clinical_assessment_tools,Experimental Usage,,,
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,Wechsler Intelligence Scale,clinical_assessment_tools,Experimental Usage,,,
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,A Developmental NEuroPSYchological Assessment (NEPSY-II),clinical_assessment_tools,Experimental Usage,,,
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,Tanner staging,clinical_assessment_tools,Experimental Usage,,,
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,Numeric Rating Scale-11,clinical_assessment_tools,Experimental Usage,,,
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,PII,clinical_assessment_tools,Experimental Usage,,,
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,PAin INtensity Scale for plexiform neurofibromas (PAINS-pNF),clinical_assessment_tools,Development,,,
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,Pain Interference Index for plexiform neurofibromas (PII-pNF),clinical_assessment_tools,Development,,,
PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,,HPLC/MS/MS method,clinical_assessment_tools,Experimental Usage,,,
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,H-score,clinical_assessment_tools,Experimental Usage,,,
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,PROMIS pain interference short form 8a,clinical_assessment_tools,Experimental Usage,,,
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,PedsQL NF1 adult module,clinical_assessment_tools,Experimental Usage,,,
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,Ablon visibility index,clinical_assessment_tools,Experimental Usage,,,
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,House and Brackmann facial nerve scale,clinical_assessment_tools,Experimental Usage,,,
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,Ras activation assay (Millipore),clinical_assessment_tools,Experimental Usage,,,
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,cAMP assay (New East Biosciences),clinical_assessment_tools,Experimental Usage,,,
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,TUNEL assay (Roche Diagnostics),clinical_assessment_tools,Experimental Usage,,,
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,dopamine assay (Rocky Mountain Diagnostics),clinical_assessment_tools,Experimental Usage,,,
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,virtual optokinetic system (VOS),clinical_assessment_tools,Experimental Usage,,,
PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,,Cogstate,clinical_assessment_tools,Experimental Usage,,,
PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,,Behavior Rating Inventory of Executive Function,clinical_assessment_tools,Experimental Usage,,,
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,Wood's lamp,clinical_assessment_tools,Experimental Usage,,,
PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,,Wechsler Intelligence Scales,clinical_assessment_tools,Experimental Usage,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,Rotarod apparatus,clinical_assessment_tools,Experimental Usage,,,
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,Distress Thermometer (DT),clinical_assessment_tools,Experimental Usage,,,
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,Children's Depression Inventory (CDI-S),clinical_assessment_tools,Experimental Usage,,,
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,Children's Depression Inventory Parent Version (CDI-P),clinical_assessment_tools,Experimental Usage,,,
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,Lansky Score,clinical_assessment_tools,Experimental Usage,,,
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,Karnofsky Score,clinical_assessment_tools,Experimental Usage,,,
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,Distress Thermometer Acceptability and Feasibility Scales,clinical_assessment_tools,Development,,,
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,,Nottingham Health Profile,clinical_assessment_tools,Experimental Usage,,,
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,,Short Form-36,clinical_assessment_tools,Experimental Usage,,,
PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,,NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3,clinical_assessment_tools,Experimental Usage,,,
PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,,Impact of Pediatric Illness (IPI) Scale,clinical_assessment_tools,Experimental Usage,,,
PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,,STIR MRI,clinical_assessment_tools,Experimental Usage,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,Fiber Photometry Trace Processing,computational_tools,Experimental Usage,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,Novoalign tool v3.02.06,computational_tools,Experimental Usage,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,PICARD tools v2.4.1,computational_tools,Experimental Usage,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,Genome Analysis Toolkit (GATK) v3.6-0,computational_tools,Experimental Usage,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,Mutect v1.1.4,computational_tools,Experimental Usage,,,
PMID:32642734 | PMID:32369930,10.1093/noajnl/vdz026 | 10.3390/genes11050499,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1. | Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,SciClone,computational_tools,Experimental Usage,,,
PMID:41468561,10.1212/WNL.0000000000214480,NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.,,LMSz,computational_tools,Experimental Usage,,,
PMID:41468561,10.1212/WNL.0000000000214480,NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.,,gamlssTools,computational_tools,Experimental Usage,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,AXION Biosystems integrated studio (AxIS) version 2.5.1,computational_tools,Experimental Usage,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,Offline sorter x64 version 4,computational_tools,Experimental Usage,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,ImageJ 1.53a,computational_tools,Experimental Usage,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,"Partek Flow software, version 10.0",computational_tools,Experimental Usage,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,STAR version 2.7.8a,computational_tools,Experimental Usage,,,
PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,Splice Site Prediction by Neural Network (SSPNN),computational_tools,Experimental Usage,,,
PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,mfold computer program version 3.0,computational_tools,Experimental Usage,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,Prism7 (GraphPad),computational_tools,Experimental Usage,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,Agilent Seahorse XF-96,computational_tools,Experimental Usage,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,STAR v2.7.8a,computational_tools,Experimental Usage,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,iDEP 9.1,computational_tools,Experimental Usage,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,Trim Galore v0.6.0,computational_tools,Experimental Usage,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,LipidSearch v5.0,computational_tools,Experimental Usage,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,Compound Discoverer v3.2,computational_tools,Experimental Usage,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,SynergyFinder R package,computational_tools,Experimental Usage,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,CEAS R Package,computational_tools,Experimental Usage,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,FactoMineR R package,computational_tools,Experimental Usage,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,FlowJo software,computational_tools,Experimental Usage,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,Orbitrap Fusion Lumos mass spectrometer,computational_tools,Experimental Usage,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,SEDFIT 16.1,computational_tools,Experimental Usage,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,SEDPHAT 14.0,computational_tools,Experimental Usage,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,EMAN2 e2boxer,computational_tools,Experimental Usage,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,Sphire,computational_tools,Experimental Usage,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,ATSAS,computational_tools,Experimental Usage,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,STAR 2.4.2a,computational_tools,Experimental Usage,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,GSEA software 4.0.1,computational_tools,Experimental Usage,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,DAVID 6.8,computational_tools,Experimental Usage,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,MaxQuant (v1.5.3.30),computational_tools,Experimental Usage,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,AxioVision 4.6 software,computational_tools,Experimental Usage,,,
PMID:33025139 | PMID:32369930 | PMID:28051113 | PMID:36598417,10.1007/s00401-020-02230-x | 10.3390/genes11050499 | 10.1038/srep39348 | 10.1158/2159-8290.CD-22-0786,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis. | Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST. | A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape. | Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.",,BwaMem,computational_tools,Experimental Usage,,,
PMID:32369930 | PMID:36598417,10.3390/genes11050499 | 10.1158/2159-8290.CD-22-0786,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST. | Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,manta,computational_tools,Experimental Usage,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,Pindel,computational_tools,Experimental Usage,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,GenVisR,computational_tools,Experimental Usage,,,
PMID:32369930 | PMID:35332608,10.3390/genes11050499 | 10.1002/humu.24370,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST. | Re-evaluation of missense variant classifications in NF2.,,COSMIC,computational_tools,Experimental Usage,,,
PMID:32369930 | PMID:40887659,10.3390/genes11050499 | 10.1186/s40246-025-00803-z,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST. | RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,ClinVar,computational_tools,Experimental Usage,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,SIFT,computational_tools,Experimental Usage,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,Polyphen,computational_tools,Experimental Usage,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,ClonEvol,computational_tools,Experimental Usage,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,Partek Flow,computational_tools,Experimental Usage,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,gplots,computational_tools,Experimental Usage,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,PantherDB,computational_tools,Experimental Usage,,,
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,CompuSyn software Version 1.0,computational_tools,Experimental Usage,,,
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,IBM SPSS Statistics software version 29.0.1.0,computational_tools,Experimental Usage,,,
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,SPIN (Signal Processing in MR Version SVN Revision 1895),computational_tools,Experimental Usage,,,
PMID:28398289 | PMID:36598417,10.1038/sdata.2017.45 | 10.1158/2159-8290.CD-22-0786,A high-throughput molecular data resource for cutaneous neurofibromas. | Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,VarDict,computational_tools,Experimental Usage,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,SvABA,computational_tools,Experimental Usage,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,MuSE,computational_tools,Experimental Usage,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,MSIprofiler,computational_tools,Experimental Usage,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,FACETS,computational_tools,Experimental Usage,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,ascatNGS,computational_tools,Experimental Usage,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,ShatterSeek,computational_tools,Experimental Usage,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,TopHat-fusion,computational_tools,Experimental Usage,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,EricScript,computational_tools,Experimental Usage,,,
PMID:33025139 | PMID:35945463 | PMID:36598417 | PMID:38216587,10.1007/s00401-020-02230-x | 10.1007/s00401-022-02478-5 | 10.1158/2159-8290.CD-22-0786 | 10.1038/s41467-023-40408-5,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis. | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA. | Epigenetic reprogramming shapes the cellular landscape of schwannoma.",,minfi,computational_tools,Experimental Usage,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,survival,computational_tools,Experimental Usage,,,
PMID:32781282 | PMID:29847659,10.1016/j.trsl.2020.08.001 | 10.1167/iovs.17-22588,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,GraphPad Prism version 6.0h,computational_tools,Experimental Usage,,,
PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,"ImageJ software (version 1.48; National Institutes of Health, Behesda, MD, USA)",computational_tools,Experimental Usage,,,
PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,ImageJ (v1.53a),computational_tools,Experimental Usage,,,
PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,NIH ImageJ (version 1.53a),computational_tools,Experimental Usage,,,
PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,DNA Engine Peltier Thermal cycler (PTC-200),computational_tools,Experimental Usage,,,
PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,"ABI Prism 7,000 Sequence Detection System",computational_tools,Experimental Usage,,,
PMID:39966622,10.1038/s41598-025-88589-x,The development of an artificial intelligence auto-segmentation tool for 3D volumetric analysis of vestibular schwannomas.,,Simpleware ScanIP,computational_tools,Experimental Usage,,,
PMID:39966622,10.1038/s41598-025-88589-x,The development of an artificial intelligence auto-segmentation tool for 3D volumetric analysis of vestibular schwannomas.,,DPP V1.0,computational_tools,Development,,,
PMID:39966622,10.1038/s41598-025-88589-x,The development of an artificial intelligence auto-segmentation tool for 3D volumetric analysis of vestibular schwannomas.,,Simpleware,computational_tools,Experimental Usage,,,
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,Phoenix WinNonlin (Version 8.1),computational_tools,Experimental Usage,,,
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,NONMEM (version 7.2),computational_tools,Experimental Usage,,,
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,Perl speaks NONMEM version 3.6.2,computational_tools,Experimental Usage,,,
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,Pirana version 2.7.1,computational_tools,Experimental Usage,,,
PMID:37378983 | PMID:31462295 | PMID:33507822 | PMID:32572180,10.1001/jamanetworkopen.2023.20599 | 10.1186/s40478-019-0792-5 | 10.1200/JCO.20.02220 | 10.1038/s41436-020-0873-7,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial. | Telomere alterations in neurofibromatosis type 1-associated solid tumors. | NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. | Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,"SAS, version 9.4",computational_tools,Experimental Usage,,,
PMID:38499890 | PMID:38811427,10.1186/s41687-024-00714-y | 10.1186/s41687-024-00732-w,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands. | Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.",,SPSS version 28.0,computational_tools,Experimental Usage,,,
PMID:29897904,10.1371/journal.pone.0197350,Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.,,www.synapse.org/SynodosNF2,computational_tools,Development,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,FastQC (version 0.11.2),computational_tools,Experimental Usage,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,Bowtie (version 1.0.0),computational_tools,Experimental Usage,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,BWA version 0.7.5,computational_tools,Experimental Usage,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,SAMtools (version 0.1.19),computational_tools,Experimental Usage,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,VarScan2 (version 2.3),computational_tools,Experimental Usage,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,STAR (version 2.3.0e),computational_tools,Experimental Usage,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,DESeq (version 1.18.0),computational_tools,Experimental Usage,,,
PMID:38115252 | PMID:35741605 | PMID:28166733,10.1097/MD.0000000000036696 | 10.3390/brainsci12060720 | 10.1186/s12864-017-3519-7,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools. | Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas. | A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,WGCNA,computational_tools,Experimental Usage,,,
PMID:35741605 | PMID:33025139 | PMID:38216572,10.3390/brainsci12060720 | 10.1007/s00401-020-02230-x | 10.1038/s41467-024-44755-9,"Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas. | Epigenomic, genomic, and transcriptomic landscape of schwannomatosis. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.",,ConsensusClusterPlus,computational_tools,Experimental Usage,,,
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,Mechanism Interrogation PlatE (MIPE 4.0) library,computational_tools,Experimental Usage,,,
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,IDAPredict.2drug function package,computational_tools,Experimental Usage,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,Barocycler NEP 2320,computational_tools,Experimental Usage,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,Easy-nLC 1200,computational_tools,Experimental Usage,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,Q Exactive HF mass spectrometer,computational_tools,Experimental Usage,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,Thermo Xcalibur 4.1,computational_tools,Experimental Usage,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,Spectronaut Pulsar,computational_tools,Experimental Usage,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,BenchMark Ultra system,computational_tools,Experimental Usage,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,NanoZoomer S60 digital slide scanner,computational_tools,Experimental Usage,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,Pannoramic Midi FL slide scanner,computational_tools,Experimental Usage,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,R software version 4.0.0,computational_tools,Experimental Usage,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,lmerTest package version 3.1-2,computational_tools,Experimental Usage,,,
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,AxioVision 4.1 software,computational_tools,Experimental Usage,,,
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,analySIS 5.0 software,computational_tools,Experimental Usage,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,Gel-Pro Analyzer 4.0,computational_tools,Experimental Usage,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,GraphPad Prism 4.0,computational_tools,Experimental Usage,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,NextGENe software v.2.3.4.1,computational_tools,Experimental Usage,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,g:Profiler,computational_tools,Experimental Usage,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,BioVenn,computational_tools,Experimental Usage,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,PathVisio software,computational_tools,Experimental Usage,,,
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,"Alamut Visual Plus, version 1.5.1",computational_tools,Experimental Usage,,,
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,R 2.7.0,computational_tools,Experimental Usage,,,
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,Axio Vision Rel. 4.8 software,computational_tools,Experimental Usage,,,
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,Graphpad Prism 6,computational_tools,Experimental Usage,,,
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,piXarray 100 DSR System,computational_tools,Experimental Usage,,,
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,XCT Research SA + peripheral quantitative computed tomography (pQCT) scanner,computational_tools,Experimental Usage,,,
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,MtestwR software,computational_tools,Experimental Usage,,,
PMID:27081657 | PMID:28725547,10.1002/acn3.288 | 10.1016/j.nicl.2017.06.032,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I. | Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,FMRIB software library (FSL),computational_tools,Experimental Usage,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,Burrows–Wheeler Aligner,computational_tools,Experimental Usage,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,control-FREEC,computational_tools,Experimental Usage,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,RStudio,computational_tools,Experimental Usage,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,APE,computational_tools,Experimental Usage,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,MEGAX,computational_tools,Experimental Usage,,,
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,XenoBase version 3.5,computational_tools,Experimental Usage,,,
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,Affymetrix Expression Console MAS 5.0,computational_tools,Experimental Usage,,,
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,StepOne Software v2.3,computational_tools,Experimental Usage,,,
PMID:32642741,10.1093/noajnl/vdaa037,Effect of age and neurofibromatosis type 1 status on white matter integrity in the optic radiations.,,FSL version 5.0.7,computational_tools,Experimental Usage,,,
PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,"iPlan Net software (Brainlab, Feldkirchen, Germany)",computational_tools,Experimental Usage,,,
PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,"Statistical Package for Social Studies (SPSS 10.0 for Windows, SPSS Inc.)",computational_tools,Experimental Usage,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of,,Human Splicing Finder (HSF) Version 2.4.1,computational_tools,Experimental Usage,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of,,Combined Annotation Dependent Depletion (CADD) v1.6,computational_tools,Experimental Usage,,,
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and,,CRISPOR,computational_tools,Experimental Usage,,,
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and,,JMP Pro 15.0.0,computational_tools,Experimental Usage,,,
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,UN-SCAN-IT gel 6.1,computational_tools,Experimental Usage,,,
PMID:36730269 | PMID:33273014 | PMID:37410426 | PMID:40723243,10.1371/journal.pone.0277305 | 10.1074/jbc.RA120.014960 | 10.1158/1078-0432.CCR-23-0749 | 10.3390/cancers17142359,"Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression. | The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.",,synergyfinder,computational_tools,Experimental Usage,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,ImageJ Cell Counter extension,computational_tools,Experimental Usage,,,
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,R version 3.5.1,computational_tools,Experimental Usage,,,
PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,R version 3.5.0,computational_tools,Experimental Usage,,,
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,Image Studio Lite software,computational_tools,Experimental Usage,,,
PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,,DINs (Deep Interactive Networks),computational_tools,Development,,,
PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,,3DQI software,computational_tools,Experimental Usage,,,
PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,,MEDx software,computational_tools,Experimental Usage,,,
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,InVivo 3.2.0 software,computational_tools,Experimental Usage,,,
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,Image-Pro Plus software,computational_tools,Experimental Usage,,,
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,"Image J1.45s, version 1.44p",computational_tools,Experimental Usage,,,
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,GraphPad 5 Prism software,computational_tools,Experimental Usage,,,
PMID:37269078,10.1177/17407745231178839,Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.,,REDCap,computational_tools,Experimental Usage,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,"IBM SPSS for Windows, version 28",computational_tools,Experimental Usage,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,GPower 3.1,computational_tools,Experimental Usage,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,netMHCpan-4.0,computational_tools,Experimental Usage,,,
PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,CatWalk XT,computational_tools,Experimental Usage,,,
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,Agilent ChemStation software (version C.01.07),computational_tools,Experimental Usage,,,
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,VivoQuant software version 4.0,computational_tools,Experimental Usage,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,MaxQuant version 1.3.05,computational_tools,Experimental Usage,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,DAVID software,computational_tools,Experimental Usage,,,
PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,log-rank Mantel-Cox test,computational_tools,Experimental Usage,,,
PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,spatial transcriptomics profiling,computational_tools,Experimental Usage,,,
PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,TRAP (Tiled Regression Analysis Package),computational_tools,Experimental Usage,,,
PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,GenomeStudio (v. 2010.2),computational_tools,Experimental Usage,,,
PMID:36890585 | PMID:33442015,10.1186/s40478-023-01525-w | 10.1038/s41591-020-01193-6,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic. | Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,MaxQuant version 1.6.10.43,computational_tools,Experimental Usage,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,Perseus (version 1.6.10.50),computational_tools,Experimental Usage,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,FlowJo Software (version 9.9.6),computational_tools,Experimental Usage,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,ImageJ (version 1.47),computational_tools,Experimental Usage,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,HALO Image Analysis Software (version 2.3),computational_tools,Experimental Usage,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,XCELLigence Real Time Cell Analysis System,computational_tools,Experimental Usage,,,
PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,Primer 3.0,computational_tools,Experimental Usage,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,Feature Extraction 10.5,computational_tools,Experimental Usage,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,Agilent Genomic Workbench 6.5,computational_tools,Experimental Usage,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,Drop-seq tools (version 1.12),computational_tools,Experimental Usage,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,Cellranger v5.0.1,computational_tools,Experimental Usage,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,Seurat (version 3.1.0),computational_tools,Experimental Usage,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,scREF,computational_tools,Experimental Usage,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,CIBERSORTx,computational_tools,Experimental Usage,,,
PMID:36322658 | PMID:33591953,10.1126/sciadv.abo5442 | 10.1172/jci.insight.146351,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Chromosome 8 gain is associated with high-grade transformation in MPNST.,,inferCNV,computational_tools,Experimental Usage,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,VECTOR,computational_tools,Experimental Usage,,,
PMID:36322658 | PMID:41591566,10.1126/sciadv.abo5442 | 10.1007/s00401-026-02979-7,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,Slingshot,computational_tools,Experimental Usage,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,CytoTRACE version 0.3.3,computational_tools,Experimental Usage,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,ArchR,computational_tools,Experimental Usage,,,
PMID:36322658 | PMID:38907342,10.1126/sciadv.abo5442 | 10.1186/s40478-024-01821-z,"Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,CellChat,computational_tools,Experimental Usage,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,DGIdb (version 3.0.2),computational_tools,Experimental Usage,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,Trim Galore (version 0.6.10),computational_tools,Experimental Usage,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,Broad's Genome Analysis ToolKit (version 4.6.0),computational_tools,Experimental Usage,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,BWA (version 0.7.17-r1188),computational_tools,Experimental Usage,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,Picard tools (version 3.2.0),computational_tools,Experimental Usage,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,ReAdW v. 3.5.1,computational_tools,Experimental Usage,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,MzXML2Search (included in TPP v. 3.5),computational_tools,Experimental Usage,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,"Scaffold (Protein Sciences, Portland Oregon)",computational_tools,Experimental Usage,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,Human Protein Atlas (proteinatlas.org),computational_tools,Experimental Usage,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,QIAGEN Ingenuity Pathway Analysis (IPA),computational_tools,Experimental Usage,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,GraphPad Prism V9,computational_tools,Experimental Usage,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,Partek Flow software (v.9.0),computational_tools,Experimental Usage,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,STAR (v.2.7.3a),computational_tools,Experimental Usage,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,ImageJ (v.2.0.0),computational_tools,Experimental Usage,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,Cell Profiler (v.3.1.9),computational_tools,Experimental Usage,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,Stereo Investigator software (mbfbioscience v2019),computational_tools,Experimental Usage,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,Image Lab software (v.6),computational_tools,Experimental Usage,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,Image Studio Lite (v.5.0.21),computational_tools,Experimental Usage,,,
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,origin8.1,computational_tools,Experimental Usage,,,
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,Nikon Elements software,computational_tools,Experimental Usage,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,BWA-MEM v 0.7.12,computational_tools,Experimental Usage,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,GATK v3.6.0,computational_tools,Experimental Usage,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,Mutect V1.1.6,computational_tools,Experimental Usage,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,Strelka v1.0.13,computational_tools,Experimental Usage,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,STAR aligner (v.2.6.0),computational_tools,Experimental Usage,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,FusionCatcher v1.1.0,computational_tools,Experimental Usage,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,Seurat version 3.0,computational_tools,Experimental Usage,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,inferCNV (v.1.1.1),computational_tools,Experimental Usage,,,
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,Affymetrix GeneChip Mouse Genome 430 2.0 Array,computational_tools,Experimental Usage,,,
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,Partex Genomics Suite Version 6.6 beta,computational_tools,Experimental Usage,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,pheatmap package,computational_tools,Experimental Usage,,,
PMID:23175151 | PMID:34010628 | PMID:28256556 | PMID:23535903,10.1038/bjc.2012.518 | 10.1016/j.stem.2021.04.029 | 10.1038/srep43315 | 10.1158/2159-8290.CD-13-0081,"MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression. | Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression. | An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system. | Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,limma package,computational_tools,Experimental Usage,,,
PMID:23685747 | PMID:23535903,10.1038/ng.2641 | 10.1158/2159-8290.CD-13-0081,"Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,GeneSpring GX v7.3.1,computational_tools,Experimental Usage,,,
PMID:24681606 | PMID:23535903,10.18632/oncotarget.1609 | 10.1158/2159-8290.CD-13-0081,"Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,CalcuSyn Version 2.1,computational_tools,Experimental Usage,,,
PMID:38173515,10.1016/j.heliyon.2023.e23445,Development of a semi-automatic segmentation technique based on mean magnetic resonance imaging intensity thresholding for volumetric quantification of plexiform neurofibromas.,,"Matlab script (Version 9.9.0, Natick, MA)",computational_tools,Development,,,
PMID:38173515,10.1016/j.heliyon.2023.e23445,Development of a semi-automatic segmentation technique based on mean magnetic resonance imaging intensity thresholding for volumetric quantification of plexiform neurofibromas.,,SSTMean,computational_tools,Development,,,
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,fastp v.0.2,computational_tools,Experimental Usage,,,
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,BWA v.0.7.17,computational_tools,Experimental Usage,,,
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,Samtools v.1.7,computational_tools,Experimental Usage,,,
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,ichorCNA tool (Broad v.0.2.0),computational_tools,Experimental Usage,,,
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,deepTools bamPEFragmentSize,computational_tools,Experimental Usage,,,
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,CRISPOR software,computational_tools,Experimental Usage,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,AnyMaze software,computational_tools,Experimental Usage,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,GraphPad Prism version 5.0d,computational_tools,Experimental Usage,,,
PMID:35393510 | PMID:35614131,10.1038/s41418-022-00991-4 | 10.1038/s41418-022-01020-0,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD | The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,Origin® 8,computational_tools,Experimental Usage,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,Prism 6.0,computational_tools,Experimental Usage,,,
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,SPSS 18,computational_tools,Experimental Usage,,,
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,SAS 9.3,computational_tools,Experimental Usage,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,UCSF500 NGS Panel,computational_tools,Experimental Usage,,,
PMID:35945463 | PMID:33025139,10.1007/s00401-022-02478-5 | 10.1007/s00401-020-02230-x,"Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,Rtsne,computational_tools,Experimental Usage,,,
PMID:35945463 | PMID:39093127,10.1007/s00401-022-02478-5 | 10.1158/1078-0432.CCR-24-0797,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,ComplexHeatmap,computational_tools,Experimental Usage,,,
PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,Prism 4.0,computational_tools,Experimental Usage,,,
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,Feature extractionTM software,computational_tools,Experimental Usage,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,Filtlong v0.2.0,computational_tools,Experimental Usage,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,Porechop v0.2.4,computational_tools,Experimental Usage,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,Flye v2.5,computational_tools,Experimental Usage,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,GCpp v1.0.0-1807624,computational_tools,Experimental Usage,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,purge_haplotigs,computational_tools,Experimental Usage,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,Juicer v1.6.2,computational_tools,Experimental Usage,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,3D-DNA v180114,computational_tools,Experimental Usage,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,BUSCO v5.7.0,computational_tools,Experimental Usage,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,QUASTv5.0.2,computational_tools,Experimental Usage,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,Liftoff v1.6.3,computational_tools,Experimental Usage,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,SnapGeneTM Version 7.2.1,computational_tools,Experimental Usage,,,
PMID:40191916 | PMID:39373898,10.1093/g3journal/jkaf067 | 10.1007/s12031-024-02271-x,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool. | Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.",,AlphaFold 3,computational_tools,Experimental Usage,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,PyMOL Version 3.0.5,computational_tools,Experimental Usage,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,Skewer v0.2.2.b,computational_tools,Experimental Usage,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,Tassel pipeline version 2,computational_tools,Experimental Usage,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,VCFtools v.0.1.16,computational_tools,Experimental Usage,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,Beagle v4.1,computational_tools,Experimental Usage,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,itol v6.9.1,computational_tools,Experimental Usage,,,
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,Smart-seq2,computational_tools,Experimental Usage,,,
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,scdDblFinder,computational_tools,Experimental Usage,,,
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,scran,computational_tools,Experimental Usage,,,
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,QuPath,computational_tools,Experimental Usage,,,
PMID:33507258,10.1001/jamanetworkopen.2020.35479,Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.,,GENIE (Genomics Evidence Neoplasia Information Exchange),computational_tools,Experimental Usage,,,
PMID:33507258 | PMID:39472976 | PMID:41564118,10.1001/jamanetworkopen.2020.35479 | 10.1186/s40478-024-01875-z | 10.1371/journal.pone.0340183,Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases. | NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes. | Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,cBioPortal,computational_tools,Experimental Usage,,,
PMID:33507258,10.1001/jamanetworkopen.2020.35479,Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.,,TCGA (The Cancer Genome Atlas),computational_tools,Experimental Usage,,,
PMID:41591566 | PMID:33591953 | PMID:38216587,10.1007/s00401-026-02979-7 | 10.1172/jci.insight.146351 | 10.1038/s41467-023-40408-5,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study. | Chromosome 8 gain is associated with high-grade transformation in MPNST. | Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,Seurat,computational_tools,Experimental Usage,,,
PMID:37770931 | PMID:33591953 | PMID:38216587,10.1186/s40478-023-01639-1 | 10.1172/jci.insight.146351 | 10.1038/s41467-023-40408-5,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas. | Chromosome 8 gain is associated with high-grade transformation in MPNST. | Epigenetic reprogramming shapes the cellular landscape of schwannoma.",,CellRanger,computational_tools,Experimental Usage,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,Signac,computational_tools,Experimental Usage,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,caret,computational_tools,Experimental Usage,,,
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,Aardex MEMS Adherence Software (ElectronReader 0.9.9),computational_tools,Experimental Usage,,,
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,NanoDrop 2000,computational_tools,Experimental Usage,,,
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,Ion Torrent Personal Genome Machine—Ion Torrent PGM™,computational_tools,Experimental Usage,,,
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,Torrent Suite software,computational_tools,Experimental Usage,,,
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,Ingenuity Variant Analysis software,computational_tools,Experimental Usage,,,
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,Integrative Genomics Viewer,computational_tools,Experimental Usage,,,
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,Alamut Visual,computational_tools,Experimental Usage,,,
PMID:40887659 | PMID:27999334,10.1186/s40246-025-00803-z | 10.3390/genes7120133,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity. | Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,Human Splicing Finder,computational_tools,Experimental Usage,,,
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,AB3130 Genetic Analyzer,computational_tools,Experimental Usage,,,
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,Sequencing Analysis software,computational_tools,Experimental Usage,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,FlowJo 7.6.5,computational_tools,Experimental Usage,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,"ImageJ software v.1.49 (NIH, USA)",computational_tools,Experimental Usage,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,SPSS v. 20.0,computational_tools,Experimental Usage,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,Karyostudio 1.3 software,computational_tools,Experimental Usage,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,Partek Flow software,computational_tools,Experimental Usage,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,Imaris software,computational_tools,Experimental Usage,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,ChAMP,computational_tools,Experimental Usage,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,glmmTMB,computational_tools,Experimental Usage,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,DMRcate,computational_tools,Experimental Usage,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,compartmap,computational_tools,Experimental Usage,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,missMethyl,computational_tools,Experimental Usage,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,PAMES,computational_tools,Experimental Usage,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,SeSAMe,computational_tools,Experimental Usage,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,betareg,computational_tools,Experimental Usage,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,emmeans,computational_tools,Experimental Usage,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,MACS version 1.4.2,computational_tools,Experimental Usage,,,
PMID:40437318,10.1186/s41747-025-00594-x,Quantitative MRI of dorsal root ganglion alterations in neurofibromatosis type 1 patients with or without pain.,,3D Slicer,computational_tools,Experimental Usage,,,
PMID:34646065,10.1155/2021/9386823,Survival and,,SPSS 25,computational_tools,Experimental Usage,,,
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,SimNIBS 3.2,computational_tools,Experimental Usage,,,
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,SPM8,computational_tools,Experimental Usage,,,
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,jMRUI5.1,computational_tools,Experimental Usage,,,
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,SPM12,computational_tools,Experimental Usage,,,
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,Psychopy2,computational_tools,Experimental Usage,,,
PMID:36316421 | PMID:33519543 | PMID:37608248,10.1038/s41598-022-21907-9 | 10.3389/fpsyt.2020.585700 | 10.1186/s11689-023-09492-y,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1. | Autism Spectrum Disorder Symptom Profile Across the RASopathies. | Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,SPSS version25,computational_tools,Experimental Usage,,,
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,R version 1.2,computational_tools,Experimental Usage,,,
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,MATLAB R2014a,computational_tools,Experimental Usage,,,
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,Imaris × 64 version 9.6–9.9,computational_tools,Experimental Usage,,,
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,IGOR Pro 6.37,computational_tools,Experimental Usage,,,
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,Prism 7,computational_tools,Experimental Usage,,,
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,wANNOVAR web server,computational_tools,Experimental Usage,,,
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,SeqMule,computational_tools,Experimental Usage,,,
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,Codon Code Aligner,computational_tools,Experimental Usage,,,
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,primer 3 (v. 0.4.0),computational_tools,Experimental Usage,,,
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,Stratagene Mx3005 – MxPro QPCR-Software,computational_tools,Experimental Usage,,,
PMID:32733557 | PMID:27458360,10.1155/2020/5976465 | 10.3389/fnhum.2016.00334,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis. | COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.",,SPSS 20.0,computational_tools,Experimental Usage,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,Incucyte S3 Live-Cell Analysis System,computational_tools,Experimental Usage,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,"ABI Prism 7000 Sequence Detection System (Applied Biosystems, version 1.1 software)",computational_tools,Experimental Usage,,,
PMID:40352015,10.7759/cureus.82033,Development of a Machine Learning Algorithm for the Prediction of WHO Grade 1 Meningioma Recurrence.,,Python version 3.10,computational_tools,Experimental Usage,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,SPSS 17.0,computational_tools,Experimental Usage,,,
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,SPSS 12.0,computational_tools,Experimental Usage,,,
PMID:22384355,10.1534/g3.111.000687,The SPRED1 Variants Repository for Legius Syndrome.,,Mutalyzer 2.0,computational_tools,Experimental Usage,,,
PMID:22384355,10.1534/g3.111.000687,The SPRED1 Variants Repository for Legius Syndrome.,,FusionCharts v3,computational_tools,Experimental Usage,,,
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,DESeq2 (version 1.12.4),computational_tools,Experimental Usage,,,
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,PRISM (version 8),computational_tools,Experimental Usage,,,
PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,Volocity software (Version 7.0.0),computational_tools,Experimental Usage,,,
PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,ImageJ 1.54g software,computational_tools,Experimental Usage,,,
PMID:29958847,10.1016/j.neurad.2018.05.006,Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.,,Insight Toolkit,computational_tools,Experimental Usage,,,
PMID:29958847,10.1016/j.neurad.2018.05.006,Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.,,Slicer,computational_tools,Experimental Usage,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,RELION,computational_tools,Experimental Usage,,,
PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,bwa-mem v0.7.10,computational_tools,Experimental Usage,,,
PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,"GATK, version 1.0.4705",computational_tools,Experimental Usage,,,
PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,VisCap,computational_tools,Experimental Usage,,,
PMID:37246765 | PMID:38000020,10.1093/neuonc/noad097 | 10.1126/sciadv.adg8876,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology. | CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,Trimmomatic v 0.39,computational_tools,Experimental Usage,,,
PMID:37246765 | PMID:38000020,10.1093/neuonc/noad097 | 10.1126/sciadv.adg8876,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology. | CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,GATK V4.2,computational_tools,Experimental Usage,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,FlowJo 10.8,computational_tools,Experimental Usage,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,PhenoCapture 3.3,computational_tools,Experimental Usage,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,Fiji 2.0,computational_tools,Experimental Usage,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,Cell Ranger pipeline v7.1.0,computational_tools,Experimental Usage,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,Seurat v4.3.0–v5,computational_tools,Experimental Usage,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,Ingenuity Pathway Analysis (IPA),computational_tools,Experimental Usage,,,
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,Illumina CASAVA software (v1.8),computational_tools,Experimental Usage,,,
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,RealSeqS,computational_tools,Experimental Usage,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,BWA version 0.7.15,computational_tools,Experimental Usage,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,GATK MuTect2 (version 4.1),computational_tools,Experimental Usage,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,ANNOVAR (version 2016-02-01),computational_tools,Experimental Usage,,,
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,SAS 9.4,computational_tools,Experimental Usage,,,
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,ParaVision 6.0.1,computational_tools,Experimental Usage,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,Trimmomatic (v0.33),computational_tools,Experimental Usage,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,HISAT2 (v2.1.0),computational_tools,Experimental Usage,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,StringTie (v1.3.4d),computational_tools,Experimental Usage,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,DESeq2 (v1.42.0),computational_tools,Experimental Usage,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,GeneAnalytics(v),computational_tools,Experimental Usage,,,
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,Bruker AutoFlex III mass spectrometer,computational_tools,Experimental Usage,,,
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,FlexImaging 4.0,computational_tools,Experimental Usage,,,
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,Thermo LTQ Velos Orbitrap mass spectrometer,computational_tools,Experimental Usage,,,
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,TagIdent,computational_tools,Experimental Usage,,,
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,protein prospector MS-product,computational_tools,Experimental Usage,,,
PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,GPL17586 Platform [HTA-2_0] Affymetrix Human Transcriptome Array 2.0,computational_tools,Experimental Usage,,,
PMID:24980480,10.1186/1479-7364-8-10,Novel age-dependent targets in vestibular schwannomas.,,Bioconductor limma package,computational_tools,Experimental Usage,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,GraphPad Prism Version 6,computational_tools,Experimental Usage,,,
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,Volocity software 7.0.0,computational_tools,Experimental Usage,,,
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,Nanoparticle Tracking Analysis software version 3.3 Dev Build 3.3.104,computational_tools,Experimental Usage,,,
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,GraphPad Prism version 8.0.1,computational_tools,Experimental Usage,,,
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,Image J software,computational_tools,Experimental Usage,,,
PMID:26219339 | PMID:31527226,10.18632/oncotarget.4858 | 10.1158/1535-7163.MCT-19-0123,"A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of",,GraphPad Prism 6.0,computational_tools,Experimental Usage,,,
PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,Oligo 5.0 computer program,computational_tools,Experimental Usage,,,
PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,,R 4.4.2 software,computational_tools,Experimental Usage,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,Sci-kit Learn,computational_tools,Experimental Usage,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,python 3.5.1,computational_tools,Experimental Usage,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,Li-COR Image Studio Lite 5.0,computational_tools,Experimental Usage,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,R version 3.2.3,computational_tools,Experimental Usage,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,nf1_inactivation GitHub repository,computational_tools,Development,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,GeneChip Human Transcriptome Array 2.0,computational_tools,Experimental Usage,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,BioNavigator software V.6.3,computational_tools,Experimental Usage,,,
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,IBM SPSS Statistics,computational_tools,Experimental Usage,,,
PMID:41411243,10.1371/journal.pgen.1011976,PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.,,PERADIGM,computational_tools,Development,,,
PMID:41411243 | PMID:32869517,10.1371/journal.pgen.1011976 | 10.1002/mgg3.1400,PERADIGM: Phenotype embedding similarity-based rare disease gene mapping. | Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,PLINK,computational_tools,Experimental Usage,,,
PMID:41411243,10.1371/journal.pgen.1011976,PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.,,Word2Vec,computational_tools,Experimental Usage,,,
PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,skyscan 1172,computational_tools,Experimental Usage,,,
PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,Labview 7.0,computational_tools,Experimental Usage,,,
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,bam-readcount,computational_tools,Experimental Usage,,,
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,regioneR,computational_tools,Experimental Usage,,,
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,CLC Genomics Workbench v6,computational_tools,Experimental Usage,,,
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,Seurat V3.0,computational_tools,Experimental Usage,,,
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,STAR 2.4.2.8,computational_tools,Experimental Usage,,,
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,GSVA package,computational_tools,Experimental Usage,,,
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,GraphPad Prism version 5.01,computational_tools,Experimental Usage,,,
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,STATA 11,computational_tools,Experimental Usage,,,
PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,Schrödinger software suite release 2017–1,computational_tools,Experimental Usage,,,
PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,AMBER16,computational_tools,Experimental Usage,,,
PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,VMD (version 1.9.3),computational_tools,Experimental Usage,,,
PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,gromacs (version 4.6),computational_tools,Experimental Usage,,,
PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,MATLAB version 2019b,computational_tools,Experimental Usage,,,
PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,PredictSNP2,computational_tools,Experimental Usage,,,
PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,iStable,computational_tools,Experimental Usage,,,
PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,Align GVGD,computational_tools,Experimental Usage,,,
PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,SNPeffect 4.0,computational_tools,Experimental Usage,,,
PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,iMutant 2.0,computational_tools,Experimental Usage,,,
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,Gel-Pro Analyzer 4.0 software,computational_tools,Experimental Usage,,,
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,R statistical package,computational_tools,Experimental Usage,,,
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,SPSS version 19.0,computational_tools,Experimental Usage,,,
PMID:33934112 | PMID:39415595,10.1038/s41419-021-03716-6 | 10.1242/dmm.050862,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,CHOPCHOP,computational_tools,Experimental Usage,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,Ethovision 11,computational_tools,Experimental Usage,,,
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,Vevo 2100 micro-imaging system,computational_tools,Experimental Usage,,,
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,Vevo software version 5.0.0,computational_tools,Experimental Usage,,,
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,Chipster software,computational_tools,Experimental Usage,,,
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,R bioconductor,computational_tools,Experimental Usage,,,
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,ARACNe-AP algorithm,computational_tools,Experimental Usage,,,
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,DESeq2 version 1.18.1,computational_tools,Experimental Usage,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,Dragen program,computational_tools,Experimental Usage,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,GATK pipeline,computational_tools,Experimental Usage,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,HudsonAlpha RNA-seq data analysis pipeline,computational_tools,Experimental Usage,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,TopHat v2.0,computational_tools,Experimental Usage,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,Cufflinks v0.9.3,computational_tools,Experimental Usage,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,Cutaneous NF Github repository,computational_tools,Development,,,
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,QuPath (v0.4.3),computational_tools,Experimental Usage,,,
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,R (version 4.3.1),computational_tools,Experimental Usage,,,
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,R v3.6.3,computational_tools,Experimental Usage,,,
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,BSDA v1.2.0,computational_tools,Experimental Usage,,,
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,gdata v2.18.0,computational_tools,Experimental Usage,,,
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,ggplot2 v3.3.2,computational_tools,Experimental Usage,,,
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,Affymetrix Mouse Gene 2.0 ST array,computational_tools,Experimental Usage,,,
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,WebGestalt webserver,computational_tools,Experimental Usage,,,
PMID:28589254,10.1007/s00259-017-3733-1,Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of,,MedCalc,computational_tools,Experimental Usage,,,
PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,Stata 15,computational_tools,Experimental Usage,,,
PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,ichorCNA,computational_tools,Experimental Usage,,,
PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,Python sklearn,computational_tools,Experimental Usage,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,10x Genomics Cell Ranger 7.0.1,computational_tools,Experimental Usage,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,Seurat V3 package,computational_tools,Experimental Usage,,,
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,SAS software Version 9.4,computational_tools,Experimental Usage,,,
PMID:33082502,10.1038/s41598-020-74920-1,Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data.,,Analyze 12.0,computational_tools,Experimental Usage,,,
PMID:33082502,10.1038/s41598-020-74920-1,Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data.,,MIM Encore 6.9.3,computational_tools,Experimental Usage,,,
PMID:41564118 | PMID:39669605,10.1371/journal.pone.0340183 | 10.1016/j.gimo.2024.101816,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,Genome Analysis Toolkit (GATK),computational_tools,Experimental Usage,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,nf-core sarek pipeline (v2.7.1),computational_tools,Experimental Usage,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,DeepVariant,computational_tools,Experimental Usage,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,nf-core rnaseq pipeline (v3.5),computational_tools,Experimental Usage,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,XF24 Extracellular Flux Analyzer,computational_tools,Experimental Usage,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,LC-MS/MS (Quattro Premier),computational_tools,Experimental Usage,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,FACSCanto II flow cytometer,computational_tools,Experimental Usage,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,FACSDiva software,computational_tools,Experimental Usage,,,
PMID:38603731,10.1371/journal.pone.0302017,Raman difference spectroscopy and U-Net convolutional neural network for molecular analysis of cutaneous neurofibroma.,,Ventana-785-Raman spectrometer,computational_tools,Experimental Usage,,,
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,SPSS software v. 21,computational_tools,Experimental Usage,,,
PMID:39881370,10.1186/s13065-024-01353-6,"Spectrophotometric and computational characterization of charge transfer complex of selumetinib with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and its utilization in developing an innovative green and high throughput microwell assay for analysis of bulk form and pharmaceutical formulation.",,GAMESS software,computational_tools,Experimental Usage,,,
PMID:39881370,10.1186/s13065-024-01353-6,"Spectrophotometric and computational characterization of charge transfer complex of selumetinib with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and its utilization in developing an innovative green and high throughput microwell assay for analysis of bulk form and pharmaceutical formulation.",,Mutiwfn 3.7,computational_tools,Experimental Usage,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,DYNAMIC software,computational_tools,Experimental Usage,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,Spectra Manager,computational_tools,Experimental Usage,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,Bindworks,computational_tools,Experimental Usage,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,MantidPlot,computational_tools,Experimental Usage,,,
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,MATLAB (2019a),computational_tools,Experimental Usage,,,
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,SPM12 (version 7771),computational_tools,Experimental Usage,,,
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,EEGLAB (version 13.6.5b),computational_tools,Experimental Usage,,,
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,ATLAS.ti (Version 9),computational_tools,Experimental Usage,,,
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,HaploReg v2,computational_tools,Experimental Usage,,,
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,SPM12 v7771,computational_tools,Experimental Usage,,,
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,MATLAB vR2020b,computational_tools,Experimental Usage,,,
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,MRIcroGL,computational_tools,Experimental Usage,,,
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,Cell Ranger 5.0.1,computational_tools,Experimental Usage,,,
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,Seurat R package,computational_tools,Experimental Usage,,,
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,Proteome Discoverer 2.4,computational_tools,Experimental Usage,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,Salmon v1.8.0,computational_tools,Experimental Usage,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,nCounter Sprint Profiler,computational_tools,Experimental Usage,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,nSolver Advanced Analysis Software version 4.0,computational_tools,Experimental Usage,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,Omics Playground v2.7.18,computational_tools,Experimental Usage,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,UCSC Xena browser,computational_tools,Experimental Usage,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,IDEP.92,computational_tools,Experimental Usage,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,ComplexHeatmap R/Bioconductor package,computational_tools,Experimental Usage,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,Scanpy,computational_tools,Experimental Usage,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,infercnvpy package,computational_tools,Experimental Usage,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,HALO Image Analysis software version 2.0.5,computational_tools,Experimental Usage,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,conumee,computational_tools,Experimental Usage,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,Haplotype Caller,computational_tools,Experimental Usage,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,MuTect1,computational_tools,Experimental Usage,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,Variant Effect Predictor,computational_tools,Experimental Usage,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,Sequenza,computational_tools,Experimental Usage,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,MAVIS,computational_tools,Experimental Usage,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,FusionCatcher,computational_tools,Experimental Usage,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,STAR aligner,computational_tools,Experimental Usage,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,AutoAnnotate,computational_tools,Experimental Usage,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,Enrichment Map,computational_tools,Experimental Usage,,,
PMID:33025139 | PMID:32098059 | PMID:37410426,10.1007/s00401-020-02230-x | 10.3390/genes11020226 | 10.1158/1078-0432.CCR-23-0749,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis. | Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1. | CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,CIBERSORT,computational_tools,Experimental Usage,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,GeneMapper software,computational_tools,Experimental Usage,,,
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of",,Agilent 1200 HPLC,computational_tools,Experimental Usage,,,
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of",,ABI 3200 MS/MS,computational_tools,Experimental Usage,,,
PMID:31527226 | PMID:24817309,10.1158/1535-7163.MCT-19-0123 | 10.1371/journal.pone.0097320,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of | Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.",,GraphPad Prism 5.0,computational_tools,Experimental Usage,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,FastQC (RRID:SCR_014583),computational_tools,Experimental Usage,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,TrimGalore (RRID:SCR_011847),computational_tools,Experimental Usage,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,STAR v2.6 (RRID:SCR_004463),computational_tools,Experimental Usage,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,HTSeq v0.9.1 (RRID:SCR_005514),computational_tools,Experimental Usage,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,deepTools v3.1 (RRID:SCR_016366),computational_tools,Experimental Usage,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,Homer v4.5 (RRID:SCR_010881),computational_tools,Experimental Usage,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,"featureCounts (v1.5.0-p1, RRID:SCR_012919)",computational_tools,Experimental Usage,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,"pheatmap (v.1.0.12, RRID:SCR_016418)",computational_tools,Experimental Usage,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,"Partek Genomics Suite (v 7.0, RRID:SCR_011860)",computational_tools,Experimental Usage,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,"FCS Express 7 Research Edition (De Novo Software, Inc.; RRID:SCR_016431)",computational_tools,Experimental Usage,,,
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,Synapse,computational_tools,Experimental Usage,,,
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,RENOVO-NF1,computational_tools,Development,,,
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,Mutation Taster,computational_tools,Experimental Usage,,,
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,HGMD,computational_tools,Experimental Usage,,,
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,LOVD,computational_tools,Experimental Usage,,,
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,PolyPhen-2,computational_tools,Experimental Usage,,,
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,ESE Finder,computational_tools,Experimental Usage,,,
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,GnomAD,computational_tools,Experimental Usage,,,
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,1000 Genomes,computational_tools,Experimental Usage,,,
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,cutpointR,computational_tools,Experimental Usage,,,
PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific,,ExplorDTI,computational_tools,Experimental Usage,,,
PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific,,Advanced Normalization Tools (ANTs),computational_tools,Experimental Usage,,,
PMID:35735230,10.1093/database/baac045,Centralizing neurofibromatosis experimental tool knowledge with the NF Research Tools Database.,,NF Research Tools Database,computational_tools,Development,,,
PMID:35735230,10.1093/database/baac045,Centralizing neurofibromatosis experimental tool knowledge with the NF Research Tools Database.,,JSON-LD schema,computational_tools,Development,,,
PMID:35735230,10.1093/database/baac045,Centralizing neurofibromatosis experimental tool knowledge with the NF Research Tools Database.,,Synapse collaborative science platform,computational_tools,Experimental Usage,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,Salmon v1.4,computational_tools,Experimental Usage,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,BWA-MEM2 v2.1,computational_tools,Experimental Usage,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,GATK v4.1.9.0,computational_tools,Experimental Usage,,,
PMID:38744290 | PMID:32098059,10.1016/j.crmeth.2024.100772 | 10.3390/genes11020226,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening. | Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,MCP-Counter,computational_tools,Experimental Usage,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,BSBolt,computational_tools,Experimental Usage,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,metilene v0.2-8,computational_tools,Experimental Usage,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,DELLY v1.1.3,computational_tools,Experimental Usage,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,InterVar,computational_tools,Experimental Usage,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,rare disease workflows,computational_tools,Experimental Usage,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,cNFOrganoidAnalysis,computational_tools,Development,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,Clustree,computational_tools,Experimental Usage,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,Statistical Parametric Mapping toolbox (SPM8),computational_tools,Experimental Usage,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,Matlab 7.12.0,computational_tools,Experimental Usage,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,kernlab R library,computational_tools,Experimental Usage,,,
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,PLIER,computational_tools,Experimental Usage,,,
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,vcf2maf,computational_tools,Experimental Usage,,,
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,MultiPLIER,computational_tools,Experimental Usage,,,
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,metaVIPER,computational_tools,Experimental Usage,,,
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,NF Data Portal,computational_tools,Experimental Usage,,,
PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,R 4.0.3,computational_tools,Experimental Usage,,,
PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,miRTarBase,computational_tools,Experimental Usage,,,
PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,connectivity map (CMap),computational_tools,Experimental Usage,,,
PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,SPSS V.23,computational_tools,Experimental Usage,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype,,CLC-workbench,computational_tools,Experimental Usage,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype,,PredictProtein,computational_tools,Experimental Usage,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype,,GraphPad Prism software v7,computational_tools,Experimental Usage,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,CRISPRscan,computational_tools,Experimental Usage,,,
PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,"MATLAB (R2008a, MathWorks, Natick, MA, USA)",computational_tools,Experimental Usage,,,
PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,"STIM 2 (Neuroscan, Charlotte, NC, USA)",computational_tools,Experimental Usage,,,
PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,Scan 4.5 (Neuroscan),computational_tools,Experimental Usage,,,
PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,"IBM SPSS Statistics, version 19",computational_tools,Experimental Usage,,,
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,MATLAB software,computational_tools,Experimental Usage,,,
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,WGCNA package v1.69,computational_tools,Experimental Usage,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,Leiden Open Variation Database (LOVD),computational_tools,Experimental Usage,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,ClinVar NCBI,computational_tools,Experimental Usage,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,Human Gene Mutation Database (HGMD),computational_tools,Experimental Usage,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,Clinical Interpretation of Variants in Cancer (CIViC),computational_tools,Experimental Usage,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,Mastermind Genomic Search Engine,computational_tools,Experimental Usage,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,Alamut Visual version 2.15,computational_tools,Experimental Usage,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,gnomAD v2.1.1,computational_tools,Experimental Usage,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,UCSC LiftOver tool,computational_tools,Experimental Usage,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,alleleFrequencyApp,computational_tools,Experimental Usage,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,CanVar-UK cancer predisposition gene variant database,computational_tools,Experimental Usage,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,Beta Imager 2000Z Digital Beta Imaging System,computational_tools,Experimental Usage,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,Siemens Focus F220,computational_tools,Experimental Usage,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,Illumina bcl2fastq v1.8.4 software,computational_tools,Experimental Usage,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,Burrows-Wheeler Aligner v0.7.10,computational_tools,Experimental Usage,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,Picard Tools v1.119,computational_tools,Experimental Usage,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,MDLVC v5.0,computational_tools,Experimental Usage,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,HaplotypeCaller (Genome Analysis Tool Kit 3.3),computational_tools,Experimental Usage,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,Integrated Genomics Viewer v2.3.4 (IGV),computational_tools,Experimental Usage,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,GraphPad Prism version 8.0,computational_tools,Experimental Usage,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,R version 3.3.2,computational_tools,Experimental Usage,,,
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,melodic v3.15,computational_tools,Experimental Usage,,,
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,fMRI Expert Analysis Tool (FEAT),computational_tools,Experimental Usage,,,
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,Multiple Imputation by Chained Equations (MICE),computational_tools,Experimental Usage,,,
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,CRISPResso2,computational_tools,Experimental Usage,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,Cellpose,computational_tools,Experimental Usage,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,Xenosplit,computational_tools,Experimental Usage,,,
PMID:37246765 | PMID:33591953,10.1093/neuonc/noad097 | 10.1172/jci.insight.146351,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology. | Chromosome 8 gain is associated with high-grade transformation in MPNST.,,Variant Effect Predictor (VEP),computational_tools,Experimental Usage,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,maftools v2.10.0,computational_tools,Experimental Usage,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,CNVkit V2.0,computational_tools,Experimental Usage,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,DESeq2 package,computational_tools,Experimental Usage,,,
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,GEOquery,computational_tools,Experimental Usage,,,
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,Biobase,computational_tools,Experimental Usage,,,
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,R statistical software version 3.5.1,computational_tools,Experimental Usage,,,
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,Seurat 3.1.0,computational_tools,Experimental Usage,,,
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,CellChatDB,computational_tools,Experimental Usage,,,
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,Space Ranger,computational_tools,Experimental Usage,,,
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,Seurat v4.0.1,computational_tools,Experimental Usage,,,
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,R Studio PKNCA package (version 0.9.3),computational_tools,Experimental Usage,,,
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,STAR mapper (Version 2.4.1d),computational_tools,Experimental Usage,,,
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,Picard tools,computational_tools,Experimental Usage,,,
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,QURNAs,computational_tools,Development,,,
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,Alamut v2.15 (Interactive Biosoftware),computational_tools,Experimental Usage,,,
PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,Burrows-Wheeler Aligner (bwa-0.7.15),computational_tools,Experimental Usage,,,
PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,Sambamba (v0.6.6),computational_tools,Experimental Usage,,,
PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,CASAVA v1.82,computational_tools,Experimental Usage,,,
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,SNP & Variation Suite v8.3.4,computational_tools,Experimental Usage,,,
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,EMMAX,computational_tools,Experimental Usage,,,
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,METAL,computational_tools,Experimental Usage,,,
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,ComPaSS-GWAS,computational_tools,Experimental Usage,,,
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,Haploview 4.2,computational_tools,Experimental Usage,,,
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,GTEx,computational_tools,Experimental Usage,,,
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,Adobe Photoshop CS2,computational_tools,Experimental Usage,,,
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,Peak Scanner software from Applied Biosystems,computational_tools,Experimental Usage,,,
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,SDS3.0,computational_tools,Experimental Usage,,,
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,COSMIC Database,computational_tools,Experimental Usage,,,
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,Prizm v.4 (GraphPad),computational_tools,Experimental Usage,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,nf-core/rnaseq (v3.11.2),computational_tools,Experimental Usage,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,salmon (v1.10.1),computational_tools,Experimental Usage,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,sva R package (v3.42.0),computational_tools,Experimental Usage,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,immunedeconv (v2.1.0),computational_tools,Experimental Usage,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,ggplot2 (v3.4.4),computational_tools,Experimental Usage,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,ggridges (v0.5.5),computational_tools,Experimental Usage,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,HALO imaging analysis software,computational_tools,Experimental Usage,,,
PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,,FreeSurfer,computational_tools,Experimental Usage,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,FACSDiva v6.1,computational_tools,Experimental Usage,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,FlowJo software v10.0.8,computational_tools,Experimental Usage,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,GraphPad Prism v8.3,computational_tools,Experimental Usage,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,HALO image analysis software v3.2,computational_tools,Experimental Usage,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,ZEN imaging software v2.3,computational_tools,Experimental Usage,,,
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,CLC Genomics Workbench 22,computational_tools,Experimental Usage,,,
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,CosinorPy Python package,computational_tools,Experimental Usage,,,
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,pCLAMP 9.2,computational_tools,Experimental Usage,,,
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,Volocity 4.2,computational_tools,Experimental Usage,,,
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,ImageJ 1.46,computational_tools,Experimental Usage,,,
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,Igor 6.22A,computational_tools,Experimental Usage,,,
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,NeuroMatic,computational_tools,Experimental Usage,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,Disambiguate v1.0,computational_tools,Experimental Usage,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,UPhyloplot2,computational_tools,Experimental Usage,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,HISAT2 version 2.2.1,computational_tools,Experimental Usage,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,StringTie version 2.2.1,computational_tools,Experimental Usage,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,DEGseq version 1.48.0,computational_tools,Experimental Usage,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,ClusterProfiler version 4.2.2,computational_tools,Experimental Usage,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,STRING version 11.5,computational_tools,Experimental Usage,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,FlowJo™ software v10.8,computational_tools,Experimental Usage,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,Seahorse Wave Pro software,computational_tools,Experimental Usage,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,GraphPad Prism version 9,computational_tools,Experimental Usage,,,
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,Agilent Tapestation 4200,computational_tools,Experimental Usage,,,
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,Varsome Clinical Software v.12.3.2,computational_tools,Experimental Usage,,,
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,Plotly v4.9.3,computational_tools,Experimental Usage,,,
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,CNVKit version 0.9.11,computational_tools,Experimental Usage,,,
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,ggplot2 v3.5.1,computational_tools,Experimental Usage,,,
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,GEPIA,computational_tools,Experimental Usage,,,
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,Cluster Profiler v.4.0,computational_tools,Experimental Usage,,,
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,UpSetR Version 1.4.0,computational_tools,Experimental Usage,,,
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,MATLAB® version R2007a,computational_tools,Experimental Usage,,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,FlowJo v10,computational_tools,Experimental Usage,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,ImageJ (v1.48),computational_tools,Experimental Usage,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,HALO (Indica Labs),computational_tools,Experimental Usage,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,Aperio Image Analysis (Leica Biosystems),computational_tools,Experimental Usage,,,
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,XF96 Extracellular Flux Analyzer (Agilent Technologies),computational_tools,Experimental Usage,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,dLight1.2,genetic_reagents,Experimental Usage,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,hChR2(H134R)-EYFP,genetic_reagents,Experimental Usage,,,
PMID:31545171 | PMID:35589737 | PMID:20200958 | PMID:19191334 | PMID:28392281 | PMID:25772366 | PMID:23685747 | PMID:17924978 | PMID:38127282 | PMID:25043591,10.7554/eLife.48983 | 10.1038/s41467-022-30466-6 | 10.1002/jbmr.42 | 10.1002/glia.20845 | 10.1016/j.expneurol.2017.04.001 | 10.1016/j.celrep.2015.02.041 | 10.1038/ng.2641 | 10.1111/j.1750-3639.2007.00105.x | 10.1158/1078-0432.CCR-23-2548 | 10.1002/jbmr.2316,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1. | Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. | Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts. | Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Human stem cell modeling in neurofibromatosis type 1 (NF1). | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression. | Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,Cre,genetic_reagents,Experimental Usage,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,eNpHR3.0-eYFP,genetic_reagents,Experimental Usage,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,mCherry,genetic_reagents,Experimental Usage,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,tTA,genetic_reagents,Experimental Usage,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,mRuby,genetic_reagents,Experimental Usage,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,mTurquoise,genetic_reagents,Experimental Usage,,,
PMID:40590220 | PMID:31545171 | PMID:21072183 | PMID:39129390 | PMID:24509877 | PMID:20049725 | PMID:25043591,10.1172/JCI188932 | 10.7554/eLife.48983 | 10.1371/journal.pone.0013791 | 10.1002/1878-0261.13704 | 10.1038/onc.2013.506 | 10.1002/emmm.200900027 | 10.1002/jbmr.2316,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1. | p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,GFP,genetic_reagents,Experimental Usage,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,iCAP-PHP.eB,genetic_reagents,Experimental Usage,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,dLight1,genetic_reagents,Experimental Usage,,,
PMID:32642734 | PMID:19191334 | PMID:25772366,10.1093/noajnl/vdz026 | 10.1002/glia.20845 | 10.1016/j.celrep.2015.02.041,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1. | Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,LacZ,genetic_reagents,Experimental Usage,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,Trim23,genetic_reagents,Experimental Usage,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,shNF1,genetic_reagents,Experimental Usage,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,shCOL1A2,genetic_reagents,Experimental Usage,,,
PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,pCR2.1-TOPO,genetic_reagents,Experimental Usage,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,NF1 gRNA,genetic_reagents,Experimental Usage,,,
PMID:20200958 | PMID:21949590,10.1002/jbmr.42 | 10.2478/v10134-010-0025-8,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts. | ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,eGFP,genetic_reagents,Experimental Usage,,,
PMID:31836666 | PMID:36689660,10.1074/jbc.RA119.010934 | 10.1073/pnas.2208960120,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,NF1 isoform 2,genetic_reagents,Experimental Usage,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,Gateway entry vector,genetic_reagents,Experimental Usage,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,baculovirus expression vector,genetic_reagents,Experimental Usage,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,E. coli expression vector,genetic_reagents,Experimental Usage,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,truXTRAC FFPE DNA,genetic_reagents,Experimental Usage,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,Kapa HyperPlus,genetic_reagents,Experimental Usage,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,HumanMethylationEPIC,genetic_reagents,Experimental Usage,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,EZ DNA methylation Gold,genetic_reagents,Experimental Usage,,,
PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,oligo-dT,genetic_reagents,Experimental Usage,,,
PMID:18670322 | PMID:21726432,10.1097/MLG.0b013e318177e20b | 10.1186/1741-7015-9-82,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors. | MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,PCR master mix,genetic_reagents,Experimental Usage,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,GLuc,genetic_reagents,Experimental Usage,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,Cas9/sgRNA,genetic_reagents,Experimental Usage,,,
PMID:38216572 | PMID:27956228 | PMID:35789380 | PMID:39415595,10.1038/s41467-024-44755-9 | 10.1053/j.gastro.2016.12.002 | 10.1158/2159-8290.CD-21-1671 | 10.1242/dmm.050862,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. | PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. | Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,sgRNA,genetic_reagents,Experimental Usage,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,Myc,genetic_reagents,Experimental Usage,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,SB10 transposase,genetic_reagents,Experimental Usage,,,
PMID:33273014 | PMID:29715273 | PMID:30274821 | PMID:26219339 | PMID:24595234,10.1074/jbc.RA120.014960 | 10.1371/journal.pone.0196726 | 10.1016/j.ebiom.2018.09.042 | 10.18632/oncotarget.4858 | 10.1371/journal.pone.0090853,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,NF2,genetic_reagents,Experimental Usage,,,
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,apterous-Gal4,genetic_reagents,Experimental Usage,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,pan-T-cell isolation,genetic_reagents,Experimental Usage,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,RASopathy gene panel,genetic_reagents,Experimental Usage,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,Luciferase reporter,genetic_reagents,Experimental Usage,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,ELK1,genetic_reagents,Experimental Usage,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,Dual luciferase reporter,genetic_reagents,Experimental Usage,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,Renilla luciferase,genetic_reagents,Experimental Usage,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,GFP fusion vector,genetic_reagents,Experimental Usage,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,cmlc1 probe,genetic_reagents,Experimental Usage,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,mApple,genetic_reagents,Experimental Usage,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,ZO-1,genetic_reagents,Experimental Usage,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,GFP-NMHC II-B,genetic_reagents,Experimental Usage,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,GFP-vinculin,genetic_reagents,Experimental Usage,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,venus-Scrib,genetic_reagents,Experimental Usage,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,EGFP-hYAP1,genetic_reagents,Experimental Usage,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,EGFP-Lats1,genetic_reagents,Experimental Usage,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,HA-AMOT p130,genetic_reagents,Experimental Usage,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,NLuc,genetic_reagents,Experimental Usage,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,4XBS2WT-Luc,genetic_reagents,Experimental Usage,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,8xGTIIC-luciferase,genetic_reagents,Experimental Usage,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,p53 WT,genetic_reagents,Experimental Usage,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,ZsGreen,genetic_reagents,Experimental Usage,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,Tet3G,genetic_reagents,Experimental Usage,,,
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,H-RAS,genetic_reagents,Experimental Usage,,,
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,SPRED1,genetic_reagents,Experimental Usage,,,
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,RAF-RBD,genetic_reagents,Experimental Usage,,,
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,BNIP3,genetic_reagents,Experimental Usage,,,
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,HIF-1α,genetic_reagents,Experimental Usage,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,Trp53,genetic_reagents,Experimental Usage,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,Brca1,genetic_reagents,Experimental Usage,,,
PMID:32461556 | PMID:38481529 | PMID:39890807 | PMID:34646065 | PMID:37446790 | PMID:34011935 | PMID:29670214 | PMID:37140985 | PMID:36241865,10.1038/s41467-020-16432-0 | 10.3389/fcell.2024.1359561 | 10.1038/s41598-024-84493-y | 10.1155/2021/9386823 | 10.3390/molecules28135128 | 10.1038/s41419-021-03802-9 | 10.1038/s41598-018-24310-5 | 10.1172/JCI168227 | 10.1038/s12276-022-00850-9,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. | Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1. | Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism. | Survival and | Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway. | Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine. | Restoring functional neurofibromin by protein transduction. | Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Nf1,genetic_reagents,Experimental Usage,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,Pten,genetic_reagents,Experimental Usage,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of,,Haloplex HS,genetic_reagents,Experimental Usage,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of,,SALSA MLPA P081/P082,genetic_reagents,Experimental Usage,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of,,Gentra Puregene,genetic_reagents,Experimental Usage,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of,,beta-globin,genetic_reagents,Experimental Usage,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of,,Lipofectamine 2000,genetic_reagents,Experimental Usage,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of,,TOPO TA,genetic_reagents,Experimental Usage,,,
PMID:39269317 | PMID:34415582 | PMID:34630515 | PMID:37164978 | PMID:32642733 | PMID:39129390 | PMID:39890807 | PMID:41036607 | PMID:41023593,10.1158/1078-0432.CCR-24-1750 | 10.1002/glia.24075 | 10.3389/fgene.2021.721045 | 10.1038/s41467-023-38432-6 | 10.1093/noajnl/vdz061 | 10.1002/1878-0261.13704 | 10.1038/s41598-024-84493-y | 10.1158/1535-7163.MCT-24-1053 | 10.1186/s10020-025-01353-9,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury. | Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism. | Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors. | Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,,Cas9,genetic_reagents,Experimental Usage,,,
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and,,PrimeSTAR GXL,genetic_reagents,Experimental Usage,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,dll4,genetic_reagents,Development,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,dlb,genetic_reagents,Development,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,hey1,genetic_reagents,Development,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,id2b,genetic_reagents,Development,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,dll4-gRNAs,genetic_reagents,Development,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,n3-gRNAs,genetic_reagents,Development,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,n3,genetic_reagents,Development,,,
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,NHE1,genetic_reagents,Experimental Usage,,,
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,Merlin,genetic_reagents,Experimental Usage,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,V-CSCW2,genetic_reagents,Experimental Usage,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,MM-121,genetic_reagents,Experimental Usage,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,SA3,genetic_reagents,Experimental Usage,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,GRDC24,genetic_reagents,Development,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,NF-targeting capsid,genetic_reagents,Development,,,
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,Human Phospho-RTK Array,genetic_reagents,Experimental Usage,,,
PMID:39269317 | PMID:39129390 | PMID:35393510,10.1158/1078-0432.CCR-24-1750 | 10.1002/1878-0261.13704 | 10.1038/s41418-022-00991-4,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,CRISPR-Cas9,genetic_reagents,Experimental Usage,,,
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,Guide RNA,genetic_reagents,Experimental Usage,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,dNf1,genetic_reagents,Experimental Usage,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,Human All Exon capture probes,genetic_reagents,Experimental Usage,,,
PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,,Fluc and mCherry,genetic_reagents,Experimental Usage,,,
PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,NF1-area probes,genetic_reagents,Experimental Usage,,,
PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,GenomeWalker adaptors,genetic_reagents,Experimental Usage,,,
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,L-[18F]FETrp,genetic_reagents,Experimental Usage,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,PDLIM2 shRNA,genetic_reagents,Experimental Usage,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,λ-phosphatase,genetic_reagents,Experimental Usage,,,
PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,Cre and gRNAs,genetic_reagents,Development,,,
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,NeoTkp,genetic_reagents,Experimental Usage,,,
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,NF31a,genetic_reagents,Experimental Usage,,,
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,NF31b,genetic_reagents,Experimental Usage,,,
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,2.5S NGF,genetic_reagents,Experimental Usage,,,
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,rhGGF2,genetic_reagents,Experimental Usage,,,
PMID:29715273 | PMID:32438526,10.1371/journal.pone.0196726 | 10.1002/lary.28671,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,empty vector,genetic_reagents,Experimental Usage,,,
PMID:24509877 | PMID:35393510 | PMID:16835260 | PMID:38000020,10.1038/onc.2013.506 | 10.1038/s41418-022-00991-4 | 10.1093/hmg/ddl165 | 10.1126/sciadv.adg8876,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD | Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling. | CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,NF1-GRD,genetic_reagents,Experimental Usage,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,MAF,genetic_reagents,Experimental Usage,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,MAF ORF,genetic_reagents,Experimental Usage,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,Tet-On,genetic_reagents,Experimental Usage,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,AP-1 luciferase,genetic_reagents,Experimental Usage,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,pLKO.1,genetic_reagents,Experimental Usage,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,shRHAMM,genetic_reagents,Experimental Usage,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,shTPX2,genetic_reagents,Experimental Usage,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,ZEB1,genetic_reagents,Experimental Usage,,,
PMID:36322658 | PMID:36148553,10.1126/sciadv.abo5442 | 10.1093/brain/awac342,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,ALDH1A1,genetic_reagents,Experimental Usage,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,StrepII tag,genetic_reagents,Experimental Usage,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,M-PER,genetic_reagents,Experimental Usage,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,BCA,genetic_reagents,Experimental Usage,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,NF1-targeting TALEN,genetic_reagents,Experimental Usage,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,Gentamicin,genetic_reagents,Experimental Usage,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,NF1 DLR,genetic_reagents,Experimental Usage,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,PBSB,genetic_reagents,Experimental Usage,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,UPF1,genetic_reagents,Experimental Usage,,,
PMID:40684195 | PMID:34040258 | PMID:34010628,10.1186/s40478-025-02075-z | 10.1038/s41586-021-03580-6 | 10.1016/j.stem.2021.04.029,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,EdU,genetic_reagents,Experimental Usage,,,
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,Lipofectamine,genetic_reagents,Experimental Usage,,,
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,Abcg1,genetic_reagents,Experimental Usage,,,
PMID:35789380 | PMID:26219339 | PMID:23685747 | PMID:41023593 | PMID:25772366,10.1158/2159-8290.CD-21-1671 | 10.18632/oncotarget.4858 | 10.1038/ng.2641 | 10.1186/s10020-025-01353-9 | 10.1016/j.celrep.2015.02.041,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,shRNA,genetic_reagents,Experimental Usage,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,GSK3B,genetic_reagents,Experimental Usage,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,AXIN1,genetic_reagents,Experimental Usage,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,CTNNB1,genetic_reagents,Experimental Usage,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,TNKS,genetic_reagents,Experimental Usage,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,RSPO2,genetic_reagents,Experimental Usage,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,CTNNB1 S33Y,genetic_reagents,Experimental Usage,,,
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,hGFAP-cre,genetic_reagents,Experimental Usage,,,
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,Nf1 flox,genetic_reagents,Experimental Usage,,,
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,Nf1 KO,genetic_reagents,Experimental Usage,,,
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,Nestin-cre ER,genetic_reagents,Experimental Usage,,,
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,R26 LacZR,genetic_reagents,Experimental Usage,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,HK2,genetic_reagents,Experimental Usage,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,D4ER,genetic_reagents,Experimental Usage,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,GCAMP6f,genetic_reagents,Experimental Usage,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,mit-Aeqmut,genetic_reagents,Experimental Usage,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,GFP-PHD,genetic_reagents,Experimental Usage,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,human neurofibromin,genetic_reagents,Experimental Usage,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,human FBXW11,genetic_reagents,Experimental Usage,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,Cre-GFP,genetic_reagents,Experimental Usage,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,CRISPRv2,genetic_reagents,Experimental Usage,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,lentiCRISPRv2,genetic_reagents,Experimental Usage,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,Cyclophilin D,genetic_reagents,Experimental Usage,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,mito-GFP1-9,genetic_reagents,Experimental Usage,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,TRAP1-GFP10,genetic_reagents,Experimental Usage,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,CyPD-GFP11,genetic_reagents,Experimental Usage,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,ATP50-GFP11,genetic_reagents,Experimental Usage,,,
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,Agilent Human miRNA Microarray V2,genetic_reagents,Experimental Usage,,,
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,miR-29c,genetic_reagents,Experimental Usage,,,
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,NF1 capture probes,genetic_reagents,Experimental Usage,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,Hematopoietic differentiation factors,genetic_reagents,Experimental Usage,,,
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,NF1 shRNA,genetic_reagents,Experimental Usage,,,
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,Human All Exon,genetic_reagents,Experimental Usage,,,
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,targeted region arrays,genetic_reagents,Experimental Usage,,,
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,COMT val158met probe,genetic_reagents,Experimental Usage,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,nuclear RFP,genetic_reagents,Experimental Usage,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,neurofibromin 2,genetic_reagents,Experimental Usage,,,
PMID:20195187 | PMID:33032988,10.1097/MAO.0b013e3181d2777f | 10.1158/0008-5472.CAN-20-1365,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,non-targeting control,genetic_reagents,Experimental Usage,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,Ras Binding Domain,genetic_reagents,Experimental Usage,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,B-Raf,genetic_reagents,Experimental Usage,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,C-Raf,genetic_reagents,Experimental Usage,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,NF2 shRNA,genetic_reagents,Experimental Usage,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,P53 shRNA,genetic_reagents,Experimental Usage,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,P53,genetic_reagents,Experimental Usage,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,CXCL12,genetic_reagents,Experimental Usage,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,firefly luciferase-GFP fusion,genetic_reagents,Experimental Usage,,,
PMID:28831766,10.1007/s12104-017-9768-1,NMR resonance assignments of the EVH1 domain of neurofibromin's recruitment factor Spred1.,,Spred1(EVH1),genetic_reagents,Experimental Usage,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,FLAG,genetic_reagents,Experimental Usage,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,HA,genetic_reagents,Experimental Usage,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,Tet-inducible,genetic_reagents,Experimental Usage,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,packaging,genetic_reagents,Experimental Usage,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,envelope,genetic_reagents,Experimental Usage,,,
PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,DNA capture system,genetic_reagents,Experimental Usage,,,
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,RABL6A shRNA,genetic_reagents,Experimental Usage,,,
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,RB1 shRNA,genetic_reagents,Experimental Usage,,,
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,β-Galactosidase,genetic_reagents,Experimental Usage,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,Tet-pLKO-puro,genetic_reagents,Experimental Usage,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,TTIGFP-MLUEX,genetic_reagents,Experimental Usage,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,shPTPN11,genetic_reagents,Experimental Usage,,,
PMID:34257279 | PMID:29670214,10.1038/s41467-021-24505-x | 10.1038/s41598-018-24310-5,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila. | Restoring functional neurofibromin by protein transduction.,,Nf1-eGFP,genetic_reagents,Development,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,Nf1 RNAi,genetic_reagents,Experimental Usage,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,rl Sem,genetic_reagents,Experimental Usage,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,nSyb,genetic_reagents,Experimental Usage,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,R57C10,genetic_reagents,Experimental Usage,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,tsh-Gal4,genetic_reagents,Experimental Usage,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,Oct-TyrR-Gal4,genetic_reagents,Experimental Usage,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,PCB-Gal4,genetic_reagents,Experimental Usage,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,SB11,genetic_reagents,Experimental Usage,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,T2/Onc15,genetic_reagents,Experimental Usage,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,EGFR,genetic_reagents,Experimental Usage,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,FOXR2,genetic_reagents,Experimental Usage,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,HPRT,genetic_reagents,Experimental Usage,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,KCNMA1,genetic_reagents,Experimental Usage,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,PRKCE,genetic_reagents,Experimental Usage,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,OPCML,genetic_reagents,Experimental Usage,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,GRIK2,genetic_reagents,Experimental Usage,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,CADM2,genetic_reagents,Experimental Usage,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,CREB5,genetic_reagents,Experimental Usage,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,CAMK1D,genetic_reagents,Experimental Usage,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,ITGB8,genetic_reagents,Experimental Usage,,,
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,Klenow (exo-),genetic_reagents,Experimental Usage,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,anti-HER1 CAR 806,genetic_reagents,Development,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,anti-HER1 CAR E2,genetic_reagents,Development,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,anti-HER1 CAR NEC,genetic_reagents,Development,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,AHR,genetic_reagents,Experimental Usage,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,gRNA,genetic_reagents,Experimental Usage,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,Luciferase-IRES-GFP,genetic_reagents,Experimental Usage,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,PB7 transposase,genetic_reagents,Experimental Usage,,,
PMID:24980480,10.1186/1479-7364-8-10,Novel age-dependent targets in vestibular schwannomas.,,Human Universal Reference RNA,genetic_reagents,Experimental Usage,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,SGK1,genetic_reagents,Experimental Usage,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,PAK1,genetic_reagents,Experimental Usage,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,RHEB,genetic_reagents,Experimental Usage,,,
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,Ultra Low Cluster Plates,genetic_reagents,Experimental Usage,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,GST-PID,genetic_reagents,Experimental Usage,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,Gst-PID L107F,genetic_reagents,Experimental Usage,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,PTPN11,genetic_reagents,Experimental Usage,,,
PMID:28051113 | PMID:36420221,10.1038/srep39348 | 10.1016/j.omtn.2022.10.026,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape. | Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype",,I2HCP panel,genetic_reagents,Development,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,shRNAs,genetic_reagents,Experimental Usage,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,β-catenin ΔN90,genetic_reagents,Experimental Usage,,,
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,D22S193,genetic_reagents,Experimental Usage,,,
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,NF2 TET,genetic_reagents,Experimental Usage,,,
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,D22S929,genetic_reagents,Experimental Usage,,,
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,D22S268,genetic_reagents,Experimental Usage,,,
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,D22S430,genetic_reagents,Experimental Usage,,,
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,BstUI,genetic_reagents,Experimental Usage,,,
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,StemSep,genetic_reagents,Experimental Usage,,,
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,biocytin,genetic_reagents,Experimental Usage,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,NucLight red,genetic_reagents,Experimental Usage,,,
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,WT1-AS,genetic_reagents,Experimental Usage,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,psPAX,genetic_reagents,Experimental Usage,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,pMD2.G,genetic_reagents,Experimental Usage,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,UAS:eGFP-KRAS G12D,genetic_reagents,Experimental Usage,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,HumanOmni2.5-8,genetic_reagents,Experimental Usage,,,
PMID:36420221 | PMID:29670214,10.1016/j.omtn.2022.10.026 | 10.1038/s41598-018-24310-5,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype | Restoring functional neurofibromin by protein transduction.,,Endo-Porter,genetic_reagents,Experimental Usage,,,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,NF1 siRNA,genetic_reagents,Experimental Usage,,,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,Control siRNA,genetic_reagents,Experimental Usage,,,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,Lipofectamine RNAiMAX,genetic_reagents,Experimental Usage,,,
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,interferon alpha-2b,genetic_reagents,Experimental Usage,,,
PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,xGen UDI-UMI Adapters,genetic_reagents,Experimental Usage,,,
PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,TruSight Oncology 500,genetic_reagents,Experimental Usage,,,
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,shSOX9,genetic_reagents,Experimental Usage,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,hTERT and mCdk4,genetic_reagents,Experimental Usage,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,hTERT,genetic_reagents,Experimental Usage,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,mCdk4,genetic_reagents,Experimental Usage,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,pBABE vectors,genetic_reagents,Experimental Usage,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,KIF15/KIF23 siRNA,genetic_reagents,Experimental Usage,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,RGS2,genetic_reagents,Experimental Usage,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,ispinesib,genetic_reagents,Experimental Usage,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,Merlin isoform 1,genetic_reagents,Experimental Usage,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,Merlin(S518D) and Merlin(S518E) mutants,genetic_reagents,Experimental Usage,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,HiTrap Chelating Sepharose™ High Performance,genetic_reagents,Experimental Usage,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,Superdex 200 10/300 GL column,genetic_reagents,Experimental Usage,,,
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,Gd-DTPA,genetic_reagents,Experimental Usage,,,
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,Human Mapping 100K Set,genetic_reagents,Experimental Usage,,,
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,GeneChip Human Genome U133 Plus 2.0 Arrays,genetic_reagents,Experimental Usage,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,PDE4A1,genetic_reagents,Development,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,PDE4A1-H229Q,genetic_reagents,Development,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,firefly luciferase-eGFP fusion,genetic_reagents,Experimental Usage,,,
PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the,,luciferase,genetic_reagents,Experimental Usage,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,PAM71,genetic_reagents,Experimental Usage,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,Microsatellite markers,genetic_reagents,Experimental Usage,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,MLPA probe set,genetic_reagents,Experimental Usage,,,
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of",,Kit Ligand,genetic_reagents,Experimental Usage,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,psPAX2,genetic_reagents,Experimental Usage,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,VSV-G,genetic_reagents,Experimental Usage,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,SUZ12,genetic_reagents,Experimental Usage,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,dCas9-BFP-KRAB,genetic_reagents,Experimental Usage,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,TAZ,genetic_reagents,Experimental Usage,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,YAP,genetic_reagents,Experimental Usage,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Scramble,genetic_reagents,Experimental Usage,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,Merlin siRNA,genetic_reagents,Experimental Usage,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,HA-Merlin,genetic_reagents,Experimental Usage,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,S518A HA-Merlin,genetic_reagents,Experimental Usage,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,IPA-3,genetic_reagents,Experimental Usage,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype,,PMOs,genetic_reagents,Experimental Usage,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype,,Gateway Gene Cloning system,genetic_reagents,Experimental Usage,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype,,FLAG Tag,genetic_reagents,Experimental Usage,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype,,Lipofectamine LTX,genetic_reagents,Experimental Usage,,,
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,NeuroD1,genetic_reagents,Experimental Usage,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,Tgfb3,genetic_reagents,Experimental Usage,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,Tgfb1b,genetic_reagents,Experimental Usage,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,tgfb3-EGFP,genetic_reagents,Development,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,nCas9n-nanos3'UTR,genetic_reagents,Experimental Usage,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,WC-10,genetic_reagents,Experimental Usage,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,telomere repeat sequence probe,genetic_reagents,Experimental Usage,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,centromeric DNA repeats probe,genetic_reagents,Experimental Usage,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,644 cancer gene panel,genetic_reagents,Experimental Usage,,,
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,Human Exome,genetic_reagents,Experimental Usage,,,
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,pcDNA3.1,genetic_reagents,Experimental Usage,,,
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,nf2a/b-4sgRNA,genetic_reagents,Experimental Usage,,,
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,LNTH-1363S,genetic_reagents,Experimental Usage,,,
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,DUSP6,genetic_reagents,Experimental Usage,,,
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,FOS,genetic_reagents,Experimental Usage,,,
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,pCW57.1,genetic_reagents,Experimental Usage,,,
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,KRAS WT,genetic_reagents,Experimental Usage,,,
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,KRAS G12D,genetic_reagents,Experimental Usage,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,Tp53,genetic_reagents,Experimental Usage,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,miR34a,genetic_reagents,Experimental Usage,,,
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,PHA,genetic_reagents,Experimental Usage,,,
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,IL-2,genetic_reagents,Experimental Usage,,,
PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,IGT-T192V1 Plus panel,genetic_reagents,Experimental Usage,,,
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,MBP fusion,genetic_reagents,Experimental Usage,,,
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,His-p55,genetic_reagents,Experimental Usage,,,
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,REPLI-g FFPE,genetic_reagents,Experimental Usage,,,
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,reprogramming factors,genetic_reagents,Experimental Usage,,,
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,"OCT4, SOX2, MYC, KLF4, NANOG, LIN28",genetic_reagents,Experimental Usage,,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,1276P NF1 GRD,genetic_reagents,Experimental Usage,,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,pac,genetic_reagents,Experimental Usage,,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,c-abl siRNA,genetic_reagents,Experimental Usage,,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,Scrambled siRNA,genetic_reagents,Experimental Usage,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Rictor,genetic_reagents,Experimental Usage,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,TUNEL,genetic_reagents,Experimental Usage,,,
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,MSCV,genetic_reagents,Experimental Usage,,,
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,Rac1 N17,genetic_reagents,Experimental Usage,,,
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,PLKO,genetic_reagents,Experimental Usage,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,pGEX 4T-1,genetic_reagents,Experimental Usage,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,SpCas9,genetic_reagents,Experimental Usage,,,
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,Custom gene panel,genetic_reagents,Experimental Usage,,,
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,Alexa Fluor 594-labeled dextrans,genetic_reagents,Experimental Usage,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,CEP 8 (D8Z2),genetic_reagents,Experimental Usage,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,LSI MYC,genetic_reagents,Experimental Usage,,,
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,PSME3,genetic_reagents,Experimental Usage,,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,Cas9 and sgRNAs targeting Nf1+Cdkn2a,genetic_reagents,Experimental Usage,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,Ref-1,genetic_reagents,Experimental Usage,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,STAT3,genetic_reagents,Experimental Usage,,,
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,Mycoplasma detection primers,genetic_reagents,Experimental Usage,,,
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,Hsp90β,genetic_reagents,Experimental Usage,,,
PMID:41022755 | PMID:38000020 | PMID:33032988,10.1038/s41467-025-63619-4 | 10.1126/sciadv.adg8876 | 10.1158/0008-5472.CAN-20-1365,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,JH-2-002,patient_derived_models,Experimental Usage,,,
PMID:41022755 | PMID:38000020 | PMID:33032988,10.1038/s41467-025-63619-4 | 10.1126/sciadv.adg8876 | 10.1158/0008-5472.CAN-20-1365,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,JH-2-031,patient_derived_models,Experimental Usage,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,JH-2-079c PDX,patient_derived_models,Experimental Usage,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,WU-225 PDX,patient_derived_models,Experimental Usage,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,WU-386 PDX,patient_derived_models,Experimental Usage,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,WU-545 PDX,patient_derived_models,Experimental Usage,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,MN-2 PDX,patient_derived_models,Experimental Usage,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,MN-3-002 PDX,patient_derived_models,Experimental Usage,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,Patient-derived xenograft (PDX) MPNST model,patient_derived_models,Experimental Usage,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,MPNST-SP-01 PDOX,patient_derived_models,Experimental Usage,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,MPNST-NF1-09 PDOX,patient_derived_models,Experimental Usage,,,
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,vestibular schwannoma xenografts,patient_derived_models,Experimental Usage,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,JH-2–009,patient_derived_models,Experimental Usage,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,JH-2–055,patient_derived_models,Experimental Usage,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,JH-2–060,patient_derived_models,Experimental Usage,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,JH-2–074,patient_derived_models,Experimental Usage,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,JH-2–077,patient_derived_models,Experimental Usage,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,MPNST PDX-1,patient_derived_models,Experimental Usage,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,Cutaneous neurofibroma samples,patient_derived_models,Experimental Usage,,,
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,human neurofibroma xenografts,patient_derived_models,Experimental Usage,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,NF1-associated MPNST-PDX,patient_derived_models,Development,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,NF1-MPNST patient-derived xenografts,patient_derived_models,Development,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,RHT-92,patient_derived_models,Experimental Usage,,,
